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Abstract 
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease, 
comprising chronic bronchitis, small airways fibrosis and emphysema.  The primary risk 
factor for developing COPD, in industrialised nations is cigarette smoking.  
Exacerbations of COPD, of which approximately half are due to bacterial infection, are 
associated with worsening quality of life, more rapid decline in FEV1 and increased 
mortality.  In healthy individuals, alveolar macrophages (AM) clear inhaled bacterial 
pathogens from the lung by phagocytosis, resulting in sterility of the lower respiratory 
tract.  However, COPD patients have increased bacterial colonisation of the lower 
airways compared to healthy smokers and non-smokers. The increased rates of 
bacterial colonisation in COPD, suggests that there may be a mechanistic defect in the 
clearance of bacteria by phagocytic cells. 
The main aim of this thesis was to investigate the hypothesis that defective innate 
immunity in COPD patients results in reduction in bacterial phagocytosis, with 
increased frequency of acute exacerbation, and that this defective phagocytosis may 
be explained by instability of microtubules.  Phagocytic ability of both macrophages 
and neutrophils from COPD patients was compared to age-matched, non-smokers and 
smokers.  Monocyte-derived-macrophages (MDMs) were used as a model of AM.  Both 
MDMs and neutrophils from all subject groups displayed equivalent phagocytosis of 
inert beads, showing that cells from all subject groups are capable of phagocytosis.  
However, both MDMs and neutrophils from smokers and COPD patients showed 
reduced uptake of both Haemophilus influenzae (by 48%, p<0.001 and 28%, p<0.01 
respectively) and Streptococcus pneumoniae (by 52%, p<0.001 and 32%, p<0.05 
respectively).  Whilst MDMs showed defective phagocytosis of bacteria, intracellular 
killing remained intact.  When COPD patients were divided into those with a history of 
frequent (≥2/y) or infrequent exacerbations (<1/y), frequent exacerbators had 
significantly reduced phagocytosis of bacteria compared to infrequent exacerbators.  
No differences were seen when phagocytosis at baseline was compared to 
phagocytosis at times of exacerbation.  
As COPD patients appear to have defective phagocytosis, and with recent meta-
analyses showing an increased risk of pneumonia with fluticasone propionate (FP), the 
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effects of both budesonide (BUD) and FP on phagocytosis by MDMs and neutrophils 
from COPD patients was assessed.  No differences were found in phagocytosis of 
bacteria by MDMs in the presence of either steroid, or in the ability of these cells to 
perform functions of intracellular killing.  In the presence of BUD, neutrophils showed 
significantly improved uptake of H. influenzae (with a maximal effect of 67%, p<0.05), 
but neither FP nor BUD had any impact on phagocytosis of beads or S. pneumoniae.  
Further investigation into the mechanisms underlying defective phagocytosis revealed 
increased susceptibility of COPD MDMs to microtubule disruption.  Associated with 
this finding was a reduced level of acetylated tubulin in COPD MDMs.  Addition of a 
microtubule stabiliser increased acetylated tubulin and significantly increased bacterial 
phagocytosis (maximal increase of 20% and 40% in phagocytosis of Haemophilus 
influenzae and Streptococcus pneumoniae respectively). In contrast, neutrophils 
displayed no differences in acetylated tubulin and showed no improvement in 
phagocytosis after exposure to microtubule stabilisers, suggesting an alternative 
mechanistic defect in neutrophils compared to MDMs.  Acetylated microtubules are 
deacetylated by the enzymes HDAC6 and SIRT2.  Exposure to the deacetylase 
inhibitors, tubacin (HDAC6 inhibitor) or AGK2 (SIRT2 inhibitor), led to increases in 
levels of acetylation of tubulin but no improvements in phagocytosis, whilst 
knockdown of either HDAC6 or SIRT2 revealed a similar picture, with increased 
acetylation but no improvements in phagocytosis.  These findings suggest that 
increased acetylation of tubulin alone is not sufficient to improve phagocytosis, but 
rather that the defect in phagocytosis is related to microtubule instability.  Knockdown 
of C6orf134, a newly discovered tubulin acetyl-transferase, in healthy MDMs led to 
reductions in levels of acetylated tubulin and reduced bacterial, but not inert bead, 
phagocytosis, mimicking the defect seen in COPD MDMs.  This suggests that 
alterations in activity or expression of this protein may account for the defective 
phagocytosis seen in COPD MDMs.  Improving phagocytosis by stabilisation of 
microtubules may therefore lead to reduced levels of bacterial colonisation and 





I am grateful to my supervisor Dr Louise Donnelly, for her invaluable advice and 
guidance, her continued enthusiasm and support throughout the last three years. I 
would also like to thank my second supervisor, Professor Peter Barnes, for giving me 
the opportunity to undertake this PhD, and for his advice and support.  Furthermore, I 
would like to thank Astra-Zeneca for funding this PhD. 
 
I would like to thank my collaborators including Professor Wisia Wedzicha and her 
team at the Royal Free and Dr Richard Russell. 
I would particularly like to thank Mr Peter Fenwick and Ms Sally Meah for their 
invaluable help, along with Miss Kirandeep Chana and Dr Rebecca Holloway.   
 
The last three years at the NHLI, Airway Disease section, has been really enjoyable 
thanks to all my friends and colleagues, in particular Kiran, Gurpreet, Nadia, Tash, Amy, 
Hanna, Phil, Christos, Corina, Nico, Charis and Pank, but also to all at the NHLI that it 
has been my pleasure to work with. 
 
Last but not least, I would like to thank my husband Alex, for always believing in me 
and for his endless support and patience, and my beautiful children for their delight on 
my return from work and study. 
 
I confirm that I have performed all experiments and analyses reported in this thesis.  
Catherine MR Thomas 
The copyright of this thesis rests with the author and is made available under a 
Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers 
are free to copy, distribute or transmit the thesis on the condition that they attribute 
it, that they do not use it for commercial purposes and that they do not alter, 
transform or build upon it. For any reuse or redistribution, researchers must make 
clear to others the licence terms of this work  
 5 
Table of Contents 
List of Figures .................................................................................................................. 15 
List of Tables .................................................................................................................... 21 
List of Abbreviations ....................................................................................................... 22 
Chapter 1 ......................................................................................................................... 26 
INTRODUCTION .................................................................................................................... 26 
1.1 Chronic Obstructive Pulmonary Disease .............................................................. 27 
1.1.1 Definition of COPD ............................................................................................. 27 
1.1.2 Epidemiology of COPD ....................................................................................... 28 
1.1.3 Pathophysiology of COPD .................................................................................. 29 
1.1.3.1 Mucus Hypersecretion ................................................................................ 29 
1.1.3.2 Chronic obstructive bronchiolitis ................................................................ 30 
1.1.3.3 Emphysema ................................................................................................. 30 
1.1.4 Pharmacotherapy for COPD ............................................................................... 31 
1.2 Exacerbations of COPD .............................................................................................. 33 
1.2.1 Defining an exacerbation - Anthonisen’s criteria .............................................. 34 
1.2.2 Causes of COPD exacerbations .......................................................................... 34 
1.2.3 Pathophysiology of COPD exacerbations ........................................................... 37 
1.2.4 Bacterial colonisation in COPD ........................................................................... 38 
1.2.4.1 Haemophilus influenzae .............................................................................. 38 
1.2.4.2 Streptococcus pneumoniae ......................................................................... 40 
1.3 The immune system and the lung ............................................................................. 40 
1.3.1 Barrier immunity ................................................................................................ 40 
 6 
1.3.2 Adaptive immunity ............................................................................................. 42 
1.3.3 Innate immunity ................................................................................................. 43 
1.3.3.1 Macrophages in the lung ............................................................................ 44 
1.3.3.2 Macrophages in COPD ................................................................................ 45 
1.3.3.3 Neutrophils in the lung ............................................................................... 48 
1.3.3.4 Neutrophils in COPD ................................................................................... 48 
1.4 Phagocytosis .............................................................................................................. 49 
1.4.1 Particle recognition ............................................................................................ 50 
1.4.1.1 Fc-Receptor and complement receptor mediated phagocytosis ............... 52 
1.4.1.2 Scavenger receptor mediated phagocytosis ............................................... 53 
1.4.2 Particle internalisation ....................................................................................... 53 
1.4.2.1 Microtubules ................................................................................................... 54 
1.5 Phagocytosis in COPD................................................................................................ 55 
1.6 Hypothesis ................................................................................................................. 57 
1.7 Aims ........................................................................................................................... 57 
Chapter 2 ......................................................................................................................... 58 
MATERIALS AND METHODS .................................................................................................... 58 
2.1. Materials .................................................................................................................. 59 
2.2 Methods .................................................................................................................... 66 
2.2.1 Subject selection ................................................................................................ 66 
2.2.1.1. Healthy volunteers ..................................................................................... 66 
2.2.1.2. Smokers ...................................................................................................... 66 
 7 
2.2.1.3. COPD patients ............................................................................................ 66 
2.2.2  Clinical measurements ...................................................................................... 67 
2.2.2.1. Spirometry .................................................................................................. 67 
2.2.2.2. Reversibility ................................................................................................ 67 
2.2.3 Blood Separation ................................................................................................ 67 
2.2.3.1 Separation of monocytes by adherence ..................................................... 68 
2.2.3.2 Separation of monocytes by negative selection ......................................... 68 
2.2.3.3 Protein assay ............................................................................................... 69 
2.2.3.4 Viability assay .............................................................................................. 69 
2.2.4 Sputum induction and processing ..................................................................... 70 
2.2.5 Bacterial Culture ................................................................................................. 70 
2.2.5.1 Streptococcus pneumoniae ......................................................................... 70 
2.2.5.2 Haemophilus influenzae .............................................................................. 72 
2.2.6 Fluorescent labelling of bacteria ........................................................................ 72 
2.2.6.1 Labelling of bacteria with Alexa-fluor 488 dye ........................................... 72 
2.2.6.2 Labelling bacteria with pHrodo™ dye ......................................................... 73 
2.2.6.3 Labelling of live bacteria ............................................................................. 73 
2.2.7 Phagocytosis Assays ........................................................................................... 73 
2.2.7.1 Phagocytosis of Beads ................................................................................. 73 
2.2.7.2 Phagocytosis of Bacteria ............................................................................. 75 
2.2.8 Measurement of TNF-α from cell supernatant .................................................. 76 
2.2.9 Western blotting ................................................................................................ 77 
 8 
2.2.9.1 Gel Electrophoresis ..................................................................................... 77 
2.2.9.2 Transfer of protein to nitrocellulose ........................................................... 78 
2.2.9.3 Immunoblotting .......................................................................................... 78 
2.2.10 Measurement of expression of cell surface markers ...................................... 79 
2.2.11 Confocal Microscopy ........................................................................................ 79 
2.2.11.1 Confirmation of phagocytosis by MDMs .................................................. 79 
2.2.11.2 Staining with Tubulin Tracker™................................................................. 80 
2.2.11.3 Visualisation .............................................................................................. 80 
2.2.12 Live imaging ...................................................................................................... 80 
2.2.13 Knockdown ....................................................................................................... 80 
2.2.14 TaqMan Real time polymerase chain reaction (rt-PCR) .................................. 81 
2.2.14.1 RNA isolation ............................................................................................. 81 
2.2.14.2 RNA analysis .............................................................................................. 82 
2.2.14.3 cDNA .......................................................................................................... 82 
2.2.15 HDAC activity assay .......................................................................................... 83 
2.2.15.1 Immunoprecipitation ................................................................................ 83 
2.2.15.2 HDAC activity assay ................................................................................... 83 
2.2.16 Intracellular killing assay .................................................................................. 84 
2.2.17 Statistics ........................................................................................................... 85 
Chapter 3 ......................................................................................................................... 86 
RELATIONSHIP BETWEEN DISEASE AND PHAGOCYTOSIS IN MACROPHAGES ....................................... 86 
3.1 Introduction .............................................................................................................. 87 
 9 
3.2 Methods .................................................................................................................... 90 
3.2.1 Subject selection ................................................................................................ 90 
3.2.2 Study timeline .................................................................................................... 90 
3.2.3 Blood separation ................................................................................................ 90 
3.2.4 Phagocytosis Assays ........................................................................................... 91 
3.2.5 Confocal microscopy .......................................................................................... 91 
3.2.6 Intracellular killing .............................................................................................. 91 
3.2.7 Sputum processing ............................................................................................. 91 
3.2.7.1 Preparation of cytospins and Quick-Diff staining ....................................... 91 
3.3 Results ....................................................................................................................... 93 
3.3.1 Subject Demographics ....................................................................................... 93 
3.3.2 Effect of monocyte isolation on generation of MDMs ...................................... 93 
3.3.3 Effect of monocyte isolation on MDMs phagocytosis ....................................... 94 
3.3.4 Establishment of optimum conditions for MDMs phagocytosis of beads ........ 95 
3.3.5 Confocal microscopy of MDMs bead phagocytosis ........................................... 97 
3.3.6 Establishment of optimum conditions for MDMs phagocytosis of bacteria ..... 98 
3.3.7 Confocal microscopy confirming bacterial phagocytosis by MDMs ................ 100 
3.3.8 Confirmation of internalisation of bacteria by MDMs, using pHrodo™ .......... 103 
3.3.9 Effect of disease on phagocytosis of beads and bacteria by MDMs ............... 104 
3.3.10 Phagocytosis assays with live bacteria ........................................................... 108 
3.3.11 Cell viability .................................................................................................... 109 
3.3.12 Intracellular killing .......................................................................................... 110 
 10 
3.3.13 Relationship between phagocytosis of gram negative and gram positive 
bacteria ..................................................................................................................... 111 
3.3.14 Effect of disease on cytokine release from MDMs ........................................ 114 
3.3.15 Effect of Exacerbation frequency on the ability of MDMs to phagocytose 
bacteria ..................................................................................................................... 115 
3.3.16 Effect of Acute Exacerbations of COPD on MDMs phagocytosis of beads and 
bacteria ..................................................................................................................... 116 
3.3.17 Phagocytosis by Sputum macrophages ......................................................... 118 
3.4 Discussion ................................................................................................................ 123 
Chapter 4 ....................................................................................................................... 132 
COMPARISON OF PHAGOCYTOSIS BY NEUTROPHILS FROM HEALTHY, SMOKER AND COPD SUBJECTS ... 132 
4.1 Introduction ............................................................................................................ 133 
4.2 Methods .................................................................................................................. 135 
4.2.1 Subject selection .............................................................................................. 135 
4.2.2 Blood separation .............................................................................................. 135 
4.2.3 Phagocytosis Assays ......................................................................................... 135 
4.2.4 Measurement of cell surface receptor expression .......................................... 135 
4.3 Results ..................................................................................................................... 137 
4.3.1 Subject Demographics ..................................................................................... 137 
4.3.2  Neutrophil phagocytosis of beads .................................................................. 137 
4.3.4 Neutrophil phagocytosis of bacteria ................................................................ 140 
4.3.5 Assessing internalisation of bacteria - pHrodoTM labelled bacteria ............... 141 
4.3.6 Effect of disease on phagocytosis of beads and bacteria by neutrophils ........ 143 
 11 
4.3.7 Neutrophil phagocytosis of Streptococcus pneumoniae ................................. 144 
4.3.8 Neutrophil phagocytosis of Haemophilus influenzae ...................................... 145 
4.3.9 Neutrophil viability ........................................................................................... 147 
4.3.10 Neutrophil cell surface receptor expression .................................................. 149 
4.4 Discussion ................................................................................................................ 151 
Chapter 5 ....................................................................................................................... 156 
A COMPARISON OF THE EFFECTS OF FLUTICASONE PROPIONATE AND BUDESONIDE ON THE PHAGOCYTIC 
ABILITY OF MDMS AND NEUTROPHILS ................................................................................... 156 
5.1 Introduction ............................................................................................................ 157 
5.2  Methods ................................................................................................................. 159 
5.2.1 Subject recruitment ......................................................................................... 159 
5.2.2 Blood Separation .............................................................................................. 159 
5.2.3 Phagocytosis Assays ......................................................................................... 159 
5.2.3.1 Phagocytosis of Beads ............................................................................... 159 
5.2.3.2 Phagocytosis of Bacteria ........................................................................... 160 
5.2.4 Intracellular killing assays................................................................................. 160 
5.2.5 Viability assays ................................................................................................. 161 
5.2.6 Confocal Microscopy ........................................................................................ 161 
5.2.6.1 Staining of cells ......................................................................................... 161 
5.2.6.2 Visualisation .............................................................................................. 161 
5.2.7 Statistical Analyses ........................................................................................... 161 
5.3  Results .................................................................................................................... 162 
 12 
5.3.1 Subject demographics ...................................................................................... 162 
5.3.2 Effect of steroids on MDMs phagocytic responses .......................................... 162 
5.3.3 Cell viability ...................................................................................................... 165 
5.3.4 Confocal Microscopy ........................................................................................ 167 
5.3.5 Intracellular killing ............................................................................................ 169 
5.3.6 Effect of steroids on neutrophil phagocytic responses ................................... 170 
5.4  Discussion ............................................................................................................... 174 
Chapter 6 ....................................................................................................................... 178 
MECHANISM UNDERLYING DEFECTIVE PHAGOCYTOSIS IN SMOKER AND COPD MDMS AND NEUTROPHILS
 ....................................................................................................................................... 178 
6.1 Introduction ............................................................................................................ 179 
6.2 Methods .................................................................................................................. 182 
6.2.1 Subject selection .............................................................................................. 182 
6.2.2 Blood separation .............................................................................................. 182 
6.2.3 Phagocytosis Assays ......................................................................................... 182 
6.2.4 Western Blot .................................................................................................... 182 
6.2.5 Immunoprecipitation ....................................................................................... 182 
6.2.6 HDAC activity assay .......................................................................................... 183 
6.2.7 Transfection ..................................................................................................... 183 
6.2.8 rt-PCR ............................................................................................................... 183 
6.2.9 Confocal microscopy ........................................................................................ 183 
6.3 Results ..................................................................................................................... 184 
 13 
6.3.1 Effect of microtubule disruptors on phagocytosis by MDMs from different 
subject groups ........................................................................................................... 184 
6.3.2. Levels of acetylated tubulin in cells from different subject groups ............... 186 
6.3.3. Staining of microtubules in MDMs with tubulin tracker™.............................. 188 
6.3.4. Effects of a microtubule stabiliser (Epothilone B) on phagocytosis by MDMs 
from smoker and COPD subjects .............................................................................. 190 
6.3.5. Effect of Epothilone B on levels of acetylated tubulin within MDMs ............. 191 
6.3.6. Effects of Epothilone B on neutrophil phagocytosis ....................................... 193 
6.3.7. HDAC6 activity within MDMs derived from different subject groups ............ 194 
6.3.8. Effects of HDAC6 inhibitor (Tubacin) on phagocytosis and levels of acetylated 
tubulin in COPD MDMs ............................................................................................. 195 
6.3.9. Effects of SIRT2 inhibitor (AGK2) on phagocytosis and levels of acetylated 
tubulin in COPD MDMs ............................................................................................. 197 
6.3.10. Transfection of COPD MDMs with siRNA to knockdown SIRT2 .................... 199 
6.3.11 Effect of knockdown of SIRT2 on the phagocytic ability of COPD MDMs ..... 200 
6.3.12. Transfection of COPD MDMs with siRNA to knockdown HDAC6 ................. 201 
6.3.13 Effect of knockdown of HDAC6 on the level of acetylated tubulin in COPD 
MDMs ........................................................................................................................ 203 
6.3.14 Effect of knockdown of HDAC6 on the phagocytic ability of COPD MDMs ... 203 
6.3.15. Transfection of Healthy MDMs with siRNA to knockdown C6orf134 .......... 204 
6.3.16. Effect of knockdown of C6orf134 on the phagocytic ability of non-smoker 
MDMs ........................................................................................................................ 206 
6.3.17. Investigation of levels of C6orf134 in COPD subjects compared to healthy 
subjects ..................................................................................................................... 206 
 14 
6.3.18. Effect of knockdown of C6orf134 on the levels of acetylated tubulin within 
healthy MDMs ........................................................................................................... 208 
6.4 Discussion ................................................................................................................ 210 
Chapter 7 ....................................................................................................................... 214 
DISCUSSION ...................................................................................................................... 214 
7.1 Discussion ................................................................................................................ 215 
7.2 Future work ............................................................................................................. 223 
Appendix A .................................................................................................................... 225 
Appendix B .................................................................................................................... 226 















List of Figures 
Chapter 1 
Figure 1.1. Causes and effect of exacerbations of COPD 
Figure 1.2. Adaptive immunity 
 
Figure 1.3. Macrophage polarisation 
Figure 1.4. Role of macrophages and neutrophils in the pathogenesis of COPD 
Figure 1.5.  The process of phagocytosis  
Figure 1.6. Receptors involved in particle recognition and phagocytosis  
Chapter 2 
Figure 2.1.  Protein standard curve used to derive unknown protein concentrations 
Figure 2.2. Growth curve of Streptococcus pneumoniae with optical density plotted 
against colony forming units at each time point 
Figure 2.3. Growth curve of Haemophilus influenzae with optical density plotted 
against colony forming units at each time point 
Figure 2.4. FACS dot plot showing a neutrophil population  
Figure 2.5. Neutrophil phagocytosis of polystyrene beads – quantified by flow 
cytometry. 
Figure 2.6.  Standard curve used to derive unknown concentrations of TNF-α 
Figure 2.7.  Protein standard curve used to derive unknown protein concentrations. 
Chapter 3 
Figure 3.1. Timeline for recruitment of subjects into study 
Figure 3.2. Comparison of average protein derived from two techniques for separating 
monocytes 
Figure 3.3. Comparison of phagocytosis of beads by MDMs derived from two monocyte 
isolation techniques. 
Figure 3.4. Effect of incubation time and bead concentration on MDMs phagocytosis of 
beads  
Figure 3.5. Effect of Cytochalasin D (CyD) on inhibiting phagocytosis of beads across 
subject groups. 
 16 
Figure 3.6. Confocal microscopy images of MDMs having undergone phagocytosis of 
beads  
Figure 3.7. Effect of incubation time and concentration of bacteria on phagocytosis by 
MDMs. 
Figure 3.8.  Effect of Cytochalasin D (CyD) on inhibition of bacterial phagocytosis. 
Figure 3.9.  Confocal microscopy images of MDMs having undergone phagocytosis of 
H. influenzae  
Figure 3.10.  Confocal microscopy images of MDMs having undergone phagocytosis of 
S. pneumoniae  
Figure 3.11.  Fluorescent microscopy images of MDMs having undergone phagocytosis 
of pHrodo-labelled H. influenzae  
Figure 3.12.  Fluorescent microscopy images of MDMs having undergone phagocytosis 
of pHrodo-labelled S. pneumoniae  
Figure 3.13. Effect of disease on phagocytosis of beads by MDMs 
Figure 3.14.  Fluorescent microscopy images of (a) healthy MDMs and (b) COPD MDMs 
having undergone phagocytosis of H. influenzae  
Figure 3.15. Effect of disease on phagocytosis of H. influenzae by MDMs. 
Figure 3.16.  Fluorescent microscopy images of (a) healthy MDMs and (b) COPD MDMs 
having undergone phagocytosis of S. pneumoniae  
Figure 3.17. Effect of disease on phagocytosis of S. pneumoniae by MDMs. 
Figure 3.18. Effect of live bacteria on phagocytosis of (a) H. influenzae and (b) S. 
pneumoniae by MDMs from different subject groups. 
Figure 3.19. Viability of MDMs from different subject groups. 
Figure 3.20. Ability of MDMs from different subject groups to kill intracellular bacteria. 
Figure 3.21. Correlation between the ability of MDMs from different subject groups to 
phagocytose H. influenzae and S. pneumoniae. 
Figure 3.22. Correlation between the age of subjects from all disease groups and ability 
of their MDMs to phagocytose H. influenzae or S. pneumoniae. 
Figure 3.23. Correlation between the FEV1 % predicted of subjects from all disease 
groups and ability of their MDMs to phagocytose H. influenzae or S. pneumoniae. 
Figure 3.24. Correlation between the FEV1/FVC ratio of subjects from all disease groups 
and the ability of their MDMs to phagocytose H. influenzae or S. pneumoniae. 
Figure 3.25. Correlation between the smoking history from smoking and COPD subjects 
and the ability of their MDMs to phagocytose H. influenzae or S. pneumoniae. 
 17 
Figure 3.26. TNF-α release from MDMs after 4h incubation with phagocytic prey 
Figure 3.28.  Effect of exacerbation frequency on ability of MDMs to phagocytose 
bacteria. 
Figure 3.30.  Effect of acute exacerbation on phagocytosis of (a) beads (b) H. influenzae 
and (c) S. pneumoniae by COPD MDMs. 
Figure 3.32a-c.  Cytospins of healthy and COPD sputum samples 
Figure 3.33. Ability of sputum macrophages from all subject groups to phagocytose 
beads. 
Figure 3.34. Ability of sputum macrophages from all subject groups to phagocytose H. 
influenzae. 
Figure 3.35. Ability of sputum macrophages from all subject groups to phagocytose S. 
pneumoniae. 
Chapter 4 
Figure 4.1.  Analysis of neutrophil viability 
Figure 4.2.  Subject demographics 
Figure 4.3. Effect of incubation time and bead concentration on phagocytosis by 
neutrophils  
Figure 4.4.  Time course of neutrophil phagocytosis of polystyrene beads 
Figure 4.5.  Effect of 4OC or Cytochalasin D on neutrophil phagocytosis of beads 
Figure 4.6a and 4.6b. Effect of incubation time and bacterial concentration on 
phagocytosis of (a) H. influenzae and (b) S. pneumoniae by neutrophils 
Figure 4.7a.  Neutrophil phagocytosis of pHrodo labelled H. influenzae 
Figure 4.7b.  Time course of neutrophil phagocytosis of pHrodo labelled H. influenzae 
Figure 4.8. Effect of disease state on (a) percentage phagocytosis of beads by 
neutrophils and (b) median fluorescent intensity of beads  
Figure 4.9.  Effect of disease state on (a) percentage phagocytosis of S. pneumoniae by 
neutrophils and (b) median fluorescent intensity of S. pneumoniae  
Figure 4.10.  Effect of disease state on (a) percentage phagocytosis of H. influenzae by 
neutrophils and (b) median fluorescent intensity of H. influenzae  
Figure 4.11.  Effect of disease state on the uptake of H. influenzae  
Figure 4.12.  Analysis of neutrophil viability 
Figure 4.13.  Effect of disease state on cell viability of neutrophils  
 18 
Figure 4.14.  Effect of disease on percentage of neutrophils expressing the receptors; 
(a) anti-CD11 (b) anti-TLR2 and (c) anti-TLR4  
Figure 4.15.  Effect of disease state on neutrophil receptor expression; (a) anti-CD11 
(b) anti-TLR2 and (c) anti-TLR4  
Chapter 5 
Figure 5.1. Effect of budesonide or fluticasone propionate on phagocytosis of 
fluorescently labelled beads by MDMs 
Figure 5.2. Effect of budesonide or fluticasone propionate on phagocytosis of 
fluorescently labelled H. influenzae by MDMs 
Figure 5.3. Effect of budesonide or fluticasone propionate on phagocytosis of 
fluorescently labelled S. pneumoniae by MDMs 
Figure 5.4. Effect of budesonide or fluticasone propionate on viability of MDMs 
incubated with fluorescently labelled beads 
Figure 5.5. Effect of budesonide or fluticasone propionate on viability of MDMs 
incubated with fluorescently labelled (a) H. influenzae and (b) S. pneumoniae 
Figure 5.6. MDMs incubated with polystyrene beads for 4 h 
Figure 5.7. MDMs incubated with particulate fluticasone propionate for 4 h  
Figure 5.8. Effect of fluticasone propionate or budesonide on intracellular killing ability 
of MDMs incubated with H. influenzae 
Figure 5.9. Effect of fluticasone propionate or  budesonide on intracellular killing ability 
of MDMs incubated with S. pneumoniae  
Figure 5.10. Effect of budesonide or fluticasone propionate on phagocytosis of 
fluorescently labelled beads by neutrophils 
Figure 5.11. Effect of budesonide or fluticasone propionate on phagocytosis of 
fluorescently labelled H. influenzae by neutrophils 
Figure 5.12. Effect of budesonide or fluticasone propionate on phagocytosis of 
fluorescently labelled S. pneumoniae by neutrophils 
Chapter 6 
Figure 6.1.  Diagram of microtubule polymerisation and depolymerisation 
Figure 6.2. Effects of nocodazole on phagocytosis by MDMs from different subject 
groups 
 





Figure 6.4a and b. Comparison of levels of acetylated tubulin in neutrophils from 
different subject groups 
Figure 6.5. MDMs stained with tubulin tracker showing the cellular location of 
polymerised microtubules 
Figure 6.6.  MDMs stained with tubulin tracker after phagocytosis of pHrodo™ labelled 
S. pneumoniae in the presence of nocodazole or Epothilone B 
Figure 6.7.  Comparison of phagocytosis by MDMs from different subject groups after 
incubation with Epothilone B 
Figure 6.8a and b. Comparison of levels of acetylated tubulin in MDMs from different 
subject groups after incubation with Epothilone B vs. prey alone 
Figure 6.9.  Comparison of phagocytosis by neutrophils from COPD and smokers after 
incubation with Epothilone B 
Figure 6.10.  Investigation of HDAC6 activity in MDMs from different subject groups  
Figure 6.11. Comparison of phagocytosis by COPD MDMs after pre-incubation with 
Tubacin  
Figure 6.12. Effect of HDAC6 inhibitor (tubacin) on levels of acetylated tubulin within 
MDMs 
Figure 6.13. Comparison of phagocytosis by COPD MDMs after incubation with AGK2  
Figure 6.14.  Effect of SIRT2 inhibitor (AGK2) on levels of acetylated tubulin within 
COPD MDMs 
Figure 6.15. Rt-PCR analysis of degree of SIRT2 knockdown after SiRNA transfection  
Figure 6.16. Viability of MDMs after SIRT2 knockdown by SiRNA transfection 
Figure 6.17.  Phagocytosis by transfected COPD MDMs after SIRT2 knockdown  
Figure 6.18.  Rt-PCR analysis of degree of HDAC6 knockdown after SiRNA transfection  
Figure 6.19. Viability of MDMs after HDAC6 knockdown by SiRNA transfection  
Figure 6.20. Western blot of acetylated tubulin levels in COPD MDMs transfected with 
HDAC6 SiRNA  
Figure 6.21.  Phagocytosis by transfected COPD MDMs after HDAC6 knockdown  
Figure 6.22. Rt-PCR analysis of degree of C6orf134 knockdown after SiRNA transfection  
Figure 6.23. Viability of MDMs after HDAC6 knockdown by SiRNA transfection  
Figure 6.24.  Phagocytosis by transfected healthy MDMs after C6orf134 knockdown 
Figure 6.25. Quantitative rt- PCR of C6orf134 in healthy vs. COPD MDMs 
 20 
Figure 6.26a and b. Quantitative rt-PCR of C6 orf134 and HPRT1 in healthy vs. COPD 
MDMs 
Figure 6.27a and b. Effect of C6orf134 knockdown on levels of acetylated tubulin 






















List of Tables 
Chapter 1 
Table 1.1. Classification of severity of COPD  
Table 1.2. Commonest causes of exacerbation in COPD patients 
Table 1.3.  Soluble constituents of airway and alveolar fluid and their role in innate    
immunity 
Chapter 2 
Table 2.1.  Antibody dilutions used for cell surface marker quantification 
Chapter 3 
Table 3.1.  Subject demographics  
Table 3.27 Demographics of the frequent vs. infrequent exacerbators 
Table 3.29 Demographics of the COPD subjects exacerbating during the study 
Table 3.31. Total cell counts in sputum from different subject groups, with differential 
as a percentage of total count 
Chapter 4 
Table 4.1.  Antibody dilutions used for quantification of cell surface receptor 
expression 
Chapter 5 
Table 5.1. Subject demographics 
Chapter 6 







List of Abbreviations 
ACD  Acid citrate dextran 
AM  Alveolar macrophage 
ANOVA Analysis of variance 
BAL   Bronchoalveolar lavage 
BHI  Brain heart infusion 
BSA  Bovine serum albumin 
CD  Cluster of differentiation 
cDNA  Copy deoxyribonucleic acid 
CFU  Colony forming units 
CCL  Chemokine (C-C) motif ligand 
COPD   Chronic obstructive pulmonary disease 
CR  Complement receptor 
CXCL  Chemokine (C-X-C motif) ligand 
DAPI  4’,6-diamidino-2-phenylindole 
DMSO  Dimethylsulphoxide 
DNA  Deoxyribonucleic acid 
dNTPs  Deoxynucleotide triphosphates 
D-PBS  Dulbecco’s phosphate buffered saline 
ECL  Enhancedchemiluminescence 
ECM  Extracellular matrix 
EDTA  Ethylene diamine tetraacetic acid 
ELISA  Enzyme linked immunosorbent assay 
FACS  Fluorescence activated cell sorting 
FcR  Fc receptor 
FCS  Foetal calf serum 
FEV1  Forced expiratory volume in 1 second 
FITC  Fluorescein isothiocyanate 
 23 
FSC  Forward scatter 
FVC  Forced vital capacity 
GM-CSF Granulocyte macrophage-colony stimulating factor 
GOLD  Global initiative for Obstructive Lung Diseases 
GROα  Growth-related oncogene protein α 
HBSS  Hanks’ balanced salt solution 
HDAC  Histone deacetylase 
HI  Haemophilus influenzae 
HLA-DR Human leukocyte antigen DR-1 
HRP  Horseradish peroxidise 
IFN-γ  Interferon-γ 
Ig  Immunoglobulin 
ICAM  Intercellular adhesion molecule 
ICS  Inhaled glucocorticosteroids 
Il  Interleukin 
L-glu  L-glutamine 
LPS  Lipopolysaccharide 
LTB4  Leukotriene B4 
MAPK  Mitogen activated protein kinase 
MCP  Monocyte chemotactic protein 
MDMs  Monocyte-derived macrophages 
MFI  Median fluorescent intensity 
MHC  Major histocompatibility complex 
MMP  Matrix metalloproteinase 
MOPS  3-(N-morpholino) propane sulphonic acid 
MPO  Myeloperoxidase 
mRNA  Messenger ribonucleic acid 
MR  Mannose receptor 
MTT  Methylthiazolydiphenyl-tetrazolium bromide 
 24 
NAD+  Nicotinamide adenine dinucleotide+ 
NE  Neutrophil elastase 
N-fMLP N-formyl-methionyl-leucyl-phenyl-alanine  
NF-κB  Nuclear factor κB 
NHS  National Health Service 
NS  Never smoker  
NTHI  Non-typeable Haemophilus influenzae 
O2
-  Superoxide ion 
OD  Optical density 
PAB  PBS supplemented with BSA and azide 
PAMP  Pathogen-associated molecular patterns  
PBMC  Peripheral blood mononuclear cell 
PE  Phycoerythrin 
PI3K  Phosphatidyl inositol-3 kinase 
PMN  Polymorphonucleocyte (granulocyte)/neutrophil 
PRR  Pattern-recognition receptors  
RNA  Ribonucleic acid 
ROS  Reactive oxygen species 
RPMI  Roswell Park Memorial Institute 
RT  Room temperature 
Rt-PCR  Real time polymerase chain reaction 
S  Smoker 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM  Standard error of the mean 
SiRNA  Small interfering RNA 
SIRT  Sirtuin 
SP  Streptococcus pneumoniae 
SR  Scavenger receptor 
SSC  Side scatter 
 25 
αTAT  α-Tubulin acetyl-transferase 
TGFβ  Transforming growth factor β 
THY  Todd Hewitt broth with yeast extract 
TLR  Toll like receptor 
TNFα  Tumour necrosis factor-α 
Tris  Trizma base 
Tris-HCL Tris hydrochloride 
v/v  Volume by volume 
w/v  Weight by volume 




























1.1 Chronic Obstructive Pulmonary Disease 
Chronic obstructive pulmonary disease (COPD) is an increasing global health problem, 
predicted to become the third commonest cause of death and the fifth most common 
burden of disease worldwide by 2020 (Lopez and Murray, 1998).  
1.1.1 Definition of COPD 
The Global Initiative for Obstructive Lung Disease (GOLD) definition states that 
“Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and 
treatable disease, characterized by persistent airflow limitation that is not fully 
reversible, is usually progressive and associated with an enhanced chronic 
inflammatory response in the airways and the lung to noxious particles or gases.  
Exacerbations and co-morbidities contribute to the overall severity in individual 
patients.  ” (GOLD, 2011).   
 
This condition is diagnosed using spirometry, whereby a ratio of FEV1:FVC of <70%, in 
patients with symptoms of dyspnoea, chronic cough and/or sputum production and a 
history of exposure to risk factors is indicative of COPD.  Reduced lung function 
parameters correlate with disease severity, with GOLD stratifying COPD into four 
stages according to FEV1 percent predicted (Table 1.1) (GOLD, 2011). 
 
GOLD stage FEV1 % predicted values 
I (Mild) >80% 
II (Moderate) 50-80% 
III (Severe) 30-50% 
IV (Very severe) <30% 
 
Table 1.1. Classification of severity of COPD 
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1.1.2 Epidemiology of COPD 
COPD is currently the fifth commonest cause of death in England, resulting in more 
than 25,000 deaths per year (Halpin, 2011).  Despite advances in the management of 
COPD over the last few decades, COPD mortality is increasing, which is in direct 
contrast to other chronic diseases including cancer, heart disease and stroke (Jemal et 
al., 2005).  The overall 5-year survival from diagnosis in mild COPD is 78% in men and 
72% in women, although these survival figures drop in severe disease to 30% and 24% 
respectively (Soriano et al., 2000).  Not only is COPD associated with significant 
mortality, but the burden of the disease to both the patient and to society in general is 
high.  In the ‘Confronting COPD’ survey, 80% of patients reported two or more 
symptoms (breathlessness, cough and sputum production) on all or most days 
(Rennard et al., 2002).  In the UK, COPD imposes a substantial financial burden on both 
the NHS and society, with direct costs, i.e. the provision of healthcare and medication, 
and indirect costs, i.e. loss of productivity and social security costs, estimated to be in 
excess of £1.2 billion per year, with costs correlating with severity of disease (Hilleman 
et al., 2000;Fletcher et al., 2011).  
 
The global prevalence of COPD is estimated to be approximately 10% in adults aged ≥ 
40 years; however, it is likely to be under-diagnosed, as an estimated 45-65% of 
patients with COPD do not seek medical attention as they perceive their symptoms to 
be “normal” (Halbert et al., 2006; Halpin and Miravitlles, 2006).   In developed 
countries, approximately 95% of cases of COPD are cigarette-smoking related, with the 
remainder being secondary to occupational and environmental exposure (Barnes et al., 
2003).  In parts of the developing world, the use of biomass fuel in home cooking is a 
major risk factor for the development of COPD (Zhang and Smith, 2007).  However, 
even after 25 years of smoking, only ~20% of smokers develop COPD, suggesting an 
underlying genetic susceptibility (Rennard and Vestbo, 2006; Lundback et al., 2003).   
COPD is also a risk factor for the development of systemic co-morbidities, including 
cardiovascular disease, depression, osteoporosis, muscle wasting and lung cancer 
(Barnes and Celli, 2009;Decramer et al., 2008).  Individuals with COPD who also have 
elevated circulating C-reactive protein (CRP), have been shown to have an increased 
risk of death from arrhythmias, acute myocardial infarction, stroke and pulmonary 
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embolism (Agusti et al., 2003).  Taken together, the evidence suggests that the 
contribution of COPD to the global health burden is enormous. 
1.1.3 Pathophysiology of COPD 
COPD can be described as comprising three distinct disease processes; (i) chronic 
bronchitis, defined by a productive cough for greater than three months on two 
consecutive years and characterised by mucus hypersecretion; (ii) small airways 
inflammation and remodelling; and (iii) emphysema with destruction of lung 
parenchyma, loss of lung elasticity and closure of small airways (GOLD, 2011).  These 
processes contribute to the chronic airflow obstruction, as measured by a reduction in 
FEV1 and in the ratio of FEV1 to FVC.  These distinct pathophysiological processes 
usually occur in combination in patients with COPD, however, the proportion of 
emphysema to obstructive bronchiolitis may differ between individuals with COPD, 
giving rise to the different phenotypes of COPD seen in clinical practice. 
1.1.3.1 Mucus Hypersecretion 
Accumulation of mucus in the airways results from increased production and secretion 
of mucus together with decreased mucociliary clearance (Burgel and Nadel, 
2008;Randell and Boucher, 2006).  Mucus hypersecretion occurs as a result of 
hyperplasia of epithelial goblet cells and hypertrophy of mucus glands (Innes et al., 
2006).  This is predominant in the larger airways, with the volume of stored mucin 
correlating with reductions in the FEV1/FVC ratio in smokers (Innes et al., 2006).  
However, in contrast to healthy airways, mucus also accumulates in the lumen of small 
conducting airways, with the degree of mucus accumulation closely associated with 
severity of airflow obstruction in COPD (Hogg et al., 2004).  This accumulation of 
airway mucus originally led to the British hypothesis of the 1950-60s, whereby 
recurrent airway infection and mucus hyper-secretion was thought to cause COPD 
(FLETCHER, 1959).  However, a subsequent study found insufficient evidence to 
support a role for bacterial infection in chronic bronchitis (Tager and Speizer, 1975).  
The British hypothesis was further refuted when tobacco smoking was shown to be the 
predominant cause of COPD (Fletcher and Peto, 1977).   More recently, the presence 
of cough and sputum production in smokers with normal lung function has shown no 
 30 
relationship to an increased risk of developing COPD, compared to the risk in healthy 
smokers (Vestbo and Lange, 2002).  However, there is now increasing evidence to 
suggest that excessive mucus production and impaired mucociliary clearance do 
contribute to airway obstruction in COPD (Fahy and Dickey, 2010).  Studies have shown 
that mucus hypersecretion is a risk factor for accelerated decline in lung function 
(Vestbo et al., 1996), with more recent evidence suggesting exacerbations of COPD 
play a direct role in accelerating the decline in FEV1 (Donaldson et al., 2002).  
Therefore, the evidence now suggests that recurrent infection and mucus 
hypersecretion does indeed have a significant role in the progression of COPD. 
1.1.3.2 Chronic obstructive bronchiolitis 
Chronic inflammation and remodelling of the terminal bronchioles, leads to narrowing 
of the small airways (airways <2mm in diameter) resulting in airflow limitation (Hogg et 
al., 2004).  There is increased thickness of the wall of small airways due to epithelial 
metaplasia, goblet cell hyperplasia and submucosal gland hypertrophy (Hogg et al., 
2004).  The degree of small airway wall thickness is related to the progression of 
disease from GOLD stage 1 to 4 (Hogg et al., 2004).  The degree to which the airway 
lumen is filled with an inflammatory exudate, and the number of airways that contain 
acute inflammatory cells organised into follicles, as well as the absolute numbers of B 
and CD8+ T lymphocytes, were all more weakly associated with disease progression, 
suggesting that airway remodelling is the major cause of small airway obstruction 
(Hogg et al., 2004).  The mechanisms of fibrosis in COPD are not well understood, 
though may relate to increased peripheral airway expression of transforming growth 
factor (TGF)-β, which in turn, induces release of connective tissue growth factor (CTGF) 
stimulating collagen deposition in the airways (Barnes et al., 2003; Takizawa et al., 
2001; Ihn 2002). 
1.1.3.3 Emphysema 
Emphysema is defined as permanent destructive enlargement of airspaces distal to the 
terminal bronchioles, leading to airflow limitation resulting from the loss of elastic 
recoil of the lung (Barnes et al., 2003).  Both panacinar and centrilobular emphysema 
may occur in smokers (Kim et al., 1991).  However, the degree of emphysema is poorly 
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reflected by measurement of spirometry, with emphysematous changes often present 
prior to any reduction in FEV1.  Changes in gas transfer are associated with emphysema 
and may precede changes in FEV1 by many years (Gould et al., 1991).  The destruction 
of the parenchyma is thought to be due to excessive proteolytic activity.  This is 
associated with increased inflammatory cell infiltrate, with activated neutrophils and 
macrophages releasing elastolytic enzymes, including neutrophil elastase and matrix-
metalloproteinase-9 (MMP-9), resulting in destruction of lung tissue, leading to 
emphysema (Stockley, 1999;Russell et al., 2002).   
1.1.4 Pharmacotherapy for COPD 
Given the global health burden of COPD, there is the need for therapies directed at the 
underlying pathophysiology of the disease, aimed at slowing disease progression and 
improving mortality.  However, smoking cessation in early disease and home oxygen 
therapy in those with persistent hypoxaemia are the only specific therapeutic 
interventions in COPD that have shown a reduction in mortality (Anthonisen et al., 
2005;MRC, 1981), whilst concomitant use of statins has also been shown to reduce the 
risk of COPD death in a matched cohort study (Frost et al., 2007).  The mainstay of 
current treatment in COPD, the use of long-acting bronchodilators and inhaled 
glucocorticosteroids (Barnes et al., 2003), have not been shown to significantly alter 
mortality (Calverley et al., 2007).  Several large trials examining the impact of inhaled 
therapy (long-acting bronchodilators and inhaled glucocorticosteroids) on lung 
function, mortality and health status, have shown improvements in health status and a 
reduction in the annual decline in FEV1 (Calverley et al., 2003b;Calverley et al., 
2003a;Pauwels et al., 1999;Calverley et al., 2007;Wedzicha et al., 2008).  Combination 
therapy, using a long-acting β2-adrenoceptor agonist in combination with an inhaled 
glucocorticosteroid, has shown greater benefits in reduction of FEV1 (by approximately 
70-90ml) over the use of individual drugs (Calverley et al., 2003b;Calverley et al., 
2003a).  This may simply be related to improved patient compliance, although, there is 
also evidence of synergy, as glucocorticosteroids overcome desensitisation of β2-
adrenoceptors by increasing gene transcription and receptor expression, whilst β2 
agonists increase nuclear translocation and prime the glucocorticoid receptor (Sarir et 
al., 2008).  
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Two large multi-centre studies have shown that combination therapy has a role in 
reducing exacerbation frequency.  The ‘Towards a revolution in COPD health’ (TORCH) 
study demonstrated a 25% reduction in the rate of exacerbations of COPD, in those 
patients taking combination therapy (salmeterol and fluticasone propionate) 
compared to placebo (Calverley et al., 2007). The INSPIRE study, which examined the 
effects of adding tiotropium to combination therapy, confirmed a reduction in 
exacerbation rates compared to both tiotropium alone, and in combination (Wedzicha 
et al., 2008).   
 
The mainstays of treatment for exacerbations of COPD are antibiotics and oral 
glucocorticosteroids (Rabe and Wedzicha, 2011). Systemic glucocorticosteroids given 
in exacerbations of COPD, reduce the length of hospital admission and post-
bronchodilator FEV1 (Davies et al., 1999), however, they have significant side effects, 
including weight gain, elevated blood glucose, hypertension and in the longer term 
cataracts and osteoporosis.  Treatment of exacerbations with glucocorticosteroids, in 
combination with antibiotics, increased the length of time to next exacerbation and 
was associated with reduced mortality (Roede et al., 2008).  The antibiotic study by 
Anthonisen et al, showed that giving antibiotics for exacerbations of COPD gave rise to 
significant benefits, with resolution of exacerbation by 21 days in ~70% of COPD 
patients who received antibiotics compared to 55% taking placebo, together with a 
more rapid improvement in lung function (Anthonisen et al., 1987).  Using antibiotics 
at exacerbation to eradicate bacteria in the airways relates to exacerbation recovery 
and reduction in inflammatory markers (myeloperoxidase and LTB4) in the sputum 
(White et al., 2003).  This suggests that antibiotics are most effective in exacerbations 
associated with increased dyspnoea, sputum volume and purulence in more severe 
COPD (Anthonisen et al., 1987; Daniels et al., 2010).  Therefore, in order to optimise 
the treatment of, and improve outcomes after, exacerbations of COPD, this requires 




1.2 Exacerbations of COPD 
Exacerbations of COPD are described as “an acute event characterized by a worsening 
of the patient’s respiratory symptoms that is beyond normal day to day variations, and 
leads to a change in underlying medication” (GOLD, 2011).   
Acute exacerbations of COPD are the commonest cause of acute medical admission to 
hospital in the UK (Wedzicha and Seemungal, 2007).   Exacerbations are associated 
with significant mortality and are a major determinant of COPD costs, ranging from 40-
63% of the total direct costs associated with COPD, with this increasing with disease 
severity (Hilleman et al., 2000;Halpin and Miravitlles, 2006).  In the UK, the in-hospital 
mortality associated with an acute exacerbation of COPD is 8%, with a further third of 
patients with an acute exacerbation readmitted within 30 days, of which 15% die 
within 90 days (COPD National Audit, 2008).  Recovery from exacerbations is slow, with 
approximately 14% of patients remaining symptomatic at 35 days after the onset of 
exacerbation, whilst in a small proportion of patients (~7%), symptoms never return to 
baseline level after an exacerbation (Seemungal et al., 2000). 
Defining exacerbation frequency is complicated, and there are many reasons for this.  
Firstly, the definition of an exacerbation is unclear, secondly, many exacerbations are 
not reported to health-care professionals and are either self-treated or untreated 
(Seemungal et al., 1998).  Nevertheless, on average, COPD patients experience one to 
two exacerbations annually (Sethi and Murphy, 2008). Exacerbations increase in 
frequency and severity with progression of the disease, as demonstrated by the fact 
that GOLD stage 2 patients have ~0.85 exacerbations/year compared to ~2/year for 
stage 4 patients (Hurst et al., 2010).  Despite the problems in defining and reporting of 
exacerbations, frequent exacerbators are generally characterised as those who 
develop two or more exacerbations per year that require physician intervention.  
These patients display a more rapid decline in FEV1, more frequent hospitalisations and 
worsening quality of life, demonstrating the role exacerbations play in the progression 
of COPD and further supporting the ‘British hypothesis’ (Donaldson et al., 
2002;Seemungal et al., 1998).   More recently the ECLIPSE study showed that, in the 
cohort of COPD patients followed, the mean decline in FEV1 was only 33ml/year, 
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however, there was a large standard deviation and exacerbations were weakly 
associated with an accelerated decline of ~2ml/year (Vestbo et al., 2011). 
1.2.1 Defining an exacerbation - Anthonisen’s criteria 
Anthonisen’s criteria were originally designed to analyse the effects of antibiotics on 
exacerbations, as opposed to defining an exacerbation and guiding patient 
management for which they are often now used  (Anthonisen et al., 1987).  The 
criteria divide patients into three groups according to their symptoms:  
 Type 1 exacerbations were defined as increased or new onset dyspnoea, 
sputum volume and sputum purulence. 
 Type 2 exacerbations require 2 of the above symptoms. 
 Type 3 exacerbations require 1 of the above symptoms, in addition to one of 
the following: 
 Upper respiratory tract infection in last 5 days 
 Increased wheeze 
 Increased cough 
 Fever 
These criteria were used to define the occurrence of an acute exacerbation in the 
COPD patients followed in the present study. 
1.2.2 Causes of COPD exacerbations 
The causes of exacerbations are complex, with the host, viral and bacterial infections, 
and environmental pollution all possibly interacting (Fig. 1.1).   
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Figure 1.1. Causes and effect of exacerbations of COPD 
Bacteria, viruses and pollution are causative factors in exacerbations of COPD, either 
individually or in conjunction with one another.  Exacerbations of COPD are associated 
with increased airway inflammation which drives symptomatology and disease 







































The commonest causes of exacerbation are shown in Table 1.2.  The majority of 
exacerbations of COPD are caused by viral and/or bacterial infections, with bacteria 
present in half of all exacerbations (Sethi and Murphy, 2008).   


















Table 1.2. Commonest causes of exacerbation in COPD patients 
These represent the commonest bacterial, viral and environmental causes of acute 
exacerbations of COPD, adapted from Wedzicha and Seemungal, 2007.    
 
Exacerbations caused by co-infection with virus and bacteria are associated with 
higher levels of inflammatory markers in sputum, including interleukin (IL)-6, CXCL-8 
and myeloperoxidase, compared with those generated by infection caused by either 
bacteria or virus alone (Wilkinson et al., 2006).  The reason for this is unclear, however, 
in vitro studies have shown that infection of bronchial epithelial cells with respiratory 
syncytial virus (RSV) increases expression of intracellular adhesion molecule (ICAM)-1 
and platelet activating-factor (PAF), which promotes increased adherence and invasion 
of non-typeable Haemophilus influenzae (NTHI) and Streptococcus pneumoniae 
(Avadhanula et al., 2006).  Rhinovirus has also been shown to induce ICAM-1 
expression on bronchial epithelial cells (Papi and Johnston, 1999).  ICAM is important 
in the recruitment of neutrophils, which are increased in number in patients with 
COPD during an exacerbation.  Rhinovirus infection of BEAS2b cells activates the 
transcription factor, Nuclear Factor-κB (NF-κB), which is important in the regulation of 
a number of pro-inflammatory genes, including CXCL8 production, which is a potent 
neutrophil chemoattractant (Biagioli et al., 1999).  In addition, rhinovirus infection of 
macrophages reduces their ability to phagocytose bacterial pathogens (Oliver et al., 
2008), which could predispose to co-infection with bacteria.   
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1.2.3 Pathophysiology of COPD exacerbations 
During exacerbations of COPD, neutrophils increase in number in the bronchial wall 
and in broncho-alveolar lavage (BAL) (Balbi et al., 1997;Saetta et al., 1994).  This is 
associated with increased levels of neutrophil chemoattractants, such as CXCL8 and 
leukotriene B4 (LTB4) (Gompertz et al., 2001).  Additionally, levels of neutrophil 
elastase are significantly increased in sputum during exacerbations, and correspond to 
the increased neutrophil count (Fujimoto et al., 2005).  COPD exacerbations are also 
associated with increased serum levels of CXCL8, soluble intercellular adhesion 
molecule (sICAM-1) and E-selectin, the latter two required for neutrophil migration 
from the circulation (Gerritsen et al., 2005). Therefore, inflammation appears to be 
amplified during exacerbation and is associated with increased neutrophil recruitment 
with resultant increased proteinase secretion.  This potentially causes further tissue 
damage and contributes to further progression of COPD (Wedzicha and Seemungal, 
2007;Sapey and Stockley, 2006).  Patients with more frequent exacerbations have 
greater levels of inflammation at both steady state and at exacerbation, with higher 
levels of sputum IL-6 and CXCL8, compared to COPD patients with infrequent 
exacerbations.   
The levels of pro-inflammatory mediators (myeloperoxidase, CXCL8, LTB4 and 
neutrophil elastase) present in the sputum of COPD patients with an exacerbation 
correlate with bacterial load, irrespective of the pathogen present (Hill et al., 2000).  
Isolation of pathogenic bacteria from bronchoalveolar lavage of COPD patients is also 
associated with increased levels of tumour necrosis factor (TNF)-α and higher 
neutrophil counts compared to those from the BAL of culture negative patients (Soler 
et al., 1999).  This suggests that the presence of bacteria in the airways is associated 
with increased inflammation, which, given that some COPD patients display bacterial 
colonisation in the stable state (Rosell et al., 2005; Wilkinson et al., 2006), may explain 
the increased inflammation in COPD airways even at stable state, increasing further 
during exacerbations. 
 38 
1.2.4 Bacterial colonisation in COPD 
Patients with COPD appear to be more prone to respiratory infections, with patients 
exhibiting bacterial colonization of the lower airways in the stable state (Rosell et al., 
2005; Wilkinson et al., 2006).  Protected specimen brush sampling of the lower airways 
showed that approximately 4% of healthy adults had greater or equal to 102 colony-
forming units (CFU)/ml of potentially pathogenic bacteria, compared to 29% of COPD 
patients with stable disease and 54% of COPD patients with an exacerbation (Rosell et 
al., 2005).  Another study of patients with moderate to severe COPD, showed that 
bacteria could be isolated from the lower airways in 48% of stable COPD patients, 
rising to 70% of patients at exacerbation, with an associated increase in bacterial load 
(Wilkinson et al., 2006).  Taken together, these studies imply that bacterial 
colonisation of the lower airway is prevalent in COPD.    Levels of TNF-α and CXCL8, as 
well as neutrophil degranulation products, including myeloperoxidase and neutrophil 
elastase, are elevated in the sputum of COPD patients with bacterial colonisation, 
compared to those without (Bresser et al., 2000).  Numbers of neutrophils and levels 
of CXCL8 and matrix-metalloproteinase (MMP) 9 in BAL have also been shown to be 
elevated in association with bacterial colonisation in COPD (Sethi et al., 2006).   
Despite the presence of colonising bacteria in the airways, it is suggested that 
acquisition of a new strain of bacteria appears to be associated with development of 
an exacerbation (Sethi et al., 2002).  However, bacterial colonisation of the lower 
airway has been shown to be positively correlated with exacerbation frequency and 
concentrations of CXCL8 in sputum (Patel et al., 2002), suggesting that bacterial load 
may drive both exacerbation frequency and neutrophilic inflammation.  Although a 
number of bacterial species have been isolated in the COPD airway (Table 1.2), one of 
the commonest bacteria to be isolated from COPD patients in both the stable state or 
at exacerbation is Haemophilus influenzae.  
1.2.4.1 Haemophilus influenzae 
Haemophilus influenzae is a gram-negative coccobacillus from the family 
Pasteurellaceae.  It is the most common pulmonary pathogen isolated from the 
airways in COPD patients, and is associated with 20-30% of all exacerbations of COPD 
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(Sethi and Murphy, 2008;Sethi et al., 2002).  The presence of H. influenzae within the 
respiratory tract may be underestimated outside of exacerbations, as the presence of 
bacteria is usually derived from positive sputum cultures, however, bacteria at 
concentrations of less than 102 CFU/ml will yield negative cultures.  Furthermore, H. 
influenzae can form biofilms, densely packed communities of cells surrounded by a 
self-produced matrix of extracellular polymeric substance, (Murphy and Kirkham, 
2002), which also reduce the sensitivity of cultures and H. influenzae may also remain 
viable inside host cells thereby evading detection (Forsgren et al., 1994;Murphy et al., 
2004;Craig et al., 2001). Therefore, H. influenzae may be present in the respiratory 
tract despite a negative culture. 
H. influenzae has been found in bronchial mucosal biopsy specimens from 87% of 
exacerbating COPD patients who required intubation, compared to 33% of stable 
COPD patients, but not in healthy subjects (Bandi et al., 2001).  Non-culture-based 
detection techniques, such as quantitative real time polymerase chain reaction (qrt-
PCR) using primers specific for particular bacterial species, identified H. influenzae in 
sputum, bronchial epithelium and inside subepithelial macrophages in COPD patients, 
suggesting that this is a colonising pathogen (Murphy et al., 2004).  Using an in vitro 
model of airway epithelium, this bacterium induced mucus hyper-secretion, reduced 
ciliary beat frequency, caused epithelial damage and enhanced release of IL-6, CXCL8 
and TNF-α (Adler et al., 1986;Wilson et al., 1985;Read et al., 1991;Khair et al., 1994), 
suggesting that this pathogen can cause many features associated with both acute 
exacerbations and the pathogenesis of COPD.   The outer-membrane protein P6 of H. 
influenzae can induce production of both CXCL8 and TNF-α from human monocyte-
derived macrophages (Berenson et al., 2005).  Strains of H. influenzae, isolated from 
COPD patients at exacerbation, have shown increased epithelial cell adherence, 
increased induction of CXCL8 and increased neutrophil recruitment compared to 
colonising strains (Chin et al., 2005).  Therefore, H. influenzae is associated with the 
ability to induce mucus hypersecretion, neutrophil recruitment and release of 
inflammatory cytokines, all of which may drive progression of COPD.  However, H. 
influenzae is not the only bacterial species that is commonly isolated from the COPD 
airway. 
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1.2.4.2 Streptococcus pneumoniae 
Streptococcus pneumoniae is found in the upper airways of healthy individuals and is 
considered a commensal bacterium; however, it is the commonest cause of 
community acquired pneumonia in adults and also causes otitis media and meningitis 
(Sethi, 2001).  Along with H. influenzae, it is amongst the commonest bacteria isolated 
from COPD patients and accounts for up to 10% of bacteria isolated from exacerbating 
COPD patients (Sapey and Stockley, 2006).  It is a Gram-positive, α-haemolytic 
diplococcus, enveloped within a polysaccharide capsule.  This capsule enhances the 
virulence of S. pneumoniae by evading phagocytic killing by leukocytes, as it prevents 
binding of C3b (complement) to the bacterium (Sethi and Murphy, 2001).  In vitro 
studies using epithelial cells have shown that S. pneumoniae induces mucus hyper-
secretion and that the cell wall polysaccharide activates complement and induces 
cytokines, including IL-1β, IL-6 and TNF-α (Adler et al., 1986;Catterall, 1999).  S. 
pneumoniae, in association with Haemophilus influenzae and Pseudomonas 
aeruginosa, can form a biofilm which increases antibiotic resistance and reduces 
culture sensitivity (Domenech et al., 2011), hence, its prevalence may be 
underestimated. 
Why patients with COPD appear to be more susceptible to colonisation with these 
particular bacterial species is unclear, but it may be that the high occurrence of 
bacterial colonisation results from defects in the host innate immune response. 
1.3 The immune system and the lung 
The immune system comprises the innate and adaptive immune systems which 
cooperate to protect the host from infection and invading organisms.  Any failure in 
the normal immune function can have detrimental consequences to the host, and may 
contribute to susceptibility to infection and disease.   
1.3.1 Barrier immunity 
Mechanical barriers are the first line of defence against pathogens entering the 
airways in humans.  Despite continuous exposure to inhaled particles, pathogenic 
bacteria and viruses, typically, the lung is maintained in a healthy state without any 
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overt inflammatory response, suggesting that most pathogens are neutralised prior to 
activation of the adaptive or innate immune system (Chaudhuri and Sabroe, 2008).  
The upper airway is colonised with commensal flora, creating an environment in which 
pathogens are unable to establish (Chaudhuri and Sabroe, 2008).  The mechanics of 
sneezing and coughing are in place to expel inhaled particles and pathogens and the 
lung lining is constantly ‘swept’ clean by the mucociliary system which removes debris 
and pathogens, leading to clearance via the digestive tract (Sabroe et al., 2007).  
Mucus lining the airways, and the fluid lining the alveoli, contain multiple soluble 
constituents which can bind to and by various mechanisms aid in elimination of 
bacteria, as outlined in Table 1.3. 
Soluble constituents  Role 
Lysozyme Lytic to bacterial membranes 
Lactoferrin Excludes iron from bacterial metabolism 
Defensins Released from leukocytes and epithelial 
cells – bind and kill bacteria via pore 
formation or prevention of protein 
synthesis 





Lung surfactant proteins - SP-A, SP-D. 
Serve as opsonins for bacterial products 
(mannose or LPS) to promote phagocytosis, 
Can trigger the complement cascade. 
Also directly inhibit bacterial growth 
Secretory IgA Prevents adhesion of pathogens to mucosal 
surfaces 
Serves as opsonin for bacterial products 
Complement and IgG Serve as opsonins for bacterial products 
Table 1.3.  Soluble constituents of airway and alveolar fluid and their role in innate    
immunity 
 
In addition to mechanical and soluble factors, an effective inflammatory response 
requires specialist cells to neutralise and clear the insult (Chaudhuri and Sabroe, 2008).  
The cellular responses are divided into the innate and adaptive immune systems; 
innate immunity is nonspecific and is activated immediately on host exposure to a 
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pathogen, whilst the adaptive immune system is antigen-specific, designed to 
eliminate a specific antigen, and takes hours to days to initiate protection (Alberts et 
al., 2002).  
1.3.2 Adaptive immunity 
The adaptive immune system consists of the humoral response, mounted by B 
lymphocytes which produce antibodies (IgG, IgM, IgA and IgE), and the cell mediated 
response, consisting of T lymphocytes (Alberts B et al., 2002) (Fig. 1.2).  The adaptive 
immune response is outside the focus of this thesis and, therefore, is outlined only in 
brief below (Fig. 1.2).  The key feature of the adaptive immune response is memory, so 
that when the host is challenged with a repeat infection, the adaptive immune 
response is strong and specific to that pathogen (Alberts et al., 2002).  B and T cells are 
produced in the bone marrow, with T cells travelling to and developing in the thymus 
(Alberts et al., 2002).  B cells, exposed to antigen, become activated, proliferate and 
differentiate into plasma cells, whilst synthesising and secreting antibody.  T cells 
differentiate into either T helper cells, after antigen presentation by MHC class II 
molecules on the surface of antigen-presenting cells, which then produce cytokines to 
regulate either humoral and cell-mediated immunity, or cytotoxic T cells, which bind 
and kill infected cells by inducing apoptosis (Alberts et al., 2002). 
In the COPD lung, cytotoxic T cells are the predominant T cell, with the numbers of T 
cells relating to worsening airflow obstruction and emphysema (Saetta et al., 1998).  
Cytotoxic T cells release proteolytic enzymes such as perforin and granzymes which, 
when activated, cause cell death through apoptosis and necrosis (Cosio et al., 2009).  B 
cells are increased in the large airways of patients with COPD, as well as being found 
organised into lymphoid follicles around smaller airways in severe disease (Hogg et al., 
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Figure 1.2. Adaptive immunity 
Schematic outline of the differentiation, activity and interaction between B and T 
lymphocytes of the humoral and cell mediated adaptive immune system. 
 
 
1.3.3 Innate immunity 
Whilst physical defences and soluble constituents play a role in clearance of pathogens 
from the airways, the cellular components of the innate immune system are 
responsible for the majority of bacterial clearance, with macrophages and neutrophils 
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1.3.3.1 Macrophages in the lung 
Alveolar macrophages (AM) account for approximately 95% of airspace leukocytes, 
with lymphocytes (1-4%) and neutrophils (1%) comprising the remainder (Martin and 
Frevert, 2005).  Therefore, the macrophage is the sentinel phagocytic cell of the innate 
immune system in the lung (Martin and Frevert, 2005).   AM are highly differentiated 
cells that mature locally from blood-borne, bone marrow-derived monocytes 
(Droemann et al., 2005).  AM are long-lived, with evidence that they may survive for 
several months, or even years (Thomas et al., 1976).  AM are avidly phagocytic and are 
responsible for clearance of inhaled particulates and pathogens that reach the alveolar 
space (Martin and Frevert, 2005).  They are also responsible for the generation of 
mediators involved in inflammation, as well as orchestrating the resolution of 
inflammation including the removal of apoptotic cells (efferocytosis), and have a role 
in antigen presentation in the initiation of an immune response, although this role is 
more effectively served by dendritic cells (Droemann et al., 2005;Aderem and 
Underhill, 1999;Chaudhuri and Sabroe, 2008).  Interstitial macrophages (IM) are 
monocyte-derived cells that reside between the pulmonary vasculature and the 
airway.  They are postulated to be precursors of AM as they are smaller in size, display 
less proficient phagocytic ability and oxidant production, but exhibit improved antigen-
presentation compared to AM (Fathi et al., 2001).  At present, it is not clear whether 
IM and AM exist as different populations of macrophages or whether they are purely a 
spectrum of macrophage differentiation. 
There is increasing evidence that macrophages exist as different phenotypes, which 
may respond differently upon exposure to local environmental conditions, similar to 
the Th1:Th2 paradigm in lymphocytes.  Interferon gamma (IFNγ) and cytokines such as 
granulocyte macrophage-colony stimulating factor (GM-CSF) and TNF-α, as well as 
bacterial products, such as lipopolysaccharide (LPS), may elicit ‘classical’ activation that 
is associated with a pro-inflammatory macrophage described as ‘M1’. (Gordon, 2003; 
(Mantovani, 2008).  M1 macrophages are characteristically less phagocytic whilst 
releasing increased levels of inflammatory cytokines and chemokines, such as TNF-α, 
IL-1β, IL-6, IL-12 and CXCL8 and reactive oxygen species (Mantovani, 2008;Chen et al., 
2003).  Alternatively activated macrophages are driven by IL-4 and IL-13 and behave 
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like ‘M2’ macrophages as described by Mantovani (Gordon, 2003; Mantovani 2008).  
Recently the M2 phenotype has enlarged and encompasses several macrophage 
phenotypes, with those activated by IL-4 and IL-13 designated M2a, those activated by 
IL-1β and LPS designated M2b and those activated by IL-10, glucocorticosteroid 
hormones or immune complexes designated M2c (Mantovani, 2008).  In general, M2 
macrophages secrete IL-10 and express high levels of mannose and scavenger 
receptors, and consequently are more phagocytic (Mantovani, 2008).  The key 
properties of M1 and M2 (including all M2 subsets (M2s)) macrophages are shown in 
Figure 1.3.  In the lung, AM are considered to display an M2 phenotype, however, in 
COPD these cells are highly pro-inflammatory and may be skewed towards an M1 
phenotype, due to the presence of TNF-α and LPS.  Latterly, it has been suggested that 
macrophages exist as a spectrum, rather than distinct phenotypes, and may display 




    
Figure 1.3. Macrophage polarisation. 
Key properties and functions of polarised macrophages, with M2 subsets (M2s) 
encompassing the diverse forms of M2 activation.  Adapted from Mantovani A; 
Macrophage diversity and polarisation. Blood, 2006 
 
1.3.3.2 Macrophages in COPD 
Macrophages are increased in number by 5-10 fold in the airways, lung parenchyma, 
sputum and BAL of smokers and patients with COPD, with numbers relating to disease 
severity (Finkelstein et al., 1995;Di et al., 1998).  This increase may arise secondary to 














macrophages (Barnes, 2004).  There are increased levels of CCL2 and CXCL1, both 
monocyte chemoattractants, in sputum and BAL of COPD patients, as well as evidence 
of increased migration of COPD monocytes towards CXCL1 (Traves et al., 2002a;Traves 
et al., 2004).  Macrophage longevity is difficult to determine, though there are reports 
of cigarette particulates being present in alveolar macrophages more than 2 years 
after smoking cessation (Marques et al., 1997).  Macrophages activated by cigarette 
smoke release chemokines (Barnes et al., 2003), leading to the recruitment of 
neutrophils and T lymphocytes.  In vitro studies have shown that macrophages from 
COPD patients release higher levels of CXCL8 at baseline, and after stimulation with 
cigarette smoke media, than macrophages from control subjects (Culpitt et al., 2003).  
Inflammatory cytokines, such as TNF-α, are also found in higher levels in the sputum of 
COPD patients (Keatings et al., 1996).   Therefore, there is evidence that alveolar 
macrophages, present in increased numbers in COPD patients, appear to have a more 
pro-inflammatory phenotype, suggesting they may drive inflammation in COPD. 
Macrophages secrete several elastolytic enzymes including MMP-2, MMP-9, MMP-12 
and cathepsins, which may contribute to airway damage, emphysema and mucus 
hyper-secretion (Barnes et al., 2003) (see Fig. 1.4).  In vitro studies have shown that 
macrophages from COPD patients have greater elastolytic activity at baseline 
compared to those from healthy smokers, with levels increased further by cigarette 
smoke (Di et al., 1998;Russell et al., 2002;Lim et al., 2000).  The predominant 
elastolytic enzyme released by human macrophages appears to be MMP-9 (Russell et 
al., 2002).  AM from COPD patients have been shown to have increased levels and 
activity of MMP-9 compared to controls, with levels further increased by both 
cigarette smoke and LPS (Russell et al., 2002). MMP-9 is strongly evident in 
emphysematous lung at sites of macrophage accumulation (Ohnishi et al., 1998), 
suggesting that MMP-9 released from macrophages contributes to emphysema with 































Figure 1.4. Role of macrophages and neutrophils in the pathogenesis of COPD 
Stimuli, including cigarette smoke, leads to activation of macrophages and release of chemokines, 
recruiting neutrophils, monocytes and CD8+ T cells, and cytokines, reactive oxygen species (ROS), nitric 
oxide (NO
.
) and superoxide anion (O2
-.
) and proteases, particularly matrix metalloproteinases (MMP), 
that contribute to the pathogenesis of COPD. (Transforming growth factor (TGF)-β, Connective tissue 
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1.3.3.3 Neutrophils in the lung 
Neutrophils are produced in the bone marrow and are the predominant granulocyte in 
the circulation (Chaudhuri and Sabroe, 2008).  At sites of infection, neutrophils are the 
first phagocyte to be rapidly recruited, migrating into tissue along a gradient of 
chemotactic factors, such as CXCL8, LTB4 and CXCL1, that are released from epithelial 
cells, macrophages and, in the case of CXCL8, neutrophils themselves (Traves et al., 
2002b;Bazzoni et al., 1991) (Fig. 1.4).   Neutrophil migration from the vascular space 
into the airway lumen occurs by a process of rolling, margination and diapedesis 
(Wagner and Roth, 2000).  Cell rolling is mediated by selectins and ICAM-1 expressed 
on endothelial cells, followed by β2integrin-mediated margination (LFA-1 
(CD11a/CD18) and macrophage-antigen (MAC)-1 (CD11b/CD18)) and diapedesis 
between endothelial cells (Wagner and Roth, 2000). 
Neutrophils exposed to bacterial products (such as N-formyl-methionyl-leucyl-phenyl-
alanine (fMLP) or pro-inflammatory mediators (such as TNF-α and IFNγ) become 
primed and initiate potent anti-microbial responses (Parker et al., 2005).  Pathogens 
are taken up and killed by release of reactive oxygen species and proteases into the 
phagosome.  Neutrophils are short lived, with resolution of neutrophilic inflammation 
occurring by initiation of neutrophil apoptosis, followed by clearance through 
efferocytosis by macrophages (Rossi et al., 2007).  Failure of this mechanism, leads to 
neutrophil necrosis and release of reactive oxygen species and proteases, such as 
neutrophil elastase and cathepsin G, into the airway, with significant associated 
proteolytic damage to the surrounding tissues, contributing to the pathogenesis of 
COPD (Parker et al., 2005).  
1.3.3.4 Neutrophils in COPD 
Sputum and BAL of patients with COPD contains higher numbers of neutrophils 
compared to smoking and non-smoking controls (70% neutrophils in COPD vs. 36% and 
25% in smokers and non-smoking controls respectively), with smaller, but significant, 
increases in the numbers of neutrophils seen in airways and lung parenchyma 
(Keatings et al., 1996;Finkelstein et al., 1995).  Indeed, sputum neutrophilia is a key 
finding in COPD patients (Keatings et al., 1996). The numbers of both circulating 
neutrophils and neutrophils in induced sputum relates to the decline in FEV1 (Keatings 
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et al., 1996;Stanescu et al., 1996).  Circulating neutrophils from COPD patients display 
enhanced chemotaxis, extracellular proteolysis and produce more reactive oxygen 
species when compared to controls (Burnett et al., 1987; Culpitt et al., 2002).  Levels of 
neutrophilic chemotactic factors, such as LTB4, CXCL8 and CXCL1, are also increased in 
COPD airways (Hill et al., 1999;Traves et al., 2002b;Tanino et al., 2002).  In addition, E-
selectin is also upregulated on endothelial cells from COPD patients and this, coupled 
with increased expression of the adhesion molecule MAC-1 (CD11b/CD18) on 
circulating neutrophils, leads to slowing down neutrophils in the circulation, allowing 
for increased migration into, and retention of neutrophils in, airway spaces (Di et al., 
1994b;Yamagata et al., 2007a).  Therefore, there is substantial evidence that there is 
increased recruitment of neutrophils into the lungs in COPD, with numbers of 
neutrophils relating to disease severity, with these cells associated with increased 
proteolytic activity, with further tissue damage and mucus hypersecretion, which in 
turn drives the progression of COPD.  Furthermore, the numbers of circulating 
neutrophils are increased during, and relate to, the severity of exacerbations of COPD 
(Papi et al., 2006).  Levels of CXCL8, LTB4 and neutrophil elastase in the airway are also 
further increased during exacerbations of COPD, and relate to bacterial load (Fujimoto 
et al., 2005;Hill et al., 2000).   
A major role for both macrophages and neutrophils in the innate immune system in 
the lung is the phagocytosis and clearance of inhaled bacterial pathogens.   As both of 
these professional phagocytes are increased in numbers in the lungs of COPD patients, 
with further increases seen at exacerbation, the increased rate of bacterial 
colonisation is suggestive of a defect in the phagocytic process. 
1.4 Phagocytosis 
Phagocytosis is a complex process by which a cell engulfs and removes a foreign 
particle or pathogen.  Many cells are capable of phagocytosis but macrophages and 
neutrophils are deemed ‘professional’ phagocytes (Rabinovitch, 1995).  Phagocytosis 
describes the uptake of particles, larger than 0.5µM in diameter, into cells by an actin-
dependent mechanism (Aderem and Underhill, 1999).  The process of phagocytosis can 
be divided into a series of steps, namely particle recognition, re-arrangement of the 




Figure 1.5.  The process of phagocytosis 
(1) Cell surface receptors recognise and bind particles; (2) induction of actin polymerisation; (3) 
actin-rich membrane extensions reach around the particle, pulling it into the cell, generating a 
phagosome; (4) this undergoes maturation and acidification prior to (a) fusion with a lysosome 
to (b) form a phagolysosome (Aderem, 2003;Aderem and Underhill, 1999).   Ingested particles 
are then destroyed by exposure to reactive oxygen intermediates and degradative enzymes 
(Droemann et al., 2005).  
1.4.1 Particle recognition  
One of the complexities of phagocytosis is the diversity of receptors capable of driving 
this response, with many particles being recognised by more than one receptor, 
receptors with dual functions, such as adhesion and internalisation, and receptor 
synergy (Aderem and Underhill, 1999) (Fig. 1.6).  It is essential that the immune system 
can differentiate pathogens from self and this requires specific recognition of 
conserved pathogen motifs by phagocytic receptors.  These pathogen-associated 
molecular patterns (PAMPs) are recognised by pattern-recognition receptors (PRRs) 
(Janeway, Jr., 1992) leading to phagocytosis.  This can be either pattern based, or occur 
as a result of opsonisation, or as a combination of the two (Aderem, 2003).  PAMPs 
include mannans in yeast walls, formylated peptides in bacteria, LPS on gram-negative 













recognising these motifs include the mannose receptor (MR) and DEC 205, that 
recognize mannons, and β2-integrins, such as CD11b/CD18, and scavenger receptors 
that recognise bacterial surface components (Aderem and Underhill, 1999).  
Components that opsonise the infectious agent before recognition via surface 
receptors include mannose binding protein, surfactant protein A, complement and 
immunoglobulins, which opsonise and are recognised through C1q, surfactant-
associated protein A receptor 210, the complement receptor C3b or C3bi or the Fc 
receptor (FcR) family respectively (Aderem and Underhill, 1999).  
 
 
Figure 1.6. Receptors involved in particle recognition and phagocytosis 
Phagocytic receptor expression on macrophages, with many receptors involved in recognition 
of more than one particle or pathogen.  Receptors involved in direct recognition of particles 
include mannose receptor (MR), scavenger receptors (SR-A, CD36, macrophage receptor with 
collagenous structure (MARCO)), CD14 and Toll like receptors (TLR), which are pattern 
recognition receptors but do not have a role in phagocytosis.  Receptors involved in indirect 
recognition include Fc receptors (FcR) and complement receptors (CR). 
Apoptotic cells 























1.4.1.1 Fc-Receptor and complement receptor mediated phagocytosis 
Current knowledge of macrophage and neutrophil phagocytosis is mostly derived from 
studying FcR-mediated phagocytosis (Lee et al., 2003).  Therefore, FcR-mediated 
phagocytosis will be briefly examined, although the phagocytic prey used in this thesis 
is unopsonised and, thus more likely to be internalised via scavenger receptors; this is 
in order to mimic inhaled particles and pathogens, which are thought less likely to be 
opsonised due to the lack of serum within the lung.  However, in those patients with 
sputum production it is possible that opsonisation may take place in the lower 
respiratory tract as sputum contains opsonins including IgA, IgG and to a lesser degree 
complement (Lever et al., 1985).  In humans, Fc-receptors include FcγRI (CD64), 
FcγRIIA (CD32) and FcγRIII (CD16), with CD16 and CD32 being the predominant 
receptors on resting neutrophils (Lee et al., 2003).  FcRs have cytoplasmic tails 
containing immunoreceptor tyrosine activation motifs (ITAMs).  Ligand binding results 
in receptor cross-linking and tyrosine phosphorylation of ITAMs by src family kinases.  
A second protein tyrosine kinase (Syk) is then recruited to the phosphorylated ITAM 
domain and activated, which in turn triggers particle internalisation by activating 
phosphoinositide (PI)3-kinase and phospholipase C (Aderem and Underhill, 1999).   
Electron microscopy studies have shown differences in internalisation of particles 
opsonised by either IgG or complement (Allen and Aderem, 1996).  During FcR-
mediated phagocytosis, pseudopods extend from the cell, reaching out around the 
particle, before fusing and drawing the particle into the cell (Allen and Aderem, 1996).  
In contrast, in complement receptor (CR)-mediated phagocytosis particles appear to 
sink into the cell, with minimal, if any, pseudopodia formation (Allen and Aderem, 
1996).  Formation of the phagosome in FcR-mediated phagocytosis is blocked by both 
protein kinase (PK)-C and tyrosine kinase inhibitors, whilst CR-mediated phagocytosis is 
blocked by PKC but not tyrosine kinase inhibition (Allen and Aderem, 1996).  In 
contrast to FcR-mediated phagocytosis, CR-mediated phagocytosis requires intact 
microtubules, with nocodazole, a microtubule destabilising agent, inhibiting 
internalisation of complement-opsonised erythrocytes but not those opsonised with 
IgG (Newman et al., 1991).  FcR-mediated phagocytosis appears to trigger release of 
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pro-inflammatory molecules such as reactive oxygen species, again contrasting with 
CR-mediated phagocytosis (Aderem et al., 1985;Wright and Silverstein, 1983). 
1.4.1.2 Scavenger receptor mediated phagocytosis 
Scavenger receptors (SR) are classified, according to their structure, into eight classes 
(A-H) and have been shown to act as PRR, recognising LPS, LTA and yeast zymosan 
(Areschoug and Gordon, 2009).  SRs are phagocytic receptors mediating non-opsonised 
phagocytosis of pathogens by macrophages, and act as co-receptors for the Toll-like 
receptors (TLR) resulting in pro-inflammatory cytokine responses to various PAMPs 
(Hoebe et al., 2005;Jeannin et al., 2005).  MARCO (macrophage receptor with 
collagenous structure) is a member of the class A SR family, which is the dominant 
phagocytic receptor for unopsonised inert particles and gram-positive and gram-
negative bacteria on human AM (Arredouani et al., 2005).  MARCO knockout mice are 
significantly more susceptible to pneumococcal infection than wild-type mice, 
suggesting a role for this receptor in phagocytosis of S. pneumoniae (Arredouani et al., 
2004). Several other SR have also been identified on macrophages, including CD36 
(class B SR), that recognises LTA and acts as a co-receptor for TLR2, with CD36 
knockout mice susceptible to infection with S. aureus (Hoebe et al., 2005).  Treatment 
of monocyte-derived macrophages (MDMs) with nocodazole reduced internalisation of 
non-opsonised latex particles by ~50%, suggesting that phagocytosis via scavenger 
receptors requires intact microtubules, similar to CR-mediated phagocytosis (Sulahian 
et al., 2008).  Inhibition of tyrosine kinases, PKC and PI-3 kinase, all reduced 
internalisation of beads, whilst inhibition of PLC had no effect on internalisation 
(Sulahian et al., 2008), confirming that the signalling pathways that are involved in the 
phagocytic process vary depending on the phagocytic receptor involved. 
1.4.2 Particle internalisation 
Internalisation of particles and pathogens requires activation of signalling pathways 
which in turn leads to rearrangement of the actin cytoskeleton, mobilisation of the 
microtubule network, and fusion of the phagosome with a lysosome to form a 
phagolysosome.  Microtubules appear to play a role in particle internalisation but 
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there is also the requirement for an intact microtubule network for the movement of 
the phagosome (Allen and Aderem, 1996).  
1.4.2.1 Microtubules 
Microtubules are the tracks for the transport of organelles, membrane vesicles and 
secretory granules (Hirokawa, 1998).  In cells in interphase, microtubules are found 
radiating out from the microtubule-organising centre (MTOC) and are required for cell 
division (Araki, 2006).  The function of microtubules is dependent on dyneins and 
kinesins, which are motor proteins that use energy derived from ATP hydrolysis for 
movement (Hirokawa, 1998).  The microtubule system controls vesicular trafficking, 
providing tracks through the cell along which components move (Araki, 2006).  In the 
process of phagocytosis, microtubules appear to play a role in particle internalisation 
via both complement and scavenger receptors, with an additional role of microtubules 
in regulating β2 integrin (part of the complement receptor) mobility and clustering in 
macrophages (Newman et al., 1991).  Furthermore, the movement of the phagosome 
requires an intact microtubule network (Allen and Aderem, 1996). After 
internalisation, the phagosome is transported through the cell, from the periphery 
toward the cell centre and towards the MTOC, fusing with endocytic organelles prior 
to fusion with a lysosome to form a phagolysosome (Allen and Aderem, 1996).   
Microtubules are thought to be required for transporting the phagosome and 
lysosome into close proximity to enable fusion, rather than driving membrane fusion 
directly (Desjardins et al., 1994).  Nocodazole, a microtubule disruptor, inhibited 
movement of the late phagosomes in macrophage phagocytosis, confirming their 
importance in this process (Desjardins et al., 1994).  In neutrophils, the phagosome 
acquires anti-microbial activity through fusion with preformed vesicles and granules 
(Lee et al., 2003).  These include primary (azurophilic) granules characterised by 
myeloperoxidase and secondary (or specific) granules, that are thought to be the main 
source of phagosomal nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 
generating reactive oxygen species which are antimicrobial (Lee et al., 2003).   
Microtubules have been shown to contribute to the localised delivery of primary 
granules to the phagosome, as this can be disrupted by colchicine, a microtubule 
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disruptor, but may not be involved in transport of secondary granules (Tapper and 
Grinstein, 1997).   
1.5 Phagocytosis in COPD 
Studies have shown defective phagocytosis and killing of Candida spp. by alveolar 
macrophages (AM) from COPD patients compared to healthy controls (Ferrara et al., 
1996;Vecchiarelli et al., 1991).  AM from COPD patients also show defective 
phagocytosis of E. coli (Finney-Hayward et al., 2005;Taylor et al., 2010).  Other studies, 
concentrating on commonly isolated respiratory pathogens, have shown significantly 
reduced phagocytosis of non-typeable H. influenzae (NTHI) by AM from COPD patients 
and smokers compared to AM from ex-smokers and healthy controls (Berenson et al., 
2006a;Marti-Lliteras et al., 2009).  Previous work in our laboratory has shown that 
MDMs from COPD subjects also display defective phagocytosis of H. influenzae, as well 
as S. pneumoniae, compared to smokers and healthy controls (Taylor et al., 2010), 
which indicates that this may be an inherent abberation of macrophages from 
susceptible individuals, rather than the result of an environmental exposure.   
Neutrophils from patients with chronic bronchitis have also shown a reduced 
phagocytic index and killing of Candida spp. by approximately 50% in comparison to 
healthy subjects (Fietta et al., 1988).  Cigarette smoking may exacerbate this response, 
since neutrophils from healthy subjects incubated in the presence of cigarette smoke 
extract (CSE) showed significantly reduced phagocytosis of Escherichia coli when 
compared to untreated neutrophils (Prieto et al., 2001).  Similarly, CSE treated 
neutrophils exposed to two different strains of Staphylococcus aureus showed 
significantly reduced phagocytosis (~15%) compared to >60% of control cells (Guzik et 
al., 2011).  This is further supported by data from COPD patients, whereby neutrophils 
show reduced phagocytosis of E. coli compared with cells from healthy controls 
(Stringer et al., 2007). Taken together these data suggest that the phagocytic 
mechanism regulating bacterial removal in COPD may not only be defective in 
macrophages, but may also be defective in neutrophils. 
 
The mechanisms underlying defective phagocytosis have been suggested to be related 
to reduced expression of phagocytic receptors, with both MARCO and the mannose 
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receptor implicated (Baqir et al., 2008; Hodge et al., 2008).  However, prior work on 
monocyte-derived macrophages showed no alterations in receptor expression when 
comparing cells from COPD patients to smoking and healthy controls (Taylor et al., 
2010).  An alternative mechanism involving alterations in PI-3 kinase signalling has also 
been postulated, with the association of reduced phagocytosis of NTHI with reduced 
phosphorylation of AkT, a downstream effector of PI3K (Marti-Lliteras et al., 2009).  
PI3K signalling is required for F-actin accumulation in the periphagosomal region at the 
cell membrane (Greenberg and Grinstein, 2002).  Alterations in PI-3 kinase signalling 
have been demonstrated to play a role in the altered chemotactic ability displayed by 
COPD neutrophils in comparison to healthy and smoker cells (Sapey et al., 2011), and 
this may represent a common defect between chemotaxis and phagocytosis in these 
cells.  The involvement of microtubules in the phagocytic defect present in COPD has 
not previously been investigated; therefore, the present study will focus on the role 




















There is evidence of increased rates of bacterial colonisation in COPD patients in the 
stable state, despite increased numbers of phagocytic cells, namely macrophages and 
neutrophils, in the lower airways.  This suggests that increased levels of bacterial 
colonisation in COPD may be due to defective phagocytosis. 
The hypothesis for this thesis states that defective innate immunity in COPD patients 
leads to a reduction in bacterial phagocytosis and that this defective phagocytosis may 
relate to microtubule instability.   
1.7 Aims 
1. Assess macrophage and neutrophil phagocytosis in COPD, compared to 
controls matched for age and smoking history 
2. Assess the effect of acute exacerbations on the phagocytic ability of 
macrophages 
3. Establish a model of sputum macrophage phagocytosis  
4. Investigate the effects of commonly prescribed inhaled corticosteroids on 
phagocytosis in COPD 































Materials used in this thesis are listed below. 
AGK2 Enzo Life Sciences, Exeter, UK 
Alexa-fluor 488 carboxylic acid Molecular Probes, Invitrogen, Paisley, UK 
Alexa-fluor 488-labelled Goat anti-
mouse IgG 
Molecular Probes, Invitrogen, Paisley, UK 
Alexa-fluor 488-labelled Goat anti-
rabbit IgG 
Molecular Probes, Invitrogen, Paisley, UK 
All stars negative control siRNA Qiagen, Crawley, UK 
Annexin V apoptosis kit Becton Dickinson, Oxford, UK 
Bio-Rad protein assay Biorad, Munich, Germany 
Brain heart infusion broth Fisher Scientific, Loughborough, UK 
β-mercaptoethanol Sigma-Aldrich, Dorset, UK 
Budesonide A gift from Astra Zeneca, Lund, Sweden 
C6orf134 (pool of 4) siRNA Qiagen, Crawley, UK 
Cell dissociation solution Sigma-Aldrich, Dorset, UK 
Cell Lights Tubulin-GFP Molecular Probes, Invitrogen, Paisley, UK 
Cell Lights Actin-RFP Molecular Probes, Invitrogen, Paisley, UK 
Cell tracker red CMPTX Molecular Probes, Invitrogen, Paisley, UK 
Citifluor Sigma-Aldrich, Dorset, UK 
Columbia agar Fisher Scientific, Loughborough, UK 
Costar 96-well black tissue culture 
plates 
Fisher Scientific, Loughborough, UK 
Costar 24- and 96-well tissue culture 
plates 
Fisher Scientific, Loughborough, UK 
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Coverslips Raymond A Lamb, Eastbourne, UK 
Cytochalasin D Sigma-Aldrich, Dorset, UK 
Di-sodium hydrogen citrate 1.5 
hydrate 
VWR International Ltd, Poole, UK 
4´,6-diamidino-2-phenylindole 
dihydrochloride hylrate (DAPI) 
Sigma-Aldrich, Dorset, UK 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich, Dorset, UK 
Dulbecco’s phosphate buffered saline 
(D-PBS) 
Sigma-Aldrich, Dorset, UK 
10x D-PBS Gibco, Invitrogen, Paisley, UK 
ECL detection solution GE healthcare, Buckinghamshire, UK 
ELISA antibodies R&D systems 
Epothilone B Sigma-Aldrich, Dorset, UK 
E.coli (K-12 strain) BioParticles 
(labelled with Alexa-fluor 488) 
Molecular Probes, Invitrogen, Paisley, UK 
FACSflow Becton Dickinson, Oxford, UK 
FACSclean Becton Dickinson, Oxford, UK 
Fluorescently labelled carboxylate 
modified polystyrene microspheres 
(2.0 µm diameter)  
Molecular Probes, Invitrogen, Paisley, UK 
Fluor-de-Lys HDAC activity assay Enzo Life Sciences, Exeter, UK 
Fluticasone propionate A gift from Astra Zeneca, Lund, Sweden 
Foetal bovine serum Gibco, Invitrogen, Paisley, UK 
Formaldehyde Sigma-Aldrich, Dorset, UK 
Full range rainbow molecular weight 
marker 
GE healthcare, Buckinghamshire, UK 
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5% (w/v) Glucose Baxter Healthcare Ltd, Norfolk, UK 
Glycerol Sigma-Aldrich, Dorset, UK 
Haemophilus influenzae Dr Paul Langford (Paediatric Infectious 
Disease, Imperial College, London) 
Haemophilus supplement Fisher Scientific, Loughborough, UK 
Hank’s balanced salt solution Sigma-Aldrich, Dorset, UK 
HDAC6 (pool of 4) siRNA Qiagen, Crawley, UK 
Hemohes 6% (w/v) Braun, Melsungen, Germany 
High Capacity cDNA Reverse 
Transcription kit. 
Applied Biosystems, Warrington, UK 
HiPerfect Qiagen, Crawley, UK 
Horse blood (defibrinated) Fisher Scientific, Loughborough, UK 
HRP-labelled Goat anti-rabbit IgG New England Biolabs, Herts, UK 
HRP-labelled Goat anti-mouse IgG  New England Biolabs, Herts, UK 
Human recombinant GM-CSF R&D systems 
Human recombinant TNFα R&D systems 
Hybond ECL Amersham Pharmacia Biotech, GE 
healthcare, Buckinghamshire, UK 
Hyperfilm ECL Amersham Pharmacia Biotech, GE 
healthcare, Buckinghamshire, UK 
L-glutamine Gibco, Invitrogen, Paisley, U 
Lab-tek Permanox chamber slides Fisher Scientific, Loughborough, UK 
Light green Sigma-Aldrich, Dorset, UK 
LS columns and collection tubes Miltenyi Biotec, Surrey, UK 
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MACS Monocyte isolation kit Miltenyi Biotec, Surrey, UK 
Methanol BDH, Poole, Dorset, UK 
Methylthiazoyldiphenyl-tetrazolium 
bromide (MTT) 
Sigma-Aldrich, Dorset, UK 
Microscope slides Raymond A Lamb, Eastbourne, UK 
Mini complete protease inhibitor 
cocktail tablets 
Roche, Mannheim, Germany 
Mouse anti-human TNFα antibody R&D systems 
Mouse monoclonal anti-acetylated 
tubulin antibody  
Sigma-Aldrich, Dorset, UK 
Mouse monoclonal anti-SIRT2 
antibody 
Sigma-Aldrich, Dorset, UK 
Mouse monoclonal anti-HDAC6 
antibody 
Sigma-Aldrich, Dorset, UK 
Nocodazole Sigma-Aldrich, Dorset, UK 
NuPage MOPS SDS running buffer Invitrogen, Paisley, UK 
Nylon mesh filters Falcon, Oxford, UK 
Paclitaxel Sigma-Aldrich, Dorset, UK 
Paraformaldehyde Sigma-Aldrich, Dorset, UK 
PE mouse anti-human TLR4 antibody eBioscience, Hatfield, UK 
PE mouse anti-human TLR2 antibody eBioscience, Hatfield, UK 
PE mouse anti-human CD11b 
antibody  
eBioscience, Hatfield, UK 
Penicillin Gibco, Invitrogen, Paisley, UK 
Percoll GE Healthcare, Buckinghamshire, UK 
pHrodo dye, succinimidyl ester Molecular Probes, Invitrogen, Paisley, UK 
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Phosphate buffered saline tablets Sigma-Aldrich, Dorset, UK 
Phosphatase inhibitor cocktail 2 Sigma-Aldrich, Dorset, UK 
Polyoxyethylene-sorbitan 
monolaurate (Tween-80) 
Sigma-Aldrich, Dorset, UK 
Polystyrene FACS tubes Becton Dickinson, Oxford, UK 
Protease inhibitor cocktail 1 Sigma-Aldrich, Dorset, UK 
QIAshredder spin column Qiagen, Crawley, UK 
Quick-Diff kit Gentaur, Belgium 
Rabbit monoclonal actin antibody  Cell signalling, New England Biolabs, 
Hertfordshire, UK 
Rabbit monoclonal alpha-tubulin 
antibody  
New England Biolabs, Herts, UK 
Rabbit polyclonal anti-SIRT2 antibody Sigma-Aldrich, Dorset, UK 
Rabbit polyclonal anti-HDAC6 
antibody  
Sigma-Aldrich, Dorset, UK 
RIPA buffer Cell signalling, New England Biolabs, 
Hertfordshire, UK  
RNase-free DNase Qiagen, Crawley, UK 
RNeasy mini RNA extraction kit Qiagen, Crawley, UK 
Roswell Park Memorial Institute 
media (RPMI)-1640 
Sigma-Aldrich, Dorset, UK 
0.9% (w/v) saline Baxter Healthcare Ltd, Norfolk, UK 
Sample buffer, Laemmli, 2x 
concentrate 
Sigma-Aldrich, Dorset, UK 
Saponin Sigma-Aldrich, Dorset, UK 
SIRT2 (pool of 4) siRNA Qiagen, Crawley, UK 
4-12% SDS-PAGE gel Invitrogen, Paisley, UK 
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Sphingosine-1-Phosphate Elisa kit Tebu-Bio, UK 
Sodium azide Sigma-Aldrich, Dorset, UK 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, Dorset, UK 
Sterile needles BDH, Poole, Dorset, UK 
Sterile water Sigma-Aldrich, Dorset, UK 
Streptococcus pneumoniae Dr Paul Langford (Paediatric Infectious 
Disease, Imperial College, London) 
Streptomycin Gibco, Invitrogen, Paisley, UK 
Sulphuric acid (H2SO4) Sigma-Aldrich, Dorset, UK 
Syringes Becton Dickinson, Oxford, UK 
TaqMan probes (C6orf134, SIRT2, 
HDAC6 and HPRT1) 
Applied Biosystems, Warrington, UK 
TaqMan universal mastermix Applied Biosystems, Warrington, UK 
Todd-Hewitt broth Fisher Scientific, Loughborough, UK 
Toludine blue Sigma-Aldrich, Dorset, UK 
Trypan blue BDH, Poole, Dorset, UK 
Triton-X-100 Sigma-Aldrich, Dorset, UK 
Trizma base (TRIS) Sigma-Aldrich, Dorset, UK 
Tubacin Enzo Life Sciences, Exeter, UK 
Tubulin Tracker Molecular Probes, Invitrogen, Paisley, UK 
Vacutainer 6ml K2 EDTA Becton Dickinson, Oxford, UK 
Vectastain ABC elite kit – Mouse IgG Vector laboratories, California, USA 
Venofundin B.Braun, Sheffield, UK 
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2.2.1 Subject selection 
Healthy volunteers and healthy smokers were recruited by the National Heart and 
Lung Institute (NHLI), Imperial College, London.  COPD patients were recruited either 
through the Royal Free Hospital, Pond Lane, London, Wexham Park Hospital, Slough or 
by the National Heart and Lung Institute (NHLI), Royal Brompton Hospital, London.  All 
subjects gave written informed consent as approved by the London Chelsea Ethics 
Committee (Ethics number 08/H0706/08).  
2.2.1.1. Healthy volunteers 
The inclusion criteria for healthy volunteers were: age 40-80 years, no history of 
respiratory disease or co-morbidity, never smokers, with normal lung function as 
predicted for sex, age and height and no evidence of atopy on skin prick tests to 
common aero-allergens. 
2.2.1.2. Smokers 
The inclusion criteria for healthy smoking volunteers were: age 40-80 years, no history 
of respiratory disease or co-morbidity, current smokers with a smoking history of >10 
pack years (where one pack year is defined as smoking one pack of cigarettes per day 
for one year) with normal lung function as predicted for sex, age and height, no 
reversibility and no evidence of atopy on skin prick tests to common aero-allergens. 
2.2.1.3. COPD patients 
The inclusion criteria for COPD patients were: aged 40-80 years, no history of other 
respiratory disease or major co-morbidity, smoking history of >10 pack years and no 
evidence of atopy on skin prick tests to common aero-allergens.  Lung function: FEV1% 
predicted <80%, FEV1:FVC ratio <0.7 and reversibility of <200ml in FEV1 (<15% FEV1% 
predicted) to inhaled β2 agonist.  In addition, for baseline samples no history of 




2.2.2  Clinical measurements 
Clinical measurements were either performed by either myself, nursing staff or lung 
function technicians at the NHLI, Royal Brompton Hospital, Royal Free or Wexham Park 
Hospital. 
2.2.2.1. Spirometry 
Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were 
measured using a spirometer (Vitalograph, Buckingham, Bucks, UK).  Values were 
taken as the best of three reproducible attempts.  Values are expressed either as 
absolute volume or as percentage predicted based on sex, weight and height and 
calculated by software (based on Crapo tables; Crapo et al., 1981).  
2.2.2.2. Reversibility 
Reversibility testing was performed according to BTS guidelines.  Subjects performed 
spirometry as outlined above (section 2.2.2.1), then were given a nebulised solution of 
salbutamol 2.5mg.  After 20 min, spirometry was performed once again.  A significant 
response was defined as a change of over 15% from the baseline FEV1 that also 
exceeded 200ml in absolute terms  (1997). 
2.2.3 Blood Separation 
Human subjects gave 60ml of whole blood by venepuncture.  Whole blood was mixed 
(1:1) with 20ml 6% (w/v) Hemohes and 5ml 0.9% (
w/v) saline and incubated at room 
temperature for 45 min to sediment red blood cells.  The top, leukocyte-rich, layer was 
aspirated and washed twice with Dulbecco’s phosphate buffered saline (D-PBS) by 
centrifugation (400 x g for 10 min).   
The resulting cell pellet contains a mixture of leukocytes, therefore, Percoll gradients, 
were used to separate the polymorphonuclear (PMN) cell fraction from the peripheral 
blood mononuclear cell (PBMC) fraction.  A 100% (v/v) Percoll solution was prepared 
using 10% (w/v) 10x PBS.  Using this solution, Percoll fractions of 81% (
v/v), 68% (
v/v) and 
55% (v/v) in 1x D-PBS were prepared.  To prepare the gradients, 4ml of 81% (
v/v) 
solution was transferred into a 15ml Falcon tube, followed by 4ml of 68% (v/v) solution.  
The cell pellet was resuspended in 3ml of the 55% (v/v) solution and overlaid onto the 
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gradient.  The cell fractions are then separated according to density by centrifugation 
at 750 x g for 25 min, at room temperature.  The PBMC fraction was harvested from 
the 55% (v/v) /68% (
v/v) Percoll interface and the granulocytes from the 68% (
v/v) /81% 
(v/v) Percoll interface. Any red blood cells in the PMN fraction were lysed using 1ml ice 
cold sterile water; cells were resuspended in water for 10 sec before adding 49ml D-
PBS. Both cell fractions were washed with D-PBS and resuspended in 1ml of RPMI 1640 
medium.  Cell counts were performed using a Neubauer haemocytometer, after 
staining with 1:100 Kimura stain (0.05% (v/v) toludine blue, 0.03% (
v/v) light green, 10% 
(v/v) saponin, 0.7M phosphate buffer). 
The granulocyte fraction was resuspended at 1x106cells/ml in RPMI 1640 medium and 
allowed to rest for 1h at 4oC to reduce neutrophil activation. In some experiments, the 
PBMC fraction was divided into two equal parts to allow for comparison of different 
techniques for the isolation of monocytes as indicated (see sections 2.2.3.1 and 
2.2.3.2).   
2.2.3.1 Separation of monocytes by adherence  
PBMC were resuspended at 1x106monocytes/ml in complete medium (RPMI 1640, 
10%  (v/v) FBS, 10mg/ml (1% (
v/v)) penicillin/streptomycin, 2mM (1% (
v/v)) L-glutamine), 
transferred to 96 well black plates at 100µl/well and incubated at 37oC, 5% (v/v) CO2 for 
2h to allow adherence of monocytes.  Media and non-adherent cells were aspirated 
from the plate and fresh media containing GM-CSF (2ng/ml) was added.  Cells were 
incubated at 37oC, 5% (v/v) CO2 for 12d, with fresh media containing GM-CSF added on 
d4 and d8. 
2.2.3.2 Separation of monocytes by negative selection 
Monocytes were isolated from the PBMC fraction by negative selection using the 
Miltenyi Monocyte Isolation Kit II as per manufacturer’s instructions.  The resulting cell 
suspension was centrifuged and resuspended in 1ml complete medium (containing 
GM-CSF at 2ng/ml) and cells counted.  The cells were then resuspended at 
1x106cells/ml in complete medium containing GM-CSF (2ng/ml) and transferred to 96 
well black plates at 100µl/well and incubated for 12d as described in section 2.2.4.1. 
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2.2.3.3 Protein assay 
Cells were lysed using a freeze thaw technique and then supernatants (1µl) were 
added in triplicate to a 96 well plate.  To produce a standard curve, 1mg/ml BSA was 
diluted in D-PBS (0.125-1mg/ml).  200µl of Bradford protein assay solution (diluted 1:5 
in distilled water (dH2O)) was added to each well and the absorbance read at λ595nm.  
A standard curve was plotted and unknown protein concentrations interpolated (level 
of sensitivity given by the standard curve was 0.0625mg/ml protein).  Interpolated x 
values were then multiplied by 5 to account for the dilution factor and protein 
concentrations derived.  





















Figure 2.1.  Protein standard curve used to derive unknown protein concentrations. 
BSA was diluted in D-PBS to given concentrations from 0.2-1mg/ml. Bradford protein 
assay reagent was added and the absorbance read at λ595nm.  Values were plotted to 
give a standard curve, from which unknown protein concentrations can be calculated. 
2.2.3.4 Viability assay 
Cell media was aspirated and 100µl of methylthiazoyldiphenyl-tetrazolium bromide 
(MTT) solution (1mg/ml) added to each well.  The plates were incubated at 37oC for 30 
min, then, after aspirating the MTT solution, 100µl of DMSO was added per well.  
Absorbance was then measured on the spectrophotometer at λ570nm.  Data was 
normalised to the viability of control cells (given as 100%), to give a measure of 
viability compared to untreated cells. 
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2.2.4 Sputum induction and processing 
Sputum induction was carried out as described by Pavord et al (Pavord et al., 1997).  
Subjects performed spirometry, followed by administration of 7ml 3% (v/v) saline using 
an ultrasonic nebuliser.  Spirometry was re-measured after each saline nebuliser – if 
FEV1 fell by <10% the process was continued using 4% (
v/v) and 5% (
v/v) saline.  
However, if the FEV1 fell >10% but <20%, nebulisation with 3% (
v/v) saline was 
repeated.  If the FEV1 fell by >20% the process was discontinued.  Patients were 
allowed to expectorate sputum at any point during induction, with the 
recommendation that prior to expectoration, the subject blew their nose, rinsed their 
mouth and then expectorated sputum into a sterile container. 
Sputum was stored and processed on ice within 2 h of obtaining sample.  Sputum plugs 
were selected from the whole sample of sputum obtained, weighed and an equal 
volume of D-PBS was added and mixed by inversion. Dithiothreitol (DTT) was added to 
give a final concentration of 0.05% (w/v).  The sample was rocked on a bench rocker at 
room temperature for 30 min, prior to filtering through 100µm nylon gauze.  The 
resulting filtrate was then centrifuged at 400xg for 10 min.  Supernatants were 
aspirated and stored at -80oC.  The cell pellet was washed in D-PBS, resuspended in 
1ml complete media containing amphotericin (1% v/v) and differential cell count 
performed. Viability was confirmed using trypan blue, with samples discarded if <70% 
viability. To confirm that the sample was from the lower respiratory tract, squamous 
cells should represent <10% of total cell count; those with >10% squamous cells were 
discarded.  Cell suspensions were adjusted to 1x106macrophages/ml with RPMI and 
100µl added to FACS tubes for use in phagocytosis assays.  Cytospins were performed 
with 50µl of cell suspension, air dried and stored at -80oC. 
2.2.5 Bacterial Culture 
2.2.5.1 Streptococcus pneumoniae 
Frozen cultures of S. pneumoniae serotype 9V, strain 10692 (strain taken from a COPD 
patient in exacerbation) were streaked onto a Columbia blood agar plate and 
incubated at 37oC and 5% (v/v) CO2 overnight.  The following morning, 20ml aliquots of 
Todd-Hewitt broth containing 5% (v/v) yeast extract (THY broth) were inoculated with 
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single colonies of bacteria from the plate.  The inoculated broth was incubated in a 
shaker incubator at 37oC, 200 rpm; each hour 1ml aliquots were taken for optical 
density (OD) readings at λ600nm.  Additionally, serial dilutions of the bacteria were 
plated on blood agar plates and incubated overnight at 37oC.  The following day 
colonies were counted and colony forming units (CFU)/ml calculated:   
CFU/ml = (Number of colonies on plate) x dilution factor 
(Amount plated (ml))  
The turbid broth was divided into fresh universal tubes (2ml of inoculated broth added 
to 18ml fresh THY broth) and bacteria incubated at 37oC, 200 rpm.  Once the cultures 
reached an optical density of 1.2 (Fig. 2.2) the bacteria were harvested by 
centrifugation at 1600xg for 15 min, then resuspended in D-PBS.  The bacteria were 
then heat killed in a water bath at 70oC for 2 h, followed by washing twice. To 
determine the efficiency of heat killing, 100µl of bacterial suspension was plated for 
overnight incubation at 37oC; a colony count of zero was taken as adequate heat 
killing. 


















Figure 2.2. Growth curve of Streptococcus pneumoniae with optical density plotted 
against colony forming units at each time point 
Bacteria were inoculated into THY broth and incubated at 37oC.  At hourly time points, 
1ml aliquots were taken for optical density reading (λ600nm), serial dilution, plating 
and then overnight incubation, before colony counting and calculation of CFU/ml.  
CFU/ml was plotted against OD. The linear portion of the graph (where growth is 
exponential) was used to derive a CFU/ml for a given OD for subsequent bacterial 
cultures. 
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2.2.5.2 Haemophilus influenzae 
H. influenzae was grown using the a similar method as described for S. pneumoniae 
(section 2.2.5.1); briefly, a frozen stock of Non-typeable H. influenzae strain 1479 
(taken from a COPD patient during exacerbation) was plated on Columbia agar 
supplemented with bovine hemin and NAD+ (10µg/µl) and incubated overnight before 
being inoculated into brain heart infusion (BHI) broth with bovine hemin and NAD+ 
(10µg/µl).  Standard growth curves were derived and bacteria were subsequently 
cultured to a given OD (Fig. 2.3) before heat killing as described in section 2.2.5.1. 

















Figure 2.3. Growth curve of Haemophilus influenzae with optical density plotted 
against colony forming units at each time point 
Bacteria were inoculated into BHI broth and incubated at 37oC.  At hourly time points, 
1ml aliquots were taken for optical density reading at λ600nm and serial dilutions 
followed by plating and incubation overnight, before colony counting and calculation 
of CFU.  CFU/ml was plotted against OD. The linear portion of the graph (where growth 
is exponential) was used to derive a CFU/ml for a given OD for subsequent bacterial 
cultures. 
 
2.2.6 Fluorescent labelling of bacteria 
2.2.6.1 Labelling of bacteria with Alexa-fluor 488 dye 
Heat-killed bacteria were resuspended in 1ml sodium bicarbonate buffer (8.4g NaHCO3 
in 100ml distilled water) before adding 10µl Alexa-fluor 488 dye ((ex λ488nm/em 
λ520nm) reconstituted in DMSO (1mg/ml)). Bacteria were then rotated overnight, in 
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the dark, at room temperature. Bacteria were then washed repeatedly in D-PBS to 
remove unbound dye, resuspended in D-PBS and stored at -20oC.  
2.2.6.2 Labelling bacteria with pHrodo™ dye 
Bacteria were resuspended in 750µl of freshly prepared 100mM sodium bicarbonate 
solution.  Stock solution of amine-reactive pHrodo SE (10mM in DMSO) was then 
added to give a final concentration of 0.5mM.  Bacteria were incubated for 45 min in 
the dark, at room temperature.  The bacteria were then washed in HBSS by 
centrifugation (15000xg, 60 s), the supernatant aspirated and bacteria resuspended in 
1ml of 100% methanol.  The bacteria were once again centrifuged (15000 x g, 60 s), 
the supernatant aspirated and resuspended in 1ml HBSS for a further two washes. 
Finally the bacteria were resuspended in 1ml of HBSS and stored at 4oC in the dark. 
2.2.6.3 Labelling of live bacteria 
Bacteria were harvested by centrifugation (1600xg, 15 min), then resuspended in a 
working solution of broth containing CellTracker Red CMPTX dye (ex λ577nm/em 
λ602nm) to give a final concentration of 12.5µM, followed by incubation at 37oC for 45 
min.  The working solution was then replaced with pre-warmed fresh broth for 30 min.  
Bacteria were washed repeatedly in D-PBS to remove free dye and stored at -20oC.  
2.2.7 Phagocytosis Assays 
2.2.7.1 Phagocytosis of Beads 
Fluorescently labelled carboxylate-modified polystyrene microspheres (2.0µm 
diameter, yellow-green fluorescence (ex λ505nm/em λ515nm)) were diluted in RPMI 
media to concentrations indicated. 
MDMs:  Bead solutions (100µl) were added to wells containing 1x105 macrophages and 
incubated at 37oC, 5% (v/v) CO2 for the times indicated.  After incubation, unbound 
beads were washed off with D-PBS.  Fluorescence of extracellular particles was 
quenched by adding 100µl/well Trypan Blue (1% (v/v)) for 1 min. Excess fluid was 
removed and fluorescence determined by fluorimetry (BMG Fluostar plate reader) at 
excitation λ480nm and emission λ520nm. 
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Neutrophils:  Bead solutions (900µl) were added to FACS tubes containing 1x105 
neutrophils and incubated at 37oC, 5% (v/v) CO2 for the times indicated. After 
incubation, tubes were placed on ice to quench phagocytosis, then washed twice 
(400xg, 5 min, 4oC) with ice cold D-PBS.  Cell pellets were resuspended and fixed in 
300µl FACSfix (0.5% (v/v) paraformaldehyde in FACSflow) ready for analysis.  Samples 
were analysed using a Becton Dickinson FACSscan machine using CellQuest software.  
Cells were gated according to forward and side scatter values correlating to 
neutrophils (Fig. 2.4) and for each analysis 10,000 events were collected. 
 
Figure 2.4. FACS dot plot showing a neutrophil population  
Cell populations were gated according to properties of forward scatter (cell size) and 
side scatter (cell density).  10,000 gated events were collected for analysis. 
 
FACS analysis of neutrophil phagocytosis shows a shift in the cell population to the 
right; as beads are taken up into cells, each cell becomes more fluorescent, the 
average fluorescence of the cell population increases (denoted as the median 
fluorescent intensity (MFI)) and the histogram moves to the right along the x-axis (Fig. 
2.5).  Percentage phagocytosis is calculated as the percentage of cells that have taken 
up ≥1 bead or bacteria and moved out of the control population.  Further analysis of 
neutrophil phagocytosis of beads by FACS can discriminate between the numbers of 










Figure 2.5. Neutrophil phagocytosis of polystyrene beads – quantified by flow 
cytometry. 
Neutrophils were incubated with 900µl of 50x106beads/ml for 15 minutes. 
Fluorescence of internalised beads was detected by FACS analysis. ■ denotes control 
population of neutrophils, ■ denotes neutrophils that have undergone phagocytosis of 
beads.  Neutrophils that ingest fluorescently-labelled beads increase in fluorescence, 
therefore the population shifts to the right along the x-axis.  Different peaks on the 
histogram plot represent increasing numbers of beads phagocytosed/cell. The average 
fluorescence of the population that has undergone phagocytosis is denoted as the 
median fluorescent intensity (MFI) - this gives a measure of the amount of prey taken 
up. Data shown are representative of n=4. 
 
2.2.7.2 Phagocytosis of Bacteria 
Bacteria were sonicated for 1 min prior to use to prevent aggregation.  Bacteria were 
diluted to the appropriate concentrations in D-PBS.  For MDMs phagocytosis assays, 
100µl of bacterial suspension was transferred to wells, whilst for neutrophil assays 
900µl of bacterial suspension was added to FACS tubes and incubated, washed and 
analysed as described above. 












2.2.8 Measurement of TNF-α from cell supernatant 
Measurement of TNF-α was performed using ELISA according to manufacturer’s 
guidelines.  Briefly, 96 well NUNC Maxisorp plates were coated with 1μg/ml 
(100μl/well) mouse anti-human TNFα antibody (capture) diluted in sterile PBS. The 
plates were incubated overnight at room temperature.  The capture antibody was 
removed and the plates were blocked with blocking buffer containing 1% (w/v) BSA, 5% 
(w/v) sucrose and 0.05% (
w/v) sodium azide (150μl/well), for 2 h at room temperature. 
Blocking buffer was removed and standards of human recombinant TNFα were added 
to appropriate wells. Cell supernatants from MDMs after 4h phagocytosis of 
beads/bacteria were diluted; 1:2 (control and beads); 1:5 (S.pneumoniae); 1:40 
(H.influenzae). The plates were incubated for 2 h at room temperature. Plates were 
washed three times in wash buffer (PBS containing 0.05% (v/v) Tween20) then 
detection antibody was added to all wells at a concentration of 0.1μg/ml before a 
further 2 h incubation at room temperature.  Plates were washed and 100μl 
streptavidin-horseradish peroxidase (HRP) added to each well, diluted 1:200 from 
stock solution. The plates were incubated for 20 min at room temperature. The plates 
were washed and 100µl substrate solution was added to each well (equal volumes of 
Colour Reagent A (H2O2) and Colour Reagent B (Tetramethylbenzidine) mixed directly 
before addition to plates).  The reaction was stopped by the addition of 50 μl/well 1M 
sulphuric acid. 
The optical density of each well was determined in a spectrophotometer, read at 
λ450nm, while subtracting values at λ650nm to account for imperfections in the plate, 
and concentrations of cytokines were derived from extrapolation from standard curves 
(level of sensitivity of standard curve 31.25pg/ml TNF-α). 
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Figure 2.6.  Standard curve used to derive unknown concentrations of TNF-α 
TNF-α standard was diluted in D-PBS to given concentrations from 31.25-2000pg/ml. 
Plates were incubated with detection antibody (0.1μg/ml) for 2 h prior to addition of 
HRP for 20 min.  Substrate solution was then added to each well and the reaction 
stopped by addition of 50 μl/well 1M sulphuric acid. The absorbance was read at 
λ450nm.  Values were plotted to give a standard curve, from which unknown TNF-α 
concentrations can be calculated.   
 
2.2.9 Western blotting  
Neutrophil cell pellets, containing 107 cells, were snap frozen in liquid nitrogen, before 
lysis directly into sample buffer (4% (w/v) SDS, 20% (
v/v) glycerol, 10% (
v/v) 2-
mercaptoethanol, 0.004% (w/v) bromphenol blue, 0.125M Tris-HCl) followed by boiling 
for 5 min, snap freezing and storage at -80oC.  MDMs cell pellets were washed in ice-
cold D-PBS prior to lysis in 25µl/well RIPA buffer (20mM Tris-HCl, 150 mM NaCl, 1mM 
Na2-EDTA, 1mM EGTA, 1% (
v/v) Triton-X, 1% (
w/v) sodium deoxycholate, 1% (
w/v) NP-40, 
2.5mM sodium pyrophosphate, 1µg/ml leupeptin) with added protease inhibitor 
cocktail and phosphatase inhibitors, before storage at -80oC.   
 
2.2.9.1 Gel Electrophoresis 
MDMs lysates were centrifuged at 1600 x g for 3 min and the resulting supernatants 
used to measure protein levels (see section 2.2.3.3). Equal protein concentrations of 
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each sample (20µg made up to 30µl of sample buffer), were then boiled for 3 min prior 
to loading onto the gel. 
SDS-PAGE gels (4-12%) were used for separation of proteins according to molecular 
size.  Gels were secured in a gel tank along with MOPS running buffer (250mM MOPS, 
250mM Tris, 5mM EDTA, 1% (w/v)  SDS).  7.5µl of a molecular weight rainbow marker 
was added to the gel.  25µl of each sample was loaded into individual wells of the gel.  
The gel tank was then connected to a power source and proteins were resolved at 120 
mA and 120V for 2 h. 
2.2.9.2 Transfer of protein to nitrocellulose 
Transfer cassettes were assembled containing two sponge pads, between which were 
placed four sheets of filter paper, all soaked in transfer buffer (0.191M glycine, 0.02M 
Tris-HCl, 20% (v/v) methanol).  The gel and Hybond nitrocellulose membrane were 
placed between the filter paper and the cassette closed.  The cassettes were placed 
into the transfer tank, along with an ice block, and transfer buffer was added. Proteins 
were transferred from gel to nitrocellulose at 200mA, 200V for 1 h. 
2.2.9.3 Immunoblotting 
In order to minimise non-specific binding of the antibodies to the membrane, the 
membrane was blocked by washing in 5% (w/v) milk dissolved in TBS-Tween 20 (0.5M 
Tris base, 9% (w/v) NaCl, 0.5% (
v/v) Tween 20) for 1 h at RT.  Blocking solution was then 
replaced with fresh 5% milk/TBS-Tween 20 containing a primary antibody against the 
protein of interest, prior to incubation for 16 h at 4oC.   
The membranes were washed repeatedly in TBS-Tween 20 then incubated with fresh 
5% (w/v) milk/TBS-Tween 20 containing an appropriate HRP-conjugated secondary 
antibody and incubated for 1 h at RT.  The membranes were washed repeatedly in TBS-
Tween 20, blotted, and then incubated with 10ml enhanced chemiluminescence (ECL) 
detection solution for 1 min at RT.  After blotting, the membranes were wrapped in 
clingfilm and exposed to Hyperfilm for appropriate times, prior to the films being 
developed using an AFP imaging developer. 
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2.2.10 Measurement of expression of cell surface markers 
For flow cytometric analysis of surface markers, neutrophils were resuspended at 
1x106cells/ml in D-PBS, with 100µl added to each FACS tubes.  Antibodies were then 
added at the dilutions specified in Table 2.1, according to manufacturer’s 
recommendations: 
Antibody Dilution 
Isotype control (0.2mg/ml) 1:10 
Anti-CD11b (0.2mg/ml) 1:10 
Anti- TLR2 (0.2mg/ml) 1:10 
Anti- TLR4 (0.4mg/ml) 1:20 
Table 2.1.  Antibody dilutions used for cell surface marker quantification 
Cells were then incubated for 30 min at 4oC in the dark, prior to washing with ice-cold 
PAB (D-PBS with 5% (w/v) BSA and 0.1% (
w/v) sodium azide) then fixed for immediate 
analysis. 
 
2.2.11 Confocal Microscopy 
2.2.11.1 Confirmation of phagocytosis by MDMs 
Monocytes (2x105) were cultured directly on Lab-tek Permanox chamber slides and 
differentiated into MDMs by incubation for 12 d in media containing GM-CSF (2ng/ml) 
(see section 2.2.3).  Fluorescently labelled beads or bacteria were added to chambers 
and incubated for 4 h.  Particles or bacteria not internalised were removed by 
aspiration and chambers washed repeatedly with D-PBS.   
Cells were then incubated at 37oC for 45 min in a working solution of media containing 
CellTracker Red CMPTX dye (12.5µM).  The working solution was then replaced with 
appropriate pre-warmed media for a further 30 min.  Cells were then fixed by 
incubating with 4% (w/v) paraformaldehyde for 15 min.  Cells were then washed with 
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D-PBS and the nuclei stained by incubation with DAPI (2µM) for 3 min.  Following 
repeated washing in D-PBS, the chambers were removed from the microscope slides 
and a coverslip mounted using Citifluo.  Slides were stored at 4oC in the dark. 
2.2.11.2 Staining with Tubulin Tracker™ 
MDMs were cultured directly on Lab-tek Permanox chamber slides (see section 2.2.3) 
and fluorescently labelled beads or bacteria were added to chambers and incubated 
for 4 h.  Particles or bacteria not internalised were removed by aspiration and 
chambers washed repeatedly with D-PBS.  Cells were then incubated with Tubulin 
Tracker (Invitrogen, UK), 250nM in RPMI media, for 30 min at 37oC, prior to fixation 
with 4% (w/v) paraformaldehyde in D-PBS.  After washing with D-PBS, slides were 
incubated with diaminidino phenylindole (DAPI) at 2µM in PBS for 3 min.  After further 
washing, slides were air dried, then mounted with citifluo and stored at 4oC in the 
dark, or visualised immediately. 
2.2.11.3 Visualisation 
Slides were viewed on a Leica SP2 upright confocal microscope with images of the 
three stains overlaid using VolocityTM software.  In order to visualise internalisation of 
the particles, images were taken at sequential slices then remodelled into orthogonal 
views using VolocityTM software. 
2.2.12 Live imaging 
MDMs were cultured as described in section 2.2.3.  MDMs in black microplates with 
clear bottoms were viewed on a heated stage.  Fluorescent phagocytic prey (diluted in 
media) was then added to wells of interest and the cells imaged with a Zeiss LSM-510 
inverted confocal microscope.  Images and videos were analysed and edited with 
VolocityTM software. 
2.2.13 Knockdown 
MDMs were transiently transfected with siRNA using the HiPerfect method (Qiagen, 
Crawley, UK).  In all experiments two controls were used; untransfected cells and cells 
transiently transfected with equal concentrations of a negative control (scramble) 
siRNA. 
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MDMs were cultured in both 24 and 96 well plates as described in section 2.2.3.  
Supernatants were aspirated and 30 µl or 100 µl of RPMI media added per well to 96 
and 24 well plates respectively.  siRNA (see Appendix A) was reconstituted in RPMI 
media as follows; for 24 well plates, 750ng of each siRNA was added, giving a total of 
3µg siRNA, in a volume of 100 µl per well, whilst for 96 well plates, 250ng of each 
siRNA (total 1µg) was added in a volume of 30µl per well.  Hiperfect (1µl/well for 
96well plates and 6µl/well for 24 well plates) was then added and the samples briefly 
vortexed, then rested for 10 min to form complexes.  In a dropwise fashion, 30µl or 
100µl was added per well of a 96 or 24 well plate respectively.  The plates were then 
returned to the incubator and after 4h, each well was topped up with 140µl or 400µl of 
complete media (96 or 24 well plate respectively).  Plates were then incubated for a 
further 48h, prior to either phagocytosis assays (96-well plates, see section 2.2.7), lysis 
for western blotting (24 well plates, see section 2.2.9) or real time-PCR (24 well plates, 
see section 2.2.14) for analysis of the degree of knockdown achieved. 
2.2.14 TaqMan Real time polymerase chain reaction (rt-PCR) 
2.2.14.1 RNA isolation 
MDMs were cultured in 24 well plates (see section 2.2.3), then the protein of interest 
was knocked down using siRNA (see section 2.2.13).  Total RNA was isolated using the 
Qiagen RNeasy miniprep extraction kit following the manufacturer’s protocol.  In brief, 
cells were lysed in RLT buffer containing 1% (v/v) β-mercaptoethanol.  The resulting 
lysate was homogenised, using a QiashredderTM column, by centrifugation at ≥8000 x g 
for 2 min.  The effluent was then diluted with an equal volume of 70% (v/v) ethanol, 
mixed well and up to 700µl transferred to a spin column.  The spin column was 
centrifuged at ≥8000 x g for 15 s, the effluent discarded, and then washed by addition 
of 350µl RW1 buffer, followed by repeat centrifugation at ≥8000 x g for 15 s.  
After discarding the effluent, any contaminating DNA was removed by 15 min 
incubation, at room temperature, with RNase-free DNase.  Samples were then washed, 
first in 350µl RW1 buffer, then twice in RPE buffer, with the final spin for 2 min at 
≥8000 x g.  In a new spin column, after dry centrifugation at ≥8000 x g for 1 min, the 
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bound RNA was eluted from the column by addition of 30µl RNase-free water and a 
final centrifugation performed at ≥8000 x g for 1 min.   
2.2.14.2 RNA analysis 
Each RNA sample was analysed by a Nanodrop ND-1000 UV-Vis spectrophotometer.  
First a zero reading was obtained with RNase-free water, then 1µl of each sample was 
analysed to give a measure of the RNA concentration in ng/µl.  Once the RNA 
concentrations was known (in ng/µl), the volume of each sample required to give 1µg 
of RNA was calculated and then made up with nuclease-free water to give a final 
amount of 1µg of RNA in 10µl nuclease-free water. 
2.2.14.3 cDNA 
Primers and probe sets for C6orf134, HDAC6 and SIRT2 were purchased for use with 
the TaqMan system.  First the RNA isolated from MDMs (see section 2.2.14.1) was 
converted to cDNA, using the High Capacity cDNA Reverse Transcription kit.  Following 
the manufacturer’s protocol a mastermix was prepared as follows:  for each reaction, 
RT buffer (2µl), dNTP mix (0.8µl), random primers (2µl), reverse transcriptase (1µl) and 
nuclease-free water (4.2µl).  In PCR tubes, 10µl of mastermix solution was mixed with 
10µl of each RNA sample (containing 1µg of RNA) and these were then loaded into a 
thermal cycler and heated for 10 min at 25oC followed by 120 min at 37oC then 5 min 
at 85oC. 
The PCR reaction was then performed in triplicate.  First the master mix was prepared: 
For each sample, 20µl TaqMan Universal PCR Master Mix, 2µl TaqMan probe (either 
C6orf134, HDAC6, SIRT2 or control, HPRT1) and 10µl nuclease-free water.  For each of 
the samples, 24µl of the above master mix was added to 9.8µl of cDNA, and from this 
total amount, 10µl was pipetted in triplicate into a 96 well PCR plate.  The plate was 
loaded into the 7500 Real Time PCR system (Applied Biosystems (Life Technologies), 
Paisley, UK) for analysis.  Analysis of Taqman data was performed using SDS software 
(Applied Biosystems, California, USA).  Graphs were obtained with data for each well of 
the plate and from this data the δδCT method was used to give a level of gene 
expression of the gene of interest (see appendix B).  This involves, firstly, taking an 
average of the triplicate values for each of the samples, then, for each averaged 
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sample, subtracting the values for gene expression of the gene of interest from those 
of the house-keeping gene (HPRT1), to normalise for variability in RNA concentrations.  
Finally, the values of the knockdown samples are divided by the control values for each 
set of samples (the standard) to give a percentage change in gene expression 
compared to the control cells (see Appendix B). 
2.2.15 HDAC activity assay 
2.2.15.1 Immunoprecipitation 
MDMs were lysed as for Western blots (section 2.2.9).  Protein assays were performed 
on samples and cell lysate, containing 200µg of protein, were reconstituted in 100 µl of 
RIPA buffer (150 mM NaCl, 1% Triton-X (v/v), 0.5% sodium deoxycholate (
w/v), 0.1% SDS 
(w/v), 50mM Tris-HCl) and transferred to a fresh tube.  5µl of rabbit polyclonal anti-
HDAC6 antibody (1mg/ml) was added and the eppendorfs rotated overnight at 4oC. 
Agarose beads (protein-A agarose) were gently pipetted to mix and 20µl added to each 
eppendorf, prior to rotation for a further 2 h at 4oC.  The eppendorfs were centrifuged 
at 3000 x g, 4oC for 20 s, the supernatant aspirated and 400µl of wash buffer added 
(0.5% RIPA buffer with ½ tablet of complete protease inhibitor).  The eppendorfs were 
centrifuged at 3000 x g, 4oC for 20 s and the wash repeated a further 2 times.   
2.2.15.2 HDAC activity assay 
After aspirating the supernatant, 110µl of HDAC assay buffer (50mM TRIS, pH 8.0, 
137mM sodium chloride, 2.7mM potassium chloride, 1mM magnesium chloride) was 
added to each tube, and gently pipetted to mix.  50µl of each sample was added to 
each well of a white 96 well plate and the volume adjusted to 80µl with HDAC assay 
buffer, followed by incubation at 37oC for 1 h.  20µl of Fluor de Lys™ developer 
concentrate was then added to each well and the plate incubated for a further 30 min 
at 37oC, prior to being analysed by fluorimetry (BMG Fluostar plate reader) at 
excitation λ480nm and emission λ520nm.  In order to assess the amount of HDAC6 
protein in each of the samples, the remaining 60µl of each sample was spun down 
(3000 x g, 30 sec), and a protein assay was performed (see section 2.2.3.3).  Following 
this, the supernatants were aspirated and then each sample was resuspended in 
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sample buffer.  The samples were then boiled for 3 min prior to Western blotting (see 
section 2.2.9).  Results were presented as the level of HDAC6 activity in a given sample, 
as a measure of relative fluorescence, relative to the protein level of HDAC6 in the 
sample. 
 
2.2.16 Intracellular killing assay 
Monocytes were cultured for 12 d in the presence of GM-CSF (2ng/ml) to generate 
MDMs, as described in section 2.2.3.  Media was removed and 100µl of live bacterial 
solutions, either H. influenzae or S. pneumoniae, were added and incubated at 37oC 
and 5% (v/v) CO2 for 4 h.  Supernatants were aspirated and serially diluted in D-PBS 
(100µl of aspirate in 900µl D-PBS, repeated 6 times to give a final dilution of 10-6); 10µl 
of each dilution was then plated onto agar plates for colony counts after 24 h (to give a 
count of extra-cellular bacteria).  The MDMs were then lysed with 100µl of dH2O, 
supernatants aspirated and serially diluted, as before, in D-PBS (100µl of aspirate in 
900µl D-PBS, repeated 4 times to give a final dilution of 10-4), with 10µl of each dilution 
plated onto agar plates, to give a count of viable intracellular bacteria.  In addition, 
100µl of live bacterial solutions, either H. influenzae or S. pneumoniae, was plated into 
empty wells and incubated at 37oC and 5% (v/v) CO2 for 4 h, after which the solutions 
were aspirated, diluted to 10-6 in D-PBS and 10µl of each dilution was then plated onto 
agar plates for colony counts after 24 h (to give a control count of total number of 
bacteria available to cells within the 4 h).  After 24 h, colony counts were performed on 
all plates and CFU/ml calculated (see section 2.2.5.1).  The following formula was then 
used to calculate intracellular killing; 
% Intracellular Killing = (1-(IC/Control-EC)) x 100 
Where IC represents the CFU/ml of intracellular bacteria, EC represents CFU/ml of 
extracellular bacteria (in the supernatant) and control is the CFU/ml of bacteria 
incubated in the well without cells. 
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To calculate the ability of cells to phagocytose and kill ingested bacteria, the following 
formula can be used; 
   % total killing = 100 – (((EC + IC)/Control) x 100) 
Where IC represents the CFU/ml of intracellular bacteria, EC represents CFU/ml of 
extracellular bacteria (in the supernatant) and control is the CFU/ml of bacteria 
incubated in the well without cells. 
2.2.17 Statistics 
Comparisons between groups (either subject groups or cell type) were carried out 
using Kruskal-Wallis (non-parametric multiple comparison) tests, followed by Dunn’s 
post correctional tests.  Comparisons between varying concentrations of drug were 
carried out using Wilcoxon signed rank tests, comparing sample medians to the 
control.  Correlation coefficients were carried out using Spearman’s rank correlation.  
Direct comparison of two groups was carried out using the Mann-Witney test. A p 
value of p<0.05 was taken to be significant.  All statistical analyses were carried out 
using GraphPad Prism (version 5) software (San Diego, USA).  Each ‘n’ represents the 


















RELATIONSHIP BETWEEN DISEASE AND 









Alveolar macrophages (AM) account for approximately 95% of airspace leukocytes and 
are the sentinel phagocyte of the innate immune system within the lung (Martin and 
Frevert, 2005). They express high levels of immunoglobulin, complement and mannose 
receptors on their cell surface, as well as numerous scavenger receptors, including 
MARCO, that facilitate phagocytosis of both opsonised and unopsonised particles 
(Gordon and Read, 2002).  In addition, receptors, such as toll-like receptors (TLR), are 
also present on the cell surface that recognise pathogens from self (Gordon and Read, 
2002).  Macrophages are increased 5-10 fold in the airways, lung parenchyma, sputum 
and bronchoalveolar lavage (BAL) of smokers and patients with COPD compared with 
healthy individuals, and their increased number correlates with disease severity 
(Finkelstein et al., 1995;Di et al., 1998).  However, in COPD patients, despite increased 
numbers of macrophages within the lung, increased bacterial colonisation is apparent 
in the lower airways, suggesting reduced bacterial clearance mechanisms.  
Studies have shown defective phagocytosis and killing of Candida spp. by AM from 
COPD patients compared to healthy controls (Ferrara et al., 1996;Vecchiarelli et al., 
1991).  AM from COPD patients also show defective phagocytosis of E. coli (Finney-
Hayward et al., 2005;Taylor et al., 2010).  Other studies have concentrated on 
commonly isolated respiratory pathogens.  AM from COPD patients and smokers have 
significantly reduced phagocytosis of non-typeable H. influenzae (NTHI) strains 
compared to AM from ex-smokers and healthy controls (Berenson et al., 2006a;Marti-
Lliteras et al., 2009). The reasons for these observations are unclear, however, 
rhinovirus exposure of macrophages from resected lung tissue impairs the ability of 
cells to phagocytose E. coli but not latex beads (Oliver et al., 2008), suggesting that 
viral exposure may alter the innate immune response.  Previous work in our laboratory 
has shown that MDMs from COPD subjects also display defective phagocytosis of H. 
influenzae, as well as S. pneumoniae, compared to healthy smokers without COPD and 
non-smoking controls (Taylor et al., 2010), which indicates that this may be an 
inherent abberation of macrophages from susceptible individuals, rather than the 
result of an environmental exposure.   
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In normal lung, airway epithelial cells may be damaged following infection or exposure 
to environmental pollution and subsequently become apoptotic (Hodge et al., 2003).  
These apoptotic cells are removed via efferocytosis.  AM from COPD patients also have 
a reduced ability to efferocytose apoptosed airway epithelial cells, leading to 
secondary necrosis of the epithelial cells, perpetuating an inflammatory response 
(Hodge et al., 2003).  Likewise, efferocytosis of apoptotic neutrophils is required to 
curtail neutrophilic inflammation within the lung.  However, Kirkham et al (2004) 
showed that, in vitro, MDMs interacting with cigarette smoke-modified extracellular 
matrix proteins down-regulated their ability to remove apoptotic neutrophils (Kirkham 
et al., 2004).  This suggests that cigarette smoke may modulate macrophage function 
indirectly.  Failure of macrophages to efferocytose neutrophils, leads to necrosis of 
neutrophils with release of reactive oxygen species and proteases with the potential 
for subsequent airway damage.   
In order to investigate macrophage function in COPD, alveolar macrophages would be 
the cell of choice; however, isolation of AM requires subjects to undergo bronchoscopy 
and lavage.  This is an invasive procedure with inherent risks, which are increased in 
subjects with COPD (Peacock M. et al., 1994). This, coupled with the problems of low 
cell yield from bronchoalveolar lavage (BAL) in healthy subjects and low recovery of 
BAL in COPD patients, makes an in vitro derived model of AM advantageous (Lofdahl et 
al., 2005).  MDMs have, therefore, been developed as a functionally equivalent model 
for AM.  Monocytes can be differentiated in the presence of growth factors, namely 
macrophage colony-stimulating factor (M-CSF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Akagawa, 2002).  However, MDMs differentiated in the 
presence of GM-CSF have been described as being more akin to AM in terms of surface 
molecular expression, resistance to oxidative stress, phagocytic capacity and 
susceptibility to pathogens (such as human immunodeficiency virus (HIV) and M. 
tuberculosis) and have a consistent and stable phenotype (Winkler et al., 2008).  Given 
the increased cellular yield available with the use of MDMs, and the increased risks of 
bronchoscopy, MDMs will be used as a model of AM for this study. 
Therefore, the aim of this chapter is to first identify the most appropriate technique 
for the isolation of monocytes and then examine the ability of the derived MDMs to 
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phagocytose beads and bacteria.  The ability of MDMs from different subject groups to 
phagocytose beads and bacteria will then be investigated.  Having assessed 
phagocytosis by MDMs, their ability to kill bacteria once they are ingested will also be 
examined. In addition, sputum macrophages will be isolated and their phagocytic 
ability compared to that of MDMs.  Sputum macrophages can be obtained from 
spontaneous or induced sputum, a procedure that is less invasive than bronchoscopy, 
but may represent an alternative model for AM.  
Having established baseline phagocytic capabilities, the ability of macrophages from 
COPD subjects to phagocytose bacteria during exacerbation will be investigated.  
Exacerbations are described as an acute worsening of symptoms often requiring a 
change in treatment in a patient with COPD (adapted from GOLD definition, 2011).  
Frequent exacerbations, defined as 2 or more exacerbations per year requiring 
treatment, are associated with a more rapid decline in lung function, worsened quality 
of life, increased likelihood of hospital admission and increased mortality (Wedzicha 
and Seemungal, 2007). COPD patients are often colonised with bacteria in the stable 
state; however, during exacerbations up to70% of patients have bacterial colonisation 
in the lower airways (Wilkinson et al., 2006; Monso et al., 2005; Zalacain et al., 1999).  
In addition, isolation of a new strain of bacteria is associated with increased risk of 
exacerbation in COPD patients (Sethi et al., 2002).  Therefore, if macrophages display 
reduced phagocytosis at baseline, this may worsen at times of exacerbation, with 
increased bacterial load or infection with new strains, in turn, leading to further 
increases in bacteria with poorer clinical outcomes.  Therefore, this chapter also aims 
to establish the capacity of MDMs, both from frequent and infrequent exacerbators to 








3.2.1 Subject selection 
Healthy, smoking and COPD subjects were recruited as described in section 2.2.1. 
3.2.2 Study timeline 
Blood (60ml) and induced sputum was taken from COPD patients and age-matched 
healthy smoking and non-smoking volunteers at baseline.  COPD patients were 
required to have been free from exacerbation or antibiotic or steroid treatment for the 
preceding 6 weeks for a baseline sample.  COPD patients were followed up, and at the 









Figure 3.1. Timeline for recruitment of subjects into study.  
3.2.3 Blood separation 
Two different techniques were initially assessed and compared for the optimal 
isolation of monocytes from blood as described in section 2.2.3.  Monocytes were then 
cultured for 12 d in the presence of GM-CSF (2ng/ml) to generate monocyte-derived 
macrophages (MDMs).  
    >2 weeks 
Baseline       Exacerbation  
   
20 COPD subjects      COPD subjects 
20 healthy smokers      60 ml blood 
20 healthy subjects       Sputum 
60ml blood        
Induced sputum        
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3.2.4 Phagocytosis Assays 
Phagocytosis assays were performed using fluorescently-labelled beads or bacteria 
exposed to MDMs for time points up to 4 h, as described in section 2.2.7. 
3.2.5 Confocal microscopy 
After phagocytosis assays were complete, MDMs were stained using Cell Tracker Red 
(Invitrogen, UK) then fixed with 4% (w/v) paraformaldehyde and imaged on a Leica SP2 
upright confocal microscope as described in section 2.2.11. 
3.2.6 Intracellular killing 
Monocytes were cultured for 12 d in the presence of GM-CSF (2ng/ml) to generate 
MDMs.  MDMs were incubated with live bacteria for 4 h and then lysed, diluted in D-
PBS and plated onto agar plates, to give a count of viable intracellular bacteria, as 
described in section 2.2.16.  The following formula was then used to calculate 
intracellular killing; 
% Intracellular Killing = (1-(IC/Control-EC)) x 100 
Where IC represents the CFU/ml of intracellular bacteria, EC represents CFU/ml of 
extracellular bacteria (in the supernatant) and control is the CFU/ml of bacteria 
incubated in the well without cells. 
3.2.7 Sputum processing 
Sputum was processed as described in section 2.2.4 and phagocytosis assays were 
then performed as described in section 2.2.7. 
3.2.7.1 Preparation of cytospins and Quick-Diff staining 
Sputum was processed as described in section 2.2.4.  Macrophages (5x104/50µl) were 
transferred into cytospin funnels attached, with a filter, to microscope slides.  Cells 
were the centrifuged for 5 min at 600 x g.  Slides were allowed to air-dry, then stored 
at -80oC for subsequent staining using the REASTAIN Quick-Diff kit. This allows for 
differential staining of cellular components of leukocytes. 
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Staining was performed as described in the manufacturer’s handbook.  In brief, each 
slide was immersed for 4 s in fixative (100 v/v methanol), 6 s in Red solution (12 
w/v 
Eosine Yellow, 0.1 w/v sodium azide), 10 s in Blue solution (0.09% 
w/v Azur II , 5% 
v/v 
Glycerol, 0.1% w/v sodium azide) and washed repeatedly in distilled water until excess 
stain was removed. Slides were allowed to air dry, before a cover slip was added and 


















3.3.1 Subject Demographics 
The characteristics of healthy, smoking and COPD subjects used in this study are shown 
in Table 3.1.  Healthy and smoking volunteers were matched for age and lung function, 
while smokers and COPD subjects were matched for smoking history. There were 
significant differences in age and lung function between COPD and control groups 
(healthy and smoker subjects). 
 Healthy Smoker COPD 
Age (years) 58 ± 2 58 ± 1  66 ± 2 * 
Gender (M:F) 11 : 12 11 : 11 16 : 8 
FEV1 (L) 2.6 ± 0.2 2.5 ± 0.1  1.2 ± 0.1 *** 
FEV1 % predicted 95 ± 2.4 86 ± 2.2  49 ± 4.1 *** 
FVC (L) 3.8 ± 0.4 3.6 ± 0.3  2.5 ± 0.2 ** 
FEV1/FVC 78 ± 1.2 74 ± 0.9  44 ± 2.5 *** 
Smoking history 
(pack years) 
0 40 ± 3.4 54 ± 5.6 
Current smokers 0 22 10 






Table 3.1.  Subject demographics 
Where * represents p<0.05, ** p<0.01 and *** p<0.001 compared to both healthy and 
smoking controls.  Data is presented as mean ± SEM. 
 
3.3.2 Effect of monocyte isolation on generation of MDMs 
To determine the most appropriate method for monocyte isolation that would yield 
MDMs suitable for future experiments, a comparison of negative selection of 
monocytes using Miltenyi beads and an adherence method was performed.  
Monocytes isolated by each of these techniques were adhered to the plates and were 
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then cultured for 12 d to generate MDMs; any non-adherent cells were removed at D4 
and d8 during media changes, therefore a population of adherent monocytes derived 
from tow techniques was studied.  MDMs were lysed and protein assays performed, to 
allow comparison of the amount of protein in each well, as a surrogate for cell 
numbers.  There was no significant difference in protein levels when comparing plates 

















Figure 3.2. Comparison of average protein derived from two techniques for separating 
monocytes 
Monocytes from healthy volunteers were isolated using either negative selection or 
adherence and cultured for 12d in the presence of GM-CSF (2ng/ml). The average 
amount of protein was ascertained as described in the methods section (2.2.3.3).  Data 
are presented as mean ± SEM, n=5. 
 
3.3.3 Effect of monocyte isolation on MDMs phagocytosis  
Having established that both monocyte isolation techniques yielded similar cell 
numbers, the next step was to confirm that the MDMs derived from the different 
methods were functionally similar.  Phagocytosis of beads was used as an indicator of 
macrophage function.  There were no significant differences observed in the ability of 
the MDMs, derived from either negative selection or adherence, to phagocytose beads 
at concentrations of 107 beads/ml or 5x107 beads/ml (Fig. 3.3).  From these results, 
given the higher yield of cells with equivalent functionality of the derived 
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macrophages, adherence was selected as the optimum technique for separating 
monocytes from the PBMC fraction. 








Figure 3.3. Comparison of phagocytosis of beads by MDMs derived from two monocyte 
isolation techniques 
Monocytes from healthy volunteers were separated using either the Miltenyi 
technique (■) or adherence (■).  Cells were cultured in complete media containing GM-
CSF (2ng/ml) for 12 d to give MDMs. Cells were incubated with 100µl of beads at either 
(a) 107 beads/ml or (b) 5x107 beads/ml for the times indicated and phagocytosis 
quantified by fluorimetry.  Data are presented as mean ± SEM, n=4. 
 
3.3.4 Establishment of optimum conditions for MDMs phagocytosis of 
beads  
Having selected the adherence technique for isolating monocytes, it was important to 
establish the optimum incubation time and concentration of fluorescently-labelled 
beads to be used for future phagocytosis assays.  MDMs were incubated for up to 4 h 
with either 5x106 beads/ml, 10x107 beads/ml or 5x107 beads/ml and phagocytosis 
quantified by fluorimetry.  Bead phagocytosis by MDMs increased in both a time and 
concentration-dependent manner (Fig. 3.4).  From these data, an incubation time of 4 
h and a bead concentration of 5x107 beads/ml were selected to give optimum 
measurement of bead phagocytosis for future experiments. 
















































































Figure 3.4. Effect of incubation time and bead concentration on MDMs phagocytosis of 
beads  
Monocytes from healthy volunteers were cultured in complete media containing GM-
CSF (2ng/ml) for 12 d to give MDMs.  Cells were incubated with 100µl of beads at 
varying concentrations; (■) 5x106 beads/ml, (■)107 beads/ml or (■) 5x107 beads/ml for 
the times indicated.   Fluorescence was then quantified by fluorimetry. Data are 
presented as mean ± SEM, n=4. 
 
To confirm that the fluorescence measured in the phagocytosis assays was related to 
internalisation of beads, and not simply due to non-specific binding of beads to cells, 
further experiments were carried out using cytochalasin D (2µM).  Cytochalasin D is an 
actin microfilament inhibitor which inhibits phagocytosis (Parod and Brain, 1986). In 
the presence of cytochalasin D, phagocytosis of beads was significantly reduced in all 
subjects groups, by a maximum of ~60% (Fig. 3.5), suggesting that non-specific binding 
accounts for approximately 40% of bead phagocytosis observed.  No differences were 
observed in the response of cells from healthy subjects, smokers or patients with 
COPD, suggesting that non-specific binding is similar across all groups, allowing for 
direct comparison of phagocytic responses (Fig. 3.5).   
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Figure 3.5. Effect of Cytochalasin D (CyD) on inhibiting phagocytosis of beads across 
subject groups 
MDMs from healthy controls (■), healthy smokers (■) and COPD patients (■)were 
incubated for 4 h with 100µl of 50x106beads/ml at 37oC with or without pre-incubation 
for 1h with Cytochalasin D (2µM). Fluorescence of internalised beads was quantified by 
fluorimetry. Data shown are mean ± SEM, Healthy n=11, smoker n=8, COPD n=9, 
where **represents p<0.01, ***p<0.001. 
 
3.3.5 Confocal microscopy of MDMs bead phagocytosis 
To further confirm that beads were being internalised, and not adhering to the cell 
surface, confocal microscopy was performed.  MDMs were cultured on chamber slides 
and incubated with 50x106beads/ml for 4 h, prior to staining of the cytoplasm and 
nucleus.  Cells were viewed on a confocal microscope, and sequential images taken 
through the cell (Fig. 3.6a).  These images were then overlaid to examine the cell in the 
x, y and z planes (Fig. 3.6b).  This confirmed internalisation of beads within the cell, 
where the bead as shown by the white arrow can be seen surrounded by cytoplasm in 







(a) MDMs with fluorescently labelled beads (b) Orthogonal view 
  
Figure 3.6. Confocal microscopy images of MDMs having undergone phagocytosis of 
beads  
MDMs were cultured on chamber slides, prior to incubation for 4 h with 100µl of 
50x106beads/ml at 37oC. Cytoplasm was stained with Cell Tracker Red ((12.5µM) 
Invitrogen, UK) for 45 min.  Cells were fixed and nuclei stained with DAPI (2µM, blue).  
Cells were imaged on a Leica SP2 upright confocal microscope (x63 objective lens, with 
5x zoom and 50 sections for z stacks) and images viewed with VolocityTM software.  
Bead shown in x, y and z planes as marked by the white arrow. Representative image 
of n=3.  
 
3.3.6 Establishment of optimum conditions for MDMs phagocytosis of 
bacteria  
Having confirmed the ability of MDMs to phagocytose fluorescently-labelled beads, 
the ability of MDMs to ingest clinically relevant bacterial pathogens was investigated.  
MDMs were incubated for up to 6 h with increasing concentrations of either gram-
positive (Streptococcus pneumoniae) or gram-negative (Haemophilus influenzae) heat-
killed bacteria (Fig 3.7).  The concentrations of bacteria were chosen to be equivalent 
to the levels of bacteria present in the airway in clinically relevant infection (where 
clinically relevant infection is given as >107 CFU/ml).  MDMs phagocytosis of bacteria 












Figure 3.7. Effect of incubation time and concentration of bacteria on phagocytosis by 
MDMs 
Monocytes from healthy volunteers were cultured in complete media containing GM-
CSF (2ng/ml) for 12 d to give MDMs. Cells were incubated with 100µl of either S. 
pneumoniae or H. influenzae solution at varying concentrations (given by CFU/ml); 
4x107/ml (▼), 1x108/ml (▲) or 4x108/ml (■), for the times indicated, then 
phagocytosis was quantified by fluorimetry.  Data are presented as mean ± SEM, n=4. 
 
From these data, the highest concentration of bacteria was chosen for future 
experiments to give the maximal window in which to measure alterations in 
phagocytosis.  At this concentration (4x108CFU/ml), the rate of uptake of bacteria 
appeared to slow from the 4-5 h time point with both strains of bacteria.  Therefore, 4 
h was chosen as the optimal incubation time for future bacterial phagocytosis assays. 
Once again, to confirm that the measurement of fluorescence was related to 
internalisation of bacteria and not non-specific binding of bacteria to cells, further 
experiments were performed in the presence of cytochalasin D.  MDMs incubated with 
cytochalasin D (2µM) had a reduction in phagocytosis of bacteria by approximately 
90% for both bacteria (Fig. 3.8), suggesting that non-specific binding accounts for 


















































approximately 10% of phagocytosis observed, irrespective of the bacterial species 
assessed. 








Figure 3.8.  Effect of Cytochalasin D (CyD) on inhibition of bacterial phagocytosis 
Healthy MDMs were incubated for 4 h with 100µl of either H. influenzae (HI■) or S. 
pneumoniae (SP■) at 37oC with or without pre-incubation for 1h with Cytochalasin D 
(2µM). Fluorescence of internalised bacteria was quantified by fluorimetry and % non-
specific binding calculated relative to control. Data shown are mean ± SEM, n=5. 
 
3.3.7 Confocal microscopy confirming bacterial phagocytosis by MDMs 
To further confirm that bacteria were internalised during phagocytosis assays, confocal 
microscopy was performed.  MDMs were incubated with bacterial solutions (H. 
influenzae and S. pneumoniae) for 4 h, prior to washing and staining of the cytoplasm 
and nucleus and fixation.  Cells were then viewed on a confocal microscope, and 
orthogonal views taken of the cells.  These show that the bacteria are within the cell, 








(a) MDMs with fluorescently labelled H. influenzae  
 
(b) Orthogonal view  
 
 
Figure 3.9.  Confocal microscopy images of MDMs having undergone phagocytosis of 
H. influenzae  
MDMs were cultured on chamber slides, prior to incubation for 4 h with 100µl of H. 
influenzae solution at 37oC. Cytoplasm was stained with Cell Tracker Red ((12.5µM) 
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Invitrogen, UK) for 45 min.  Cells were fixed and nuclei stained with DAPI (2µM, blue).  
Cells were imaged on a Leica SP2 upright confocal microscope (x63 objective lens, with 
5x zoom and 50 sections for z stacks) and images viewed with VolocityTM software. 
Representative image of n=3. 
(a) MDMs with fluorescently labelled S. pneumoniae  
 
(b) Orthogonal view 
 
Figure 3.10.  Confocal microscopy images of MDMs having undergone phagocytosis of 
S. pneumoniae  
MDMs were cultured on chamber slides, prior to incubation for 4 h with 100µl of S. 
pneumoniae solution at 37oC. Cytoplasm was stained with Cell Tracker Red ((12.5µM) 
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Invitrogen, UK) for 45 min.  Cells were fixed and nuclei stained with DAPI (2µM, blue).  
Cells were imaged on a Leica SP2 upright confocal microscope (x63 objective lens, with 
5x zoom and 50 sections for z stacks) and images viewed with VolocityTM software. 
Representative image of n=3. 
3.3.8 Confirmation of internalisation of bacteria by MDMs, using 
pHrodo™ 
It remained a possibility that although bacteria are entering the cell, the process of 
phagocytosis was aberrant.  To confirm that the phagosome was fusing correctly with 
the lysosome during the phagocytic process, bacteria were labelled with an alternative 
dye.  pHrodoTM (Invitrogen, UK) is a pH sensitive dye that will only fluoresce at low pH 
which occurs under the acidic conditions found inside the phagolysosome.  MDMs 
incubated with pHrodo-labelled H. influenzae or S. pneumoniae show low levels of 
fluorescence at 1 h (Fig. 3.11a and 3.12a), in comparison to high fluorescence at 4 h 
(Fig. 3.11b and 3.12b), confirming internalisation of bacteria by MDMs. 
(a) MDMs at 1 h     (b) MDMs at 4 h 
  
Figure 3.11.  Fluorescent microscopy images of MDMs having undergone phagocytosis 
of pHrodo-labelled H. influenzae  
Monocytes from healthy volunteers were cultured in complete media containing GM-
CSF (2ng/ml) for 12 d to give MDMs. Cells were incubated with 100µl of pHrodo 
labelled H. Influenzae solution for 4h, with images taken every 30 min.  Cells viewed on 





(a) MDMs at 1 h    (b) MDMs at 4 h 
  
Figure 3.12.  Fluorescent microscopy images of MDMs having undergone phagocytosis 
of pHrodo-labelled S. pneumoniae  
Monocytes from healthy volunteers were cultured in complete media containing GM-
CSF (2ng/ml) for 12 d to give MDMs. Cells were incubated with 100µl of pHrodo 
labelled S. pneumoniae solution for 4h, with images taken every 30 min.  Cells viewed 
on an inverted fluorescent microscope, x40 objective lens.  Representative image of 
n=4 experiments. 
 
3.3.9 Effect of disease on phagocytosis of beads and bacteria by MDMs 
Having established optimum conditions for phagocytosis experiments, the effect of 
disease on phagocytic function was assessed.  Monocytes were isolated from healthy, 
smoker and COPD subjects, MDMs were derived and their ability to phagocytose beads 
was compared. Over a time course of 1-4 h, there were no significant differences in the 
ability of MDMs derived from COPD patients, healthy or smoking subjects to 
phagocytose beads (Fig. 3.13).  This confirms that MDMs from all subject groups are 
capable of phagocytosis. 
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Figure 3.13. Effect of disease on phagocytosis of beads by MDMs 
Monocytes from healthy controls (■), healthy smokers (■) and COPD patients (■) were 
cultured in complete media containing GM-CSF (2ng/ml) for 12 d to give MDMs. Cells 
were incubated with 100µl of 50x106beads/ml for the times indicated, then quantified 
by fluorimetry.  Data are presented as mean ± SEM, n=20 for healthy, n=22 for 
smokers, n=23 for COPD. 
 
Having confirmed that MDMs from all subject groups were capable of equivalent 
uptake of inert particles, the next step was to assess whether disease state had any 
effect on the phagocytosis of bacteria.  Fluorescence microscopy images of MDMs 
isolated from COPD subjects show qualitatively reduced uptake of fluorescently 
labelled H. influenzae compared to healthy controls (Fig. 3.14a-b).  When all subject 
groups were compared, smoker MDMs showed significantly reduced uptake of H. 
influenzae at all time points (Fig 3.15), whilst COPD MDMs showed significantly 
reduced phagocytosis of H. influenzae at 2-4 h (Fig. 3.15).  At 4 h, phagocytosis of H. 
influenzae was reduced by 28% and 58% in COPD and smoker MDMs respectively, 





(a) Healthy MDMs incubated with HI (b) COPD MDMs incubated with HI 
  
Figure 3.14. Fluorescent microscopy images of (a) healthy MDMs and (b) COPD MDMs 
having undergone phagocytosis of H. influenzae  
Monocytes were cultured in complete media containing GM-CSF (2ng/ml) for 12 d to 
give MDMs. Cells were incubated with 100µl of Alex-fluor 488 (Invitrogen, UK) labelled 
H. influenzae solution for 4h. Cells were washed then viewed on an inverted 












Figure 3.15. Effect of disease on phagocytosis of H. influenzae by MDMs. 
Monocytes from healthy controls (■), healthy smokers (■) and COPD patients (■) were 
cultured in complete media containing GM-CSF (2ng/ml) for 12 d to give MDMs. Cells 
were incubated with 100µl of H. influenzae solutions for the times indicated, then 
quantified by fluorimetry.  Data are presented as mean ± SEM, n=20 for healthy and 
smoker subjects, n=24 for COPD subjects, where * represents p<0.05, ** p<0.01 and 
*** p<0.001. 
 






















MDMs phagocytosis of S. pneumoniae showed a similar pattern to H. influenzae, with 
fluorescence microscopy images suggestive of reduced uptake of S. pneumoniae by 
COPD subjects compared to healthy controls (Fig. 3.16a-b).  Smoker MDMs showed 
significantly reduced uptake at all time points (Fig. 3.17), whilst COPD MDMs showed 
reduced phagocytosis at all time points, reaching significance at 4 h (Fig. 3.17).  At 4 h, 
phagocytosis of S. pneumoniae was reduced by 32% and 52% in COPD and smoker 
MDMs respectively, compared to healthy MDMs. 
(a) Healthy MDMs incubated with SP  (b) COPD MDMs incubated with SP 
  
Figure 3.16. Fluorescent microscopy images of (a) healthy MDMs and (b) COPD MDMs 
having undergone phagocytosis of S. pneumoniae  
Monocytes were cultured in complete media containing GM-CSF (2ng/ml) for 12 d to 
give MDMs. Cells were incubated with 100µl of Alexa-fluor 488 (Invitrogen, UK) 
labelled SP solution for 4h. Cells were washed then viewed on an inverted fluorescent 
























Figure 3.17. Effect of disease on phagocytosis of S. pneumoniae by MDMs 
Monocytes from healthy controls (■), healthy smokers (■) and COPD patients (■) were 
cultured in complete media containing GM-CSF (2ng/ml) for 12 d to give MDMs. Cells 
were incubated with 100µl of bacterial solutions for the times indicated, then 
quantified by fluorimetry.  Data are presented as mean ± SEM, n=21 for healthy 
subjects, n=20 for smoker subjects and n=24 for COPD, where * represents p<0.05 and 
*** p<0.001. 
 
3.3.10 Phagocytosis assays with live bacteria 
The bacterial phagocytosis assays performed above used heat-killed bacteria.  
Therefore, to ensure that the altered bacterial phagocytosis seen with smoker and 
COPD MDMs was not related to the use of heat-killed bacteria, experiments were 
repeated using live bacteria of the same strains.  These experiments were performed 
at a 1 h timepoint to minimise bacterial growth during the phagocytosis assay.  
Experiments with live bacteria confirmed the previous findings, with COPD MDMs 
showing significantly reduced phagocytosis of both H. influenzae and S. pneumoniae in 

































Figure 3.18. Effect of live bacteria on phagocytosis of (a) H. influenzae and (b) S. 
pneumoniae by MDMs from different subject groups 
Monocytes from healthy controls (■), healthy smokers (■) and COPD patients (■) were 
cultured in complete media containing GM-CSF (2ng/ml) for 12 d to give MDMs. Cells 
were incubated with 100µl of live bacterial solutions for 1 h, and then quantified by 
fluorimetry.  Data are presented as mean ± SEM, n=10 for healthy and COPD subjects, 
n=8 for smoker subjects, where *represents p<0.05 COPD vs healthy controls. 
 
3.3.11 Cell viability 
To confirm that the alterations in phagocytosis observed with both smoker and COPD 
MDMs were not simply a consequence of reduced viability in these cells, in 
comparison to healthy cells, MTT assays were performed.  After phagocytosis assays 
were complete, cells were incubated with MTT solution for 30 min and absorbance 
read on the spectrophotometer.  No differences were seen in cell viability between 
MDMs from healthy, smoker and COPD subjects (Fig. 3.19). 






































Figure 3.19. Viability of MDMs from different subject groups 
Monocytes from healthy controls (●), healthy smokers (■) and COPD patients (▲) 
were cultured in complete media containing GM-CSF (2ng/ml) for 12 d to give MDMs. 
Cells were used in phagocytosis assays prior to incubation with 100µl of MTT solution 
for 30 min at 37oC.  Supernatants were aspirated and 100µl of DMSO added.  Plates 
were read at λ570nm on a spectrophotometer.  Data presented here are values from 
control cells (without prey) but are representative of those cells with prey. Data are 
presented as mean ± SEM, n=8 for healthy, n=10 for smoker subjects and n=16 for 
COPD subjects. 
 
3.3.12 Intracellular killing 
Having established that MDMs from smoker and COPD subjects showed reduced 
uptake of bacteria compared to healthy controls,  it was important to determine 
whether these cells also had altered ability to kill intracellular bacteria.  Therefore, 
MDMs were incubated for 4 h with live bacteria, after which cells were lysed and the 
supernatants plated onto agar for colony counting after 24 h.  The number of bacteria 
ingested by cells was calculated as shown in section 3.2.5.  There were no significant 
differences seen in the ability of MDMs from healthy, smoker or COPD subjects to kill 





















Figure 3.20. Ability of MDMs from different subject groups to kill intracellular bacteria 
Monocytes from healthy controls (■), smokers (■) and COPD patients (■) were 
cultured in complete media containing GM-CSF (2ng/ml) for 12 d to give MDMs. Cells 
were incubated with live H. influenzae for 4 h at 37oC.  Supernatants were aspirated, 
diluted and plated on agar for 24 h colony counts.  MDMs were lysed, supernatants 
diluted and plated for 24 h colony counts.  Intracellular killing was calculated using the 
equation described in section 3.2.5. Data are presented as mean ± SEM, n=4 for all 
groups. 
 
3.3.13 Relationship between phagocytosis of gram negative and gram 
positive bacteria 
When the ability of MDMs from all subject groups to phagocytose H. influenzae (HI) 
was compared to the ability of MDMs from all subject groups to phagocytose S. 
pneumoniae (SP), a strong positive correlation was found (Fig. 3.21), suggesting that 
any defect in uptake of bacterial pathogens is non-specific.   
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Figure 3.21. Correlation between the ability of MDMs from different subject groups to 
phagocytose H. influenzae and S. pneumoniae 
 
To assess whether reduced phagocytic ability was related to age, lung function or 
smoking history, correlations between phagocytosis of either gram positive or gram 
negative bacteria, and these parameters were performed.  No correlations were seen 
between the ability of MDMs to phagocytose either H. influenzae or S. pneumoniae 
and age, lung function parameters or smoking history, neither when performed within 
subject groups nor when subjects from all disease group were analysed as a whole (Fig. 
3.22-25). 







Figure 3.22. Correlation between the age of subjects from all disease groups and ability 
of their MDMs to phagocytose (a) H. influenzae or (b) S. pneumoniae 
Spearman r = 0.78 
P<0.0001 
































Figure 3.23. Correlation between the FEV1 % predicted of subjects from all disease groups and 
ability of their MDMs to phagocytose (a) H. influenzae or (b) S. pneumoniae 








Figure 3.24. Correlation between the FEV1/FVC ratio of subjects from all disease groups and 
the ability of their MDMs to phagocytose (a) H. influenzae or (b) S. pneumoniae 







Figure 3.25. Correlation between the smoking history from smoking and COPD subjects and 
the ability of their MDMs to phagocytose (a) H. influenzae or (b) S. pneumoniae 

























































































3.3.14 Effect of disease on cytokine release from MDMs 
Having shown that MDMs from smokers and COPD patients had altered phagocytic 
responses compared with healthy subjects, another functional output was investigated 
to assess whether there were other similar alterations.  The release of TNFα from 
MDMs, after 4 h incubation with prey, was analysed by ELISA.  There was no significant 
difference in baseline release of TNFα in untreated MDMs from healthy, smoker or 
COPD subjects (Fig. 3.26a-c).  TNF-α release from MDMs incubated with beads and 
bacteria (gram-positive and gram-negative) was significantly increased from baseline 
values in all subject groups (p<0.001) (Fig. 3.26a-c).  COPD MDMs, incubated with 
beads, released significantly more TNF-α compared to healthy or smoker MDMs.  In 
comparison, smoker MDMs released higher levels of TNF-α after incubation with S. 
pneumoniae, (p<0.01 smoker vs. COPD) whilst healthy MDMs released significantly 
more TNF-α compared to COPD and smoker MDMs when incubated with H. influenzae 
(p<0.05 healthy vs. smokers).  There was an approximate 10 fold greater TNF-α release 
after incubation with S. pneumoniae compared to beads, with a further 5 fold increase 
after incubation with H. influenzae compared to S. pneumoniae (Fig. 3.26a-c).  







Figure 3.26. TNF-α release from MDMs after 4h incubation with phagocytic prey 
Supernatants, taken from MDMs post 4 h phagocytosis assays with either beads or 
bacteria, were diluted as appropriate and an ELISA performed as per manufacturers’ 
protocol. Non-treated MDMs (NS ■) n=4 all groups. Treated MDMs, healthy (■) n=8, 



























































































































3.3.15 Effect of Exacerbation frequency on the ability of MDMs to 
phagocytose bacteria 
Frequent exacerbators are defined as those experiencing 2 or more exacerbations per 
year, requiring treatment.  To assess whether exacerbation frequency had any effect 
on phagocytosis, the COPD subjects were divided into frequent and infrequent 
exacerbators on the basis of their exacerbation history over the previous 2 years.  The 
demographics of frequent and infrequent exacerbators are shown in Table 3.27.  The 
only significant difference between the two groups is the smoking history with 






Age (years) 69 ± 2 69 ± 2 
Gender (M:F) 7:5 8:4 
FEV1 (l) 1.1 ± 0.14 1.4 ± 0.14 
FEV1 % predicted 46 ± 5.5 52 ± 5.6 
FEV1/FVC (%) 42 ± 2.5 47 ± 4.4 
Smoking history (pack 
years) 
64 ± 8 44 ± 6** 
Current smokers 6 4 
Exacerbations in prior yr 0.8 ± 0.11 2.4 ± 0.15 
Treatment Seretide n=8 
Becotide n=2 





Table 3.27.  Demographics of the frequent vs. infrequent exacerbators 
Where * represents p<0.01 frequent vs. infrequent exacerbators. Data is presented as 
mean ± SEM.   
 116 
Comparison of phagocytosis of either H. influenzae or S. pneumoniae between 
frequent and infrequent exacerbators showed that frequent exacerbators have 
significantly lower uptake of both bacteria compared to infrequent exacerbators (Fig. 
3.28). 
(a) H. influenzae     (b) S. pneumoniae 


























Figure 3.28.  Effect of exacerbation frequency on ability of MDMs to phagocytose 
bacteria 
Monocytes from COPD patients were cultured in complete media containing GM-CSF 
(2ng/ml) for 12 d to give MDMs. Phagocytosis assays were performed with either H. 
influenzae or S. pneumoniae and phagocytosis analysed by fluorimetry. Patients were 
divided on exacerbation history into infrequent (≤1 exacerbation/y (mean 
exacerbations 0.8 ± 0.11), n=12(■)) or frequent (≥2 exacerbations/y (mean 
exacerbations 2.4 ± 0.15), n=12(●)). Data are presented with line at median, where * 
represents p<0.05, ** represents p<0.01. 
 
3.3.16 Effect of Acute Exacerbations of COPD on MDMs phagocytosis of 
beads and bacteria 
Given that MDMs from all COPD patients display reduced phagocytosis at baseline, the 
next step was to determine whether there was any further reduction in phagocytosis 
of bacteria at times of acute exacerbation.  Acute exacerbations were defined on the 
basis of Anthonisen’s criteria; ≥2 major symptoms of increased or new dyspnoea, 
sputum purulence or volume, or 1 major and minor symptoms including cough, fever, 
wheeze and cold.  The demographics of those COPD patients who developed an acute 
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exacerbation over the course of the study are shown below (Table 3.29).  There were 
no differences between these patients in terms of age, lung function or smoking 
history when compared to the COPD cohort as a whole (Table 3.1). 
 
Age (years) 67 ± 1 
Gender (M:F) 5:5 
FEV1 (l) 1.1 ± 0.1 
FEV1 % predicted 47 ± 4.0 
FVC (l) 2.3 ± 0.1 
FEV1/FVC (%) 44 ± 2.6 
Smoking history (pack years) 62 ± 6 
Current smokers 3 
Exacerbations in prior yr  1.8 ± 0.33 




Table 3.29.  Demographics of the COPD subjects exacerbating during the study  
Data is presented as mean ± SEM. 
Blood was sampled from the patients on day 1 of an exacerbation, prior to starting 
antibiotics or oral glucocorticosteroids.  Monocytes were then isolated and MDMs 
derived.  These MDMs were then used in phagocytosis assays and the results 
compared to baseline values for each patient. No differences were seen in the ability 
of COPD MDMs to phagocytose either beads or gram negative or positive bacteria at 
exacerbation compared to baseline (Fig. 3.30). 
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Figure 3.30.  Effect of acute exacerbation on phagocytosis of (a) beads (b) H. influenzae 
and (c) S. pneumoniae by COPD MDMs 
Monocytes from COPD patients taken at baseline (■) and at exacerbation (■) were 
cultured in complete media containing GM-CSF (2ng/ml) for 12 d to give MDMs. Cells 
were incubated with 100µl of bead or bacterial solutions for the times indicated, then 
quantified by fluorimetry.  Data are presented as mean ± SEM, n=10. 
 
3.3.17 Phagocytosis by Sputum macrophages 
Having shown that MDMs could be used to assess phagocytosis in different subject 
groups, sputum macrophages were examined to see if they showed similar defects in 
phagocytosis.  Sputum samples were discarded if the squamous cell count was >10% 
(suggesting oropharyngeal contamination of the sample) or if viability, as assessed by 
trypan blue, was <70%.  Differential cell counts were performed using Kimura staining.  
Of all the sputum samples obtained 6 samples from each of healthy and smoker 
subjects were discarded due to squamous cell contamination or poor cellularity, whilst 
5 samples from COPD patients were discarded due to poor viability.  The differential 
count of sputum samples that were used in phagocytosis assays are shown in Table 
3.31.  Overall, COPD patients had the highest total cell count, but the majority of these 
cells were neutrophils (Table 3.31) 
 







































 Healthy (n=8) Smokers (n=9) COPD (n=14) 
Total non-squamous cell count 
(x106/ml) 
2.6±0.5 3.1±0.8 3.9 ±1.1 
Macrophages (% of total cell count) 41.1±5.3 42.6±5 20.3±3 
Neutrophils (% of total cell count) 29.1±2.8 31.8±5.5 64.7±4 
Other (primary epithelial cells, 
lymphocytes) (% of total cell count) 
16.1±2.7 16.5±3.3 10.2±2 
 
Table 3.31. Total cell counts in sputum from different subject groups, with differential 
as a percentage of total count 
Sputum was obtained from healthy controls, healthy smokers and COPD patients and 
cell counts were performed using Kimura staining.  Macrophages were resuspended at 
1x105 macrophages per FACS tube in RPMI media for phagocytosis assays. Data are 
presented as mean ± SEM. 
 
Cytospins were performed of each sputum sample and stained with Quick-Diff™ 
(Gentaur, Belgium).  Comparing a sample from a healthy and COPD subject below (Fig. 
3.32a and b) it can be seen that the COPD sample already contains bacterial 
contamination.  The bacterial contamination can be more clearly seen when the same 









(a) Healthy subject    (b) COPD patient 
   
(c) COPD patient 
 
Figure 3.32a-c.  Cytospins of healthy and COPD sputum samples 
Cytospins were performed on 50µl of each sputum sample, allowed to air dry and then 
stained with Diff Quik™, as per the manufacturer’s protocol.  Slides were then viewed 
on a Zeiss microscope with (a, b) an x40 objective lens and (c) an x100 objective lens. 











Experiments were then performed to investigate the phagocytic responses of sputum 
macrophages using flow cytometry.  Sputum macrophages isolated from smokers 
showed increased phagocytosis compared to both healthy controls and COPD subjects 
(Fig. 3.33a) and increased uptake of beads in comparison to COPD macrophages (Fig. 
3.33 b). 







Figure 3.33. Ability of sputum macrophages from all subject groups to phagocytose 
beads 
Sputum of healthy controls (■), healthy smokers (■) and COPD patients (■) was 
processed and macrophages were resuspended at 1x105 macrophages per FACS tube 
in RPMI media. Cells were incubated with 900µl of 50x106beads/ml for 4 h, and then 
quantified by flow cytometry.  Macrophages were gated according to properties of size 
and granularity.  Data are presented as mean ± SEM, n=6 for healthy, n=6 for smokers, 
n=9 for COPD, where * represents p<0.05 and **p<0.01. 
 
In contrast to MDMs, sputum macrophages from all subject groups showed equivalent 
phagocytosis and uptake of H. influenzae (Fig. 3.34a and b).  Uptake of S. pneumoniae 
by sputum macrophages was similar to that seen with beads.  Smoker macrophages 
showing increased percentage phagocytosis compared to both healthy and COPD 


































Figure 3.34. Ability of sputum macrophages from all subject groups to phagocytose H. 
influenzae 
Sputum of healthy controls (■), healthy smokers (■) and COPD patients (■) was 
processed and macrophages were resuspended at 1x105 macrophages per FACS tube 
in RPMI media. Cells were incubated with 900µl of bacterial solution for 4 h, and then 
quantified by flow cytometry.  Macrophages were gated according to properties of size 
and granularity.  Data are presented as mean ± SEM, n=6 for healthy, n=7 for smokers, 
n=9 for COPD, where * represents p<0.05 and **p<0.01. 








Figure 3.35. Ability of sputum macrophages from all subject groups to phagocytose S. 
pneumoniae 
Sputum of healthy controls (■), healthy smokers (■) and COPD patients (■) was 
processed and macrophages were resuspended at 1x105 macrophages per FACS tube 
in RPMI media. Cells were incubated with 900µl of bacterial solution for 4 h, and then 
quantified by flow cytometry.  Macrophages were gated according to properties of size 
and granularity.  Data are presented as mean ± SEM, n=6 for healthy, n=6 for smokers, 














































Examining two techniques for the isolation of monocytes showed that the final yield of 
MDMs was similar whether Miltenyi negative selection or the adherence technique 
was used.  The technique of Miltenyi negative selection employs a column of magnetic 
beads to bind cells that are not required (including CD3, CD7, CD19, CD56, CD123 and 
Glycophorin A positive beads), allowing monocytes to pass through the column.  
Included in the magnetic beads are those to bind CD16+ cells.  There are several 
monocyte subsets, which are divided into classical (CD14++, CD16-), intermediate 
(CD14++ CD16+) and non-classical (CD14+CD16++) (Ziegler-Heitbrock, 2007). CD16+ 
monocytes have been postulated to be more mature, pro-inflammatory (with 
increased cytokine release and chemokine receptor expression) and have increased 
HLA-DR expression with associated increased antigen presenting capacity (Ziegler-
Heitbrock, 2007;Merino et al., 2011).  They have been shown to express similar 
patterns of surface antigens to tissue macrophages, which are reported to be less 
phagocytic compared to alveolar macrophages (Ziegler-Heitbrock, 2007).  In addition, 
CD16+ monocytes have also been found to have increased senescence (Merino et al., 
2011).  One could therefore postulate that the isolation of monocytes by negative 
selection may exclude a subset of monocytes, whilst adherence would include all 
monocyte subsets.  MDMs derived from the CD16+ subset of monocytes may 
therefore differ in their phagocytic ability; however, experiments presented herein 
showed that the MDMs derived from monocytes isolated by Miltenyi or adherence 
had equivalent ability to phagocytose beads.  Additionally, Taylor et al showed 
defective bacterial phagocytosis in COPD MDMs similar to that presented in this study, 
using MDMs derived from monocytes isolated using negative selection, as compared 
to adherence used in this study (Taylor et al., 2010).  
MDMs phagocytosis of both inert particles and bacteria increased in a time and 
concentration dependent manner, with maximal uptake around 4 h, similar to current 
evidence on macrophage phagocytosis in the literature (Takizawa et al., 1996;Cannon 
and Swanson, 1992).  Examining phagocytosis at 4 h was selected, as the level of 
fluorescence obtained at 4 h enables small alterations in phagocytosis to be clearly 
evident.  In addition, using multiple time points in future assays would give a true level 
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of the phagocytic defect.  Macrophages appear to have an immense capacity for 
uptake of particles or pathogens; it has been estimated that, when necessary, 
macrophages can internalize the equivalent of >100% of their surface area within 30 
min (Greenberg and Grinstein, 2002).  The ability of macrophages to ingest significant 
numbers of particles is further exemplified by their capability to ingest particles 3-
times their volume (Cannon and Swanson, 1992).  
Treatment of MDMs with cytochalasin D revealed that 40-50% of measurable bead 
phagocytosis and 10-15% of measurable bacterial phagocytosis were due to non-
specific binding.  Therefore, particles were adhering to the cell surface, increasing 
measurable cellular fluorescence, without being internalised.  Macrophages have been 
shown to exhibit similar levels of non-specific binding in the presence of cytochalasin, 
with one study showing ~30% non-specific binding after 30 min incubation with latex 
beads, whilst another showed ~60% reduction in bead internalisation after 20 min 
incubation with beads in the presence of cytochalasin D (15µM) (Winkler et al., 
2008;Sulahian et al., 2008).  The increase in non-specific binding with latex beads 
compared to bacteria may be related to size; the beads used herein are 2µM in 
diameter, whilst the bacteria measure 1-2µM in maximum length.  Therefore it may be 
related to speed of uptake, with evidence in the literature of slower internalisation of 
larger particles (Lee et al., 2011).  In addition, the receptor involved in phagocytosis 
alters the rate of internalisation of particles and pathogens, therefore it may be that 
particles and pathogens are being taken up by differing receptors resulting in 
differences in non-specific binding (Lee et al., 2011).   
MDMs from all subject groups showed equivalent phagocytosis of beads, showing that 
all were capable of phagocytosis.  However, MDMs from smoker and COPD subjects 
showed significantly reduced phagocytosis of both gram positive and gram negative 
bacteria.  Both MDMs and AM have been shown in previous studies to have equivalent 
bead phagocytosis, whilst phagocytosis of alternative prey has again been shown to be 
defective across different subject groups (Taylor et al., 2010;Hodge et al., 2003).  
Importantly the defect in phagocytosis of bacteria by MDMs was not related to the use 
of heat-killed bacteria, as similar reductions in phagocytosis of bacteria were seen with 
the use of live bacteria.  The alterations in phagocytosis showed no correlation with 
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age, smoking history or lung function, suggesting that defective phagocytosis is not 
simply a phenomenon of ageing, nor is it simply associated with disease severity.  This 
suggests that the defect leading to reduced uptake of bacteria by MDMs is inherent 
within the cells of the patient and is not caused by worsening disease or increased 
exposure to cigarette smoke.  There was, however, a correlation between the ability of 
MDMs to phagocytose gram positive bacteria and their ability to phagocytose gram 
negative bacteria, with the correlation strongest at lower levels of phagocytosis,  
suggesting that the defect underlying reduced bacterial uptake is not specific to type 
or strain of bacteria.   
In the study by Taylor et al, (Taylor et al., 2010), whilst there was a trend to reduced 
phagocytosis of bacteria in smokers, this was not significant, in comparison to findings 
in the present study. The smoker subjects used herein are older (mean 58y vs. 53y) 
with an increased pack year history (mean 40 vs. 33); however, the evidence from the 
correlation data suggests that these parameters should have no effect on 
phagocytosis.  Therefore, it may be related to the experimental design; a single time 
point of 1 h was used by Taylor et al, whereas examination of phagocytosis at longer 
time points may have shown a more marked reduction in phagocytosis by smoker 
MDMs.  The different time points used may also explain the discrepancy between heat 
killed and live bacteria, where smoker cells have higher levels of phagocytosis 
compared to COPD with H. influenzae in live bacteria compared to heat killed.  The 
longer time points used in this study were to ensure that the reduction seen in 
phagocytosis in COPD MDMs, (Taylor et al., 2010), was due to an inherent defect in 
phagocytosis in these cells and not simply due to slower rate of uptake of bacteria by 
cells from COPD patients compared to healthy subjects.  
This findings of reduced phagocytosis in the smoker population appears to suggest an 
effect of current smoking on phagocytosis, however, in the study by Taylor et al, the 
smoker subjects were all current smokers yet had improved levels of phagocytosis 
compared to COPD and this is also seen in this study when phagocytosis was 
performed using live H. influenzae.  In addition, within the COPD cohort nearly half the 
subjects were current smokers, with no discernible differences found in levels of 
phagocytosis between smoking and non-smoking COPD subjects.  It has previously 
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been shown that MDMs interacting with cigarette smoke-modified extracellular matrix 
proteins displayed reduced efferocytosis (Kirkham et al., 2004) suggesting active 
smoking would lead to reduced phagocytosis, however, it is not clear why the effect 
was so marked in this study and differed to previous results and this requires further 
investigation.       
Whilst there are clear alterations in the ability to ingest bacteria by smoker and COPD 
MDMs, this study showed no differences in the ability of cells from different subject 
groups to kill bacteria once internalised.  This suggests that once bacteria are 
internalised into the phagosome, the functions of lysosomal fusion and the anti-
microbial activity within the formed phagolysosome remains intact. This is supported 
by the literature, where no differences were found in intracellular bacterial killing 
between macrophages from healthy, smokers and COPD subjects (Berenson et al., 
2006a), whilst murine AM exposed to CSE have been shown to have increased 
intracellular killing ability (Marti-Lliteras et al., 2009).   
The release of TNF-α from MDMs does, however, show further discrepancies in 
macrophage function between different subject groups.  COPD MDMs released 
significantly higher levels of TNF-α in response to phagocytosis of inert particles 
compared to healthy and smoker cells, suggesting an abnormal inflammatory 
response.  TNF-α is reported to be increased in blood, sputum and BAL of patients with 
COPD (Keatings et al., 1996;Di et al., 1994a); therefore, this heightened inflammatory 
response to inert particles may be expected in COPD.  However, in response to H. 
influenzae, COPD MDMs produced significantly less TNF-α, suggesting a blunted 
response.  Mouse AM exposed to CSE have been shown to produce attenuated levels 
of TNF-α compared to non-exposed controls (Gaschler et al., 2008).  AM from COPD 
patients have shown reduced release of TNF-α in response to NTHI, compared to 
smokers and healthy controls (Berenson et al., 2006b).  Rhinovirus exposure of AM has 
also been shown to significantly impair the LPS-induced secretion of TNF-α (Oliver et 
al., 2008). Given that the attenuated levels of TNF-α are seen predominantly in 
response to gram negative bacteria, it is suggestive of altered recognition via or 
signalling from TLR4 in COPD cells. However, whilst expression of TLR2 appears to be 
variable in COPD, with both increased and reduced expression reported on peripheral 
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blood monocytes and AM, respectively, compared to healthy controls (Droemann et 
al., 2005(Pons et al., 2006), in both studies, TLR4 expression was unaltered.  Work 
carried out previously by our group has also shown no alterations in either TLR2 or 
TLR4 expression on MDMs from COPD patients compared to controls (Taylor et al., 
2010).  It may be that COPD and smoker MDMs release reduced levels of cytokines at 
an individual cellular level, however, due to the increased numbers of cells present in 
the lungs of smokers and COPD patients, the overall levels of cytokine are increased.  
Alternatively, it may be that COPD MDMs release cytokines at a different rate to 
healthy MDMs, as a limitation of the present study was that only a single time point 
was measured.  
When COPD patients were classified based on their exacerbation history over the prior 
2 y, frequent exacerbators were shown to have significantly reduced phagocytosis, of 
both gram positive and gram negative bacteria, compared to infrequent exacerbators.  
Interestingly, the frequent exacerbator group had a significantly lower pack year 
history and overall slightly better lung function compared to the infrequent 
exacerbators, once again confirming that this defect in phagocytosis is not related to 
disease severity or smoking history.  Previous work by Patel et al has shown that 
frequent exacerbators have higher rates of bacterial colonisation compared to 
infrequent exacerbators, (Patel et al., 2002), and this reduced ability to phagocytose 
bacteria may, in part, explain this observation.  Therefore, a reduction in phagocytosis 
in COPD may lead to increased bacterial load within the lung and increased 
susceptibility to infection, driving more frequent exacerbations.  Frequent 
exacerbations of COPD are associated with more rapid decline in FEV1, increased 
hospitalisations, increased mortality and increased costs (Wedzicha and Seemungal, 
2007).  In addition, frequent exacerbations have a marked effect on patient quality of 
life, with increased dyspnoea, reduced exercise capacity and a greater likelihood of 
becoming housebound (Sapey and Stockley, 2006).  Examining the ability of 
macrophages from COPD patients to phagocytose bacteria may then highlight a group 
of patients in whom targeted anti-microbial therapy may have significant benefits. 
Whether the defect exists within phagocytic cells and drives exacerbation frequency or 
vice versa is not entirely clear. However, given that the cells used in this study are 
circulating cells and have not been exposed to the lung environment, it suggests that 
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the defect leading to reduced bacterial phagocytosis is inherent within the cell.  
Furthermore, acute exacerbations of COPD did not significantly alter phagocytosis 
beyond baseline levels.  This adds further weight to the suggestion that the defect 
underlying reduced phagocytosis is inherent within the cell and is not particularly 
susceptible to environmental changes.  A limitation of the present study is the small 
numbers of paired baseline and exacerbation phagocytosis data, thus only allowing for 
limited conclusions to be drawn on this data.  A further limitation is the paucity of data 
on whether the exacerbations were related to a viral or bacterial exacerbation, and, 
with regards to the latter, whether this involved a strain change from the colonising 
bacteria, as this may have variable impact on the phagocytic defect. 
In contrast to the defective phagocytosis of bacteria in MDMs from smokers and COPD 
patients compared to healthy controls, sputum macrophages showed reduced 
phagocytosis of beads and S. pneumoniae by COPD macrophages only in contrast to 
smoker cells.  Berenson et al found similar data, with COPD AM showing reduced 
phagocytosis of H. influenzae only when compared to smoker and not healthy controls 
(Berenson et al., 2006a). It has been shown that induced sputum predominantly 
obtains cells from the surface of central but not peripheral airways, (Alexis et al., 
2001), and therefore sputum macrophages may not be fully representative of alveolar 
macrophages.  Sputum from COPD patients has been shown to have an increased 
percentage of neutrophils and lower percentage of macrophages when compared to 
smokers, whilst smokers have been shown to have an increased percentage of 
macrophages compare to healthy controls (Rufino et al., 2007;Lensmar et al., 1998).   
In the present study, in sputum from COPD patients, neutrophils represented the 
majority of the cells with a reduced percentage of macrophages, compared to both 
smoker and healthy subjects where macrophages were the predominant phagocytic 
cell.  This differing ratio of phagocytic cells within each sample represents one of the 
main problems with this phagocytosis assay in sputum.  In COPD sputum samples, 
where there is a significantly increased proportion of neutrophils, the phagocytic prey 
used in the assay is likely to be taken up predominantly by the neutrophils, given the 
rapidity with which neutrophils phagocytose prey, potentially thus appearing to alter 
macrophage phagocytosis.  In addition, pre-existing bacterial contamination was often 
seen in the COPD samples, but not healthy or smoker samples, which may also have an 
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effect on the subsequent phagocytosis assays.  To truly measure macrophage 
phagocytosis in sputum, the macrophages would need to be isolated.   
This study has shown that smoker and COPD MDMs have defective uptake of bacteria, 
but show no alterations in bead uptake in comparison to healthy controls.  The 
discrepancy between uptake of particles versus pathogens is suggestive of a defect at 
the level of the pathogen recognition receptors, resulting either in down-regulation or 
reduced expression of receptors leading to reduced uptake. Rat bone marrow derived 
macrophages incubated with apoptotic neutrophils for 30 min, then re-exposed to 
identical prey after 48 h, showed ~50% reduction in uptake of apoptotic neutrophils on 
the second exposure (Erwig et al., 1999).  However, their ability to engulf apoptotic 
neutrophils, after an initial exposure to opsonised erythrocytes, (uptake via a different 
receptor) was unaffected (Erwig et al., 1999), suggesting either down regulation of 
receptor expression or an element of satiety to the same exposure.  It was 
subsequently shown that ligation of cell surface integrins reduced uptake of apoptotic 
neutrophils, but not of other particles, similar to effects of prior exposure, indicating 
desensitisation to the same prey.  The monocytes used in this thesis are circulating 
cells; therefore, are unlikely to have been exposed to prey.  Therefore, it is unlikely 
that altered receptor expression due to a desensitisation mechanism could account for 
the defects in bacterial phagocytosis seen in these cells.   
Therefore, it could be that the differences seen in phagocytic capacity for beads and 
bacteria could be explained by reduced receptor availability, with different receptors 
involved in uptake of particles versus pathogens. Exposure of THP-1 cell-derived 
macrophages to cigarette smoke extract resulted in significantly reduced MARCO 
expression, with an associated reduction in bacterial clearance of Mycoplasma 
pneumonia (Baqir et al., 2008).  MARCO has been shown to be one of the main 
phagocytic receptors for unopsonised pathogenic bacteria, including S. pneumoniae 
(Arredouani et al., 2004).  In a murine model, influenza infection led to release of 
interferon-γ, which inhibited bacterial clearance by AM and correlated with 
downregulation of MARCO on AM (Sun and Metzger, 2008).  However, previous work 
in our group has shown no differences in expression of MARCO, nor altered expression 
of other pathogen recognition receptors including CD206, CD163 and CD36 on MDMs 
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from COPD patients compared to controls (Taylor et al., 2010).  Therefore, whilst 
reduced MARCO expression has been shown to lead to reduced phagocytosis, this 
latter study suggests that altered receptor expression may not account for the 
reduction in phagocytosis of bacteria seen in the present study suggesting the defect 
may be related to signalling pathways beyond the receptors and the subsequent 
cytoskeletal rearrangements required for effective phagocytosis, which will be 
investigated further in Chapter 6. 
In conclusion, MDMs from smokers and COPD patients show defective phagocytosis of 
pathogenic bacteria, but retain the ability to perform intracellular killing.  It is unlikely 
that the use of ICS or LABA were related to reductions in phagocytosis as healthy 
smokers had lower levels of phagocytosis with no exposure to treatment.  Previous 
work in the laboratory has shown that phagocytosis by MDMs from COPD subjects was 
unaltered by exposure to tiotropium, LABA or theophylline, with improvements in 
phagocytosis shown with budesonide (Taylor et al., 2010).  The effects of ICS on 
phagocytosis in COPD have been explored in more detail in Chapter 5 of this thesis.  
This altered uptake of bacteria is not associated with increasing age or disease 
progression, nor with smoking history, suggesting the defect is inherent within the cell 
and not caused by worsening disease.  Furthermore, there was a distinct association 
between the phagocyctic ability of MDMs and the frequency of exacerbations.  This 
may allow for the ability of MDMs to ingest bacteria to be used as a predictor for those 
patients in whom targeted and aggressive anti-microbial therapy may have increased 
benefits. 
As neutrophils are the other main phagocyte in the lung at times of infection, the next 
chapter will examine whether neutrophil phagocytosis is in anyway altered and the 
mechanisms underlying defective phagocytosis will subsequently be examined. 
3.4.1 Limitations 
Experiments should be repeated in stable state with alveolar macrophages to ensure 
the defect is seen in alveolar macrophages as well as MDMs.  Increased numbers of 
paired baseline and exacerabation samples would be needed to ensure that there was 
truly no differences seen in phagocytosis.  A further limitation was that the type of 
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exacerbation, viral or bacterial, was not known in this study, as the type of 
exacerbation may lead to altered effects on phagocytosis at time of exacerbation.  The 
sputum data was limited as there was a mix of phagocytic cells contributing to the 
phagocytosis measured, therefore, this should be repeated with separation of 


















COMPARISON OF PHAGOCYTOSIS BY 
NEUTROPHILS FROM HEALTHY, SMOKER 








Neutrophils are the first phagocyte to be recruited to sites of infection, thus 
dominating the early immune response to foreign material (Lee et al., 2003).  The role 
of neutrophils in the lung is to clear bacterial pathogens to prevent colonisation, hence 
a pulmonary bacterial infection often leads to massive neutrophil influx from the 
circulation into the lung (Lee et al., 2003).   
Neutrophils are increased in number in the lungs of patients with COPD compared to 
those of smokers without respiratory disease (Stanescu et al., 1996).  In addition, the 
numbers of pulmonary neutrophils correlates with the degree of airway obstruction 
and an increased rate of decline in FEV1 (Stanescu et al., 1996;Donaldson et al., 2002).  
This may be related to either increased neutrophil recruitment as a result of the 
disease, with chemotaxis towards increased levels of inflammatory chemokines, or 
may result from delayed apoptosis.  Studies in patients with neutrophilic asthma have 
shown increased neutrophil longevity in the lung (Rytila et al., 2006). This contrasts 
with COPD and smokers, where significantly reduced numbers of neutrophils undergo 
spontaneous apoptosis compared to healthy controls (Rytila et al., 2006;Pletz et al., 
2004).  Nonetheless, neutrophil numbers are increased in the lungs of smokers 
compared to healthy controls, yet despite these increased numbers, smokers show 
increased susceptibility to pulmonary infections, which has been suggested to be due 
to an impaired neutrophil anti-bacterial capability (Bagaitkar et al., 2008).   
An important anti-bacterial function of neutrophils is the ability to phagocytose 
bacterial pathogens.  Impairment of this function could lead to an increased propensity 
for bacterial colonisation.  Evidence for this possibility includes the observation that 
neutrophils from patients with chronic bronchitis have a reduced phagocytic index and 
killing of Candida spp. by approximately 50% in comparison to healthy subjects (Fietta 
et al., 1988).  Cigarette smoking may exacerbate this response, since neutrophils from 
healthy subjects incubated in the presence of cigarette smoke media (CSE) showed 
significantly reduced phagocytosis of Escherichia coli when compared to untreated 
neutrophils (Prieto et al., 2001).  Similarly, CSE treated neutrophils exposed to two 
different strains of Staphylococcus aureus showed significantly reduced phagocytosis 
(~15%) compared to >60% of control cells (Guzik et al., 2011).  This is further 
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supported by data from COPD patients, whereby neutrophils show reduced 
phagocytosis of E. coli compared with cells from healthy controls (Stringer et al., 2007). 
Taken together these data suggest that the phagocytic mechanism regulating bacterial 
removal in COPD may not be defective in macrophages alone, but may also be 
defective in neutrophils. 
Therefore, this chapter aims to investigate the ability of neutrophils to phagocytose 
both inert particles and pathogenic bacteria, and compare the responses of 



















4.2.1 Subject selection 
Healthy, smoking and COPD subjects were recruited as described in section 2.2.1. 
4.2.2 Blood separation 
Neutrophils were isolated from blood as described in section 2.2.3.  Neutrophils were 
rested for 1 h prior to use in experiments. 
4.2.3 Phagocytosis Assays 
Phagocytosis assays were performed using fluorescently labelled beads or bacteria 
that were incubated with neutrophils for time points up until 1 h, at the 
concentrations indicated, as described in section 2.2.7. 
4.2.4 Measurement of cell surface receptor expression 
Receptor expression was analysed by flow cytometry (see section 2.2.10).  The 
following antibodies were used at the dilutions specified in table 4.1. 
Antibody Dilution 
Isotype control 1:10 
Anti-CD11b 1:10 
Anti- TLR2 1:10 
Anti- TLR4 1:20 
Table 4.1.  Antibody dilutions used for quantification of cell surface receptor 
expression. 
 
Receptor expression was described as the median fluorescent intensity (MFI) of 
neutrophils incubated with the antibody of interest, divided by the MFI of neutrophils 
incubated with isotype control (to account for non-specific binding). 
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4.2.5 Assessment of viability of neutrophils 
Viability was assessed using the Annexin apoptosis kit (BD, Oxford, UK), following the 
protocol as described by the manufacturer.  In brief, 1x105 neutrophils were re-
suspended in binding buffer (supplied in the kit; 0.1 M Hepes/NaOH (pH 7.4), 1.4 M 
NaCl, 25 mM CaCl2).  Annexin-V (a marker of apoptosis) and 7-AAD (a marker of 
cellular necrosis) were added to the tube, at a 1:20 dilution, then incubated in the dark 
for 15 min at RT.  Neutrophil viability was analysed by flow cytometry.  Cells were 
gated (see section 2.2.7) and a quadrant marker set up round the control population.  
Cells displaying apoptosis will increase in fluorescence along the x-axis, while those 
displaying necrosis will increase in fluorescence on the y-axis.  The percentage of cells 
falling into different quadrants can then be analysed (Fig. 4.1). 
Figure 4.1.  Analysis of neutrophil viability 
Annexin and 7-AAD were added to the tube containing 1x105 neutrophils, at a 1:20 
dilution, then incubated in the dark for 15 min at RT.  Neutrophil viability was analysed 
by flow cytometry.  The percentage of cells falling in each of the four quadrants could 














Firstly, experiments were performed to establish the ability of neutrophils to 
phagocytose beads and bacteria. 
4.3.1 Subject Demographics 
The characteristics of healthy, smoking and COPD subjects used in this study are shown 
in Table 4.2.  There were significant differences in age and lung function between 
COPD and control groups (healthy and smoker subjects). 
 Healthy Smoker COPD 
Age (years) 58 ± 2 58 ± 1  66 ± 2 * 
Gender (M:F) 11 : 12 11 : 11 16 : 8 
FEV1 (l) 2.6 ± 0.2 2.5 ± 0.1  1.2 ± 0.1 *** 
FEV1 % predicted 95 ± 2.4 86 ± 2.2  49 ± 4.1 *** 
FVC (l) 3.8 ± 0.4 3.6 ± 0.3  2.5 ± 0.2 ** 
FEV1/FVC (%) 78 ± 1.2 74 ± 0.9  44 ± 2.5 *** 
Smoking history 
(pack years) 
0 40 ± 3.4 54 ± 5.6 
Table 4.2.  Subject demographics 
Where * represents p<0.05, ** p<0.01 and *** p<0.001 compared to both healthy and 
smoking controls.  Data is shown as mean ± SEM. 
 
4.3.2  Neutrophil phagocytosis of beads 
Initial experiments were performed to establish the optimum time point and 
concentration of beads at which to measure neutrophil phagocytosis. Cells were 
incubated with beads for increasing times and phagocytosis measured by FACS.  These 
experiments revealed rapid uptake of beads by neutrophils, with the maximum 
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number of cells phagocytosing beads within 5 min (Fig. 4.3).  This did not change over 
the following hour, indicating that phagocytosis was dependent on the concentration 
of beads (Fig. 4.3).   
 
From these data, a sub-maximal concentration of 10x106beads/ml was chosen for use 
in future experiments.  Given that maximal neutrophil phagocytosis had been reached 
by the first time point of 5 min, further experiments were carried out at shorter time 
points.  Neutrophils showed a rapid uptake of beads, with maximal phagocytosis 
reached at 2 min, with no change in percentage phagocytosis up to 30 min (Fig. 4.4). 
























Figure 4.3. Effect of incubation time and bead concentration on phagocytosis by 
neutrophils  
Neutrophils from healthy volunteers were isolated using Percoll gradients.  
Polystyrene bead solutions (900µl) (▼5x106/ml, ▲10x106/ml or ■50x106/ml) 
were added to 1x105 neutrophils in FACS tubes, and incubated at 37OC for the 
times indicated.  Phagocytosis was stopped with ice cold PBS, cells washed, 
resuspended in FACSfix and analysed on FACScan with WinMDI software. Data 




4.3.3 Determination of non-specific binding 
Given the rapidity of bead uptake by neutrophils, further experiments were carried out 
to confirm that the measurement of fluorescence was related to phagocytosis and not 
due to non-specific binding of beads to cells.  Experiments were performed either at 
4oC or in the presence of cytochalasin D (2µM), an actin microfilament inhibitor, both 
of which inhibit active phagocytosis (Parod and Brain, 1986).  
Both cytochalasin D and reducing the temperature to 4oC caused an approximate 60% 
reduction in phagocytosis (Fig. 4.5).  This suggests that non-specific binding accounts 
for up to 40% of bead phagocytosis measured.   
 
 


























Figure 4.4. Time course of neutrophil phagocytosis of polystyrene beads 
Neutrophils from healthy volunteers were isolated using Percoll gradients.  
Polystyrene beads (10x106/ml) were added to 1x105 neutrophils in FACS tubes, and 
incubated at 37OC for the times indicated.  Phagocytosis was stopped with ice cold D-
PBS, cells washed, resuspended in FACSfix and analysed on FACScanto using 





4.3.4 Neutrophil phagocytosis of bacteria 
Having established the ability of neutrophils to ingest inert particles, their ability to 
ingest clinically relevant pathogens was examined.  Neutrophils phagocytosed both 
Gram-positive and Gram-negative bacteria rapidly, within 5 min, in a concentration-
dependent manner (Fig. 4.6).  The highest concentration of bacterial solution and a 





























Figure 4.5.  Effect of 4OC or Cytochalasin D on neutrophil phagocytosis of beads 
Neutrophils from healthy volunteers were isolated using Percoll gradients.  
Neutrophils (1x105) were incubated with 900µl of 10x106beads/ml at 4OC (▲) or 
37OC (■), or at 37OC after 30 min pre-treatment with cytochalasin D (2µM) (▼). 
Phagocytosis was stopped with ice cold PBS, cells washed, resuspended in FACSfix 
and analysed on FACScan with WinMDI software. Data shown are mean+/-SEM, 




4.3.5 Assessing internalisation of bacteria - pHrodoTM labelled bacteria 
To further investigate the non-specific binding of neutrophils with bacteria, H. 
influenzae was labelled with pHrodo dyeTM (Invitrogen, UK), a pH specific fluorescent 
dye that only fluoresces at acidic pH (i.e. within the phagolysosome).  This revealed 
that 100% of cells phagocytosed the bacteria from 5 min onwards, as shown by the 
phagocytic (blue) population having shifted in entirety to the right from the control 






(a) % phagocytosis of HI   (b) % phagocytosis of SP 































































































Figure 4.6a and 4.6b. Effect of incubation time and bacterial concentration on 
phagocytosis of (a) H. influenzae and (b) S. pneumoniae by neutrophils  
Neutrophils from healthy volunteers were isolated using Percoll gradients.  Bacterial 
solutions, given by CFU/ml, (■4x107/ml, ▲1x108/ml or ▼4x108/ml) were added to 
1x105 neutrophils in FACS tubes and incubated at 37OC for the times indicated.  
Phagocytosis was stopped with ice cold PBS, cells washed, resuspended in FACSfix and 





Figure 4.7a.  Neutrophil phagocytosis of pHrodo labelled H. influenzae  
Neutrophils from healthy volunteers were isolated using Percoll gradients.  pHrodo 
labelled H. influenzae was added to 1x105 neutrophils in FACS tubes, and incubated at 
37OC for 5 min.  Phagocytosis was stopped with ice cold PBS and analysed on 
FACScanto with FACSDiva software. The population to the left of the x-axis is the 
control population, whilst neutrophils taking up bacteria become fluorescent – 
phagocytic population. Data shown is representative of n=4. 
 
 
Analysis of the median fluorescent intensity of the phagocytosing neutrophils 
population showed that the amount of bacteria ingested increased to the 15 min time 























Figure 4.7b.  Time course of neutrophil phagocytosis of pHrodo labelled H. influenzae 
Neutrophils from healthy volunteers were isolated using Percoll gradients.  pHrodo 
labelled H. influenzae was added to 1x105 neutrophils in FACS tubes, and incubated at 
37OC for the times indicated.  Phagocytosis was stopped with ice cold PBS and 
analysed on FACScanto using FACSDiva software. Data shown are mean+/-SEM, n=4. 
 
4.3.6 Effect of disease on phagocytosis of beads and bacteria by 
neutrophils  
Data presented in Chapter 3 showed that MDMs from smoking and COPD subjects, 
whilst capable of phagocytosis, displayed defective uptake of bacteria in comparison to 
healthy controls.  Whether this phenomenon was also apparent in neutrophils was not 
known.  Therefore, having established an assay for neutrophil phagocytosis of both 
inert particles and bacteria, a comparison of phagocytosis by neutrophils from non-
smokers, smokers and COPD patients was performed.  Neutrophils from COPD patients 
showed an equivalent ability to phagocytose beads when compared to non-smoking 
and smoking controls, with no significant differences in the amount of beads taken up 





(a) Percentage phagocytosis   (b) Median fluorescent intensity 
 
Figure 4.8. Effect of disease state on (a) percentage phagocytosis of beads by 
neutrophils and (b) median fluorescent intensity of beads  
Neutrophils from healthy (■), smoking (▲) volunteers and COPD (▼) patients were 
isolated using Percoll gradients.  Polystyrene beads (10x106/ml) were added to 1x105 
neutrophils in FACS tubes, and incubated at 37OC for the times indicated.  Phagocytosis 
was stopped with ice cold PBS, cells washed, resuspended in FACSfix and analysed on 
FACScanto with FACSDiva software. Data shown are mean+/-SEM, n=20 for all groups. 
 
Approximately half of the neutrophils within the gated population, from both COPD 
and control subjects, had taken up beads at 5 min (Fig. 4.8a).  With increasing time 
there was no further increase in either the percentage of cells ingesting beads (Fig. 
4.8a), or in the number of beads ingested by each cell (Fig. 4.8b). 
 
4.3.7 Neutrophil phagocytosis of Streptococcus pneumoniae 
Having confirmed that all neutrophils were capable of phagocytosing beads in a similar 
manner, the capacity of neutrophils to remove bacterial pathogens was also 
investigated.  Neutrophils from all subjects displayed equivalent ability to phagocytose 
S. pneumoniae (Fig. 4.9).  However, differences were seen in the amount of S. 
pneumoniae taken up by neutrophils, with those cells isolated from smoker and COPD 
patients ingesting significantly less S. pneumoniae when compared to neutrophils 
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isolated from control subjects (Fig 4.9).  Neutrophils from COPD patients showed 
significantly reduced uptake at 5 min compared to healthy controls (Fig. 4.9b).  
(a) Percentage phagocytosis   (b) Median fluorescent intensity 













































Figure 4.9.  Effect of disease state on (a) percentage phagocytosis of S. pneumoniae by 
neutrophils and (b) median fluorescent intensity of S. pneumoniae  
Neutrophils from healthy (▼), smoking (▲) volunteers and COPD (■) patients were 
isolated using Percoll gradients.  Bacterial solutions (900µl) were added to 1x105 
neutrophils in FACS tubes, and incubated at 37OC for the times indicated.  Phagocytosis 
was stopped with ice cold PBS, cells washed, resuspended in FACSfix and analysed on 
FACScanto with FACSDiva software. Data shown are mean+/-SEM, n=20 for non-
smoker and smoker volunteers, n=21 for COPD, where * represents p<0.05 COPD vs. 
healthy. 
 
4.3.8 Neutrophil phagocytosis of Haemophilus influenzae 
Having shown a small but significant difference between COPD and healthy neutrophils 
in the uptake of gram positive bacteria, the uptake of H. influenzae was then 
investigated. Neutrophils incubated with H. influenzae (gram negative bacterium) 
showed no differences in percentage phagocytosis across the three disease groups 
(Fig. 4.10a).  However, whilst neutrophils from healthy volunteers show increasing 
ingestion of H. influenzae with time, neutrophils from both smoking and COPD subjects 
showed a significantly reduced capacity to ingest equivalent amounts of H. influenzae 
when compared to healthy controls (Fig. 4.10b).  At 30 min, neutrophils from smokers 
and COPD subjects show a 28% and 48% reduction in uptake of H. influenzae, 
respectively, in comparison to neutrophils from healthy subjects (Fig. 4.10b) 
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(a) Percentage phagocytosis   (b) Median fluorescent intensity 




































































Figure 4.10. Effect of disease state on (a) percentage phagocytosis of H. influenzae by 
neutrophils and (b) median fluorescent intensity of H. influenzae  
Neutrophils from healthy (●), smoking (■) volunteers and COPD (▲) patients were 
isolated using Percoll gradients.  Bacterial solutions (900µl) were added to 1x105 
neutrophils in FACS tubes, and incubated at 37OC for the times indicated.  Phagocytosis 
was stopped with ice cold PBS, cells washed, resuspended in FACSfix and analysed on 
FACScanto with FACSDiva software. Data shown are mean+/-SEM, n=21 for all groups, 
where * represents p<0.05, ** p<0.01, ***p<0.001 COPD vs. healthy and # represents 
p<0.05 COPD vs. smoker. 
 
This data is depicted below in an overlaid histogram, clearly showing the differences in 
the ability of neutrophils from different subject groups to ingest H. influenzae.  The 
population of COPD cells is least fluorescent (lowest uptake), with healthy cells taking 




Figure 4.11.  Effect of disease state on the uptake of H. influenzae  
Neutrophils from healthy (■), smoking (■) volunteers and COPD (■) patients were 
isolated using Percoll gradients.  Bacterial solutions (900µl) were added to 1x105 
neutrophils in FACS tubes, and incubated at 37OC for the times indicated.  Phagocytosis 
was stopped with ice cold PBS, cells washed, resuspended in FACSfix and analysed on 
FACScanto with FACSDiva software.  
 
4.3.9 Neutrophil viability 
Having shown that neutrophils from different subject groups showed altered uptake of 
bacteria, it was important to ensure that cells from smoker and COPD subjects did not 
have altered viability that could account for differences seen in phagocytosis.  Cells 
from all subject groups (both control cells and cells incubated with prey) were 
incubated with Annexin-V, a marker of apoptosis, and 7-AAD, a marker of cell necrosis, 
and then analysed by flow cytometry (see section 4.2.5).  An example of the dot plot 










COPD Smoker Healthy 
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Figure 4.12.  Analysis of neutrophil viability 
Annexin and 7-AAD were added to 100µl of 1x105 neutrophils, at a 1:20 dilution, then 
incubated in the dark for 15 min at RT.  Neutrophil viability was analysed by flow 
cytometry.  The percentage of cells falling in each quadrant could then be analysed. 
Assessment of neutrophil viability indicated that there were no differences were seen 
















Figure 4.13.  Effect of disease state on cell viability of neutrophils  
Neutrophils from healthy (●), smoking (■) volunteers and COPD (▲) patients were 
isolated using Percoll gradients.  Neutrophils at 1x105 in FACS tubes were incubated 
with 5µl of Annexin PE (marker of apoptosis) and 5µl of 7-AAD (marker of necrosis) at 
RT in the dark for 15 min.  Neutrophils were analysed on FACScanto with FACSDiva 
software. Data presented is control cells and is representative of cells exposed to prey.  









4.3.10 Neutrophil cell surface receptor expression 
In order to investigate whether decreased uptake of bacteria could be associated with 
reduced cell surface receptor expression of CD11b (a cell adhesion molecule and part 
of the CR3 receptor), toll-like receptor 2 (TLR2, involved in recognition of Gram 
positive bacteria) and toll-like receptor 4 (TLR4, involved in recognition of Gram 
negative bacteria).  There were no significant differences seen in neither the 
percentage of neutrophils expressing CD11b, TLR2 or TLR4 (Fig. 4.14a-c), nor the level 
of expression of CD11b, TLR2 or TLR4 on neutrophils from healthy or smoking 
volunteers or COPD patients (Fig. 4.15a-c).  
 






Figure 4.14. Effect of disease on percentage of neutrophils expressing the receptors; 
(a) anti-CD11 (b) anti-TLR2 and (c) anti-TLR4  
Neutrophils from healthy (■), smoking (■) volunteers and COPD (■) patients were 
isolated using Percoll gradients.  Neutrophils (1x105) were added to FACS tubes. 
Fluorescently labelled antibodies (1:10 dilution for CD11 and TLR2, 1:20 dilution for 
TLR4) or isotype control (1:10 dilution) were added to individual tubes, then incubated 
at 4OC for 30 min, washed with ice cold PBS and resuspended in FACSfix prior to 














































































Figure 4.15. Effect of disease state on neutrophil receptor expression; (a) anti-CD11 (b) 
anti-TLR2 and (c) anti-TLR4  
Neutrophils from healthy (■), smoking (■) volunteers and COPD (■) patients were 
isolated using Percoll gradients.  Neutrophils (1x105) were added to FACS tubes. 
Fluorescently labelled antibodies (1:10 dilution for CD11 and TLR2, 1:20 dilution for 
TLR4) or isotype control (1:10 dilution) were added to individual tubes, then incubated 
at 4OC for 30 min, washed with ice cold PBS and resuspended in FACSfix prior to 
























































Initial experiments on neutrophil phagocytosis showed that the neutrophils ingested 
particles extremely rapidly, with phagocytosis of fluorescently-labelled beads 
plateauing from around 2 min, suggesting a degree of activation.  However this speed 
of uptake is confirmed by previous studies, which have shown that neutrophils 
ingesting latex beads showed rapid uptake that was largely complete by 90 s, with 
particle uptake and vacuole closure completed within 20 s (Segal et al., 1980).  As seen 
with phagocytosis of beads, neutrophil phagocytosis of both Gram positive and Gram 
negative bacteria is maximal at 5 min.  It is likely that, as with beads, the maximal 
phagocytosis of bacteria is reached already at an even shorter time point.  This is in 
direct contrast to macrophages that take several minutes to engulf particles (Henry et 
al., 2004).  A comparison of the uptake of zymosan versus antibody-coated latex beads 
(3µM) by neutrophils revealed that the time taken for engulfment (particle uptake and 
vacuole closure) was on average 167 s for zymosan compared to 66 s for opsonised 
latex beads (Lee et al., 2011).  Increasing the size of the beads (to 5µM) reduced speed 
of engulfment to ~90 s, suggesting that the longer engulfment time for zymosan is not 
simply target-size related, but rather a combination of size and different receptors 
involved in the phagocytic process (Lee et al., 2011).  The engulfment time of the 
particles used in the present study is likely to be more rapid than that given for 
zymosan, reflecting their smaller particle size (polystyrene beads and H. influenzae 
~2µM and S. pneumoniae ~1 µM).   
Treatment of neutrophils with cytochalasin D or incubation at 4oC revealed that ~40% 
of measurable phagocytosis of beads was due to non-specific binding.  Therefore, 
particles were bound to the surface of the cell increasing cellular fluorescence but not 
internalised.  This is similar to studies of macrophages where non-specific binding of 
approximately 30%, after incubation with latex beads for 30 min (Winkler et al., 2008).  
Neutrophil phagocytosis of latex beads showed that even at 0 s, ~14% of cells had 
associated particles; this is unlikely to represent phagocytosis, and therefore is 
considered to be a measure of non-specific binding (Segal et al., 1980).  
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As there appears to be a relatively high level of non-specific binding, it was important 
to determine that internalisation could be confirmed and measured.  Therefore, 
bacteria labelled with pHrodoTM dye (Invitrogen, UK) were used to determine the 
degree of internalisation of bacteria incubated with neutrophils; this particular dye has 
low level fluorescence at neutral pH, with marked fluorescence at acidic pH, i.e. within 
the phagolysosome.  At the earliest time point of 5 min, all cells had internalised 
bacteria.  The fluorescence emitted from neutrophils was reduced in comparison to 
that of macrophages (chapter 3).  This may be due to the increased acidic nature of the 
phagolysosome of the macrophage (pH<5) compared with neutrophils (Lee et al., 
2003).  In neutrophils, activation of the oxidative burst, after fusion of granules with 
the neutrophil phagosome, leads to consumption of H+ ions, which increases pH 
transiently, leading to alkalinisation of the phagolysosome, which subsides after 
minutes (Nordenfelt and Tapper, 2011).  It is then unclear whether the pH remains 
neutral or becomes more acidic and it has been speculated that the phagosomal pH 
may be lower than that measured during in vitro studies (Lee et al., 2003;Nordenfelt 
and Tapper, 2011). Therefore, measuring earlier time points of phagocytosis with 
pHrodoTM dye, may not generate fluorescence due to a more alkaline environment 
within the phagosome.  However, from 5 min it is likely that the pH of the phagosome 
returns to neutral or even as speculated becomes more acidic, allowing the dye to 
fluoresce (Lee et al., 2003;Nordenfelt and Tapper, 2011).  Nonetheless, these studies 
indicate that bacteria are engulfed and processed rapidly. 
When the effect of disease on neutrophil phagocytosis was examined, it was clear that 
neutrophils from all subject groups were capable of phagocytosis.  However, smoker 
and COPD neutrophils showed defective uptake of bacteria.  This defect was more 
marked following exposure to H. influenzae than S. pneumoniae, with COPD 
neutrophils showing reduced uptake at all time points and smoker neutrophils showing 
reduced uptake after 10 min.  Whilst neutrophils from healthy subjects continued to 




Exactly why this is the case is unclear as there is little data in the literature regarding 
the ‘stop’ signals regulating phagocytosis.  One possibility would be that available 
receptors on the cell surface become depleted and are no longer available to bind the 
particle of interest.  As both the inert particles and bacteria used in these experiments 
were unopsonised, phagocytosis of the different prey may be triggered by the same 
receptors. However, neutrophils from all subject groups were capable of ingesting 
similar amounts of beads, suggesting there was sufficient receptor expression in 
neutrophils from all subjects.  There is little in the literature regarding expression of 
scavenger or mannose receptors (these being the likely receptors involved in 
phagocytosis of non-opsonised prey) on neutrophils in smokers or COPD subjects.   
Analysis of the distinct receptors involved in recognition of gram positive and negative 
bacteria (TLR2 and TLR4 respectively) and CD11b (part of the complement receptor) 
showed no differences in expression across the disease groups.  As discussed in the 
previous chapter, TLR2 has been found to be both up- and down-regulated on 
monocytes and AM respectively in COPD (Droemann et al., 2005;Pons et al., 2006).  
Blood neutrophils from COPD patients have been shown to have no differences in TLR2 
or TLR4 expression compared to healthy controls (von, I et al., 2011).  Another study 
has shown increased TLR4 expression on BAL cells from COPD compared to healthy 
and smoking controls, with the majority of these TLR4+ cells being neutrophils (Pace et 
al., 2011).  In contrast, levels of TLR2 expression were found to be similar across the 
three groups (Pace et al., 2011).  This latter study recruited patients from intensive 
care with respiratory failure, which may account for some of the differences seen in 
expression of TLR.  Neutrophils in the submucosa of bronchial biopsies have been 
shown to have increased CD11b and CD44 co-expression in COPD compared to 
smokers (Di et al., 2009).  Expression of CD11b on circulating neutrophils has also been 
shown to be higher in COPD subjects compared to healthy controls (Noguera et al., 
2001;Yamagata et al., 2007b) in contrast to the findings in this present study.  These 
differences may be due to different study populations, including severity of disease 
and concomitant infection. 
Stringer et al showed defective phagocytosis of E. coli in CSE-exposed neutrophils 
compared to healthy controls was associated with suppression of caspase-3 activity 
(Stringer et al., 2007).  Caspase-3 is required for spontaneous neutrophil apoptosis and 
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phagocytosis-induced neutrophil death (Zhang et al., 2003), although there is no 
evidence of a causal link between suppression of caspase-3 and reduced phagocytosis.  
Prieto et al also showed reduced phagocytic function in neutrophils from COPD 
patients compared to healthy controls (Prieto et al., 2001).  Glycophosphopeptical, an 
immunomodulator, improved the percentage of COPD neutrophils undergoing 
phagocytosis, but did not improve uptake of bacteria (Prieto et al., 2001).  
Glycophosphopeptical has been shown to improve natural killer cell activity in mice 
(Prieto et al., 2001).  The underlying mechanism behind the effect of 
glycophosphopeptical was not examined.  However, it may prime neutrophils, so 
altering composition of cell surface receptors and activating actin polymerisation 
(Nordenfelt and Tapper, 2011).  It has been shown that neutrophils primed with TNF-α 
have been shown to have increased killing of opsonised S. aureus, increased 
phagocytosis of complement-opsonised NTHI (associated with elevated levels of CR3 
and CR4), whilst neutrophils primed with hydrogen peroxide show increased 
phagocytosis of opsonised (IgG) erythrocytes (Ferrante et al., 1993;Pricop et al., 
1999;Tan et al., 1995). 
In order to investigate the mechanism underlying the defective phagocytosis of 
bacteria displayed by neutrophils from smokers and COPD, it is appropriate to examine 
the ability of neutrophils from the same subject groups to undergo chemotaxis. The 
processes of chemotaxis and phagocytosis appear to converge during signalling to the 
cytoskeleton during the formation of protrusions (Heinrich and Lee, 2011).  
Chemotaxis has also been shown to be altered in COPD patients compared to healthy 
and smoking subjects.  COPD patients show increased neutrophil migration toward 
fMLP compared to healthy controls (Burnett et al., 1987) and display increased rolling, 
tethering and migration, compared to healthy and smoking controls (Woolhouse et al., 
2005). Neutrophils from COPD patients display increased random speed but reduced 
directed speed and reduced accuracy to chemoattractants including CXCL8, CXCL1, 
fMLP and sputum, compared to neutrophils from healthy and smoking subjects (Sapey 
et al., 2011).  
No differences were found in receptor expression (CXCR1, CXCR2 and FPR1), however, 
COPD neutrophils produced less pseudopods compared to healthy and smoker cells 
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(Sapey et al., 2011).  Activation of the small GTPase, rac drives both protrusions both in 
cell migration and during phagocytosis (Castellano et al., 2000;Heinrich and Lee, 
2011;Levskaya et al., 2009).  Therefore, it may be that defects in cytoskeletal 
rearrangement affecting chemotaxis in neutrophils may also lead to altered 
phagocytosis.  Sapey et al showed that COPD neutrophils incubated with PI3-kinase 
inhibitors had reduced distance travelled, whilst improved directed speed and 
accuracy towards chemoattractants, whereas the inhibitors had minimal effect in 
healthy and smokers cells (Sapey et al., 2011).  Activation of the PI3K pathway is 
required for phagocytosis, resulting in the localisation of F-actin to specific points on 
the cell membrane for phagocytic cup formation (Greenberg and Grinstein, 2002).  
Therefore, it may be that there is a common defect in the signalling pathway 
accounting for both defects in chemotaxis and phagocytosis in neutrophils in COPD. 
In conclusion, these data show significantly reduced uptake of pathogenic bacteria by 
neutrophils from both COPD and smoking subjects in comparison to healthy controls.  
The possible mechanisms underlying this defect will be examined further in the 
subsequent chapter.  
4.4.1 Limitations 
Assays should be performed to ensure neutrophils from all groups are not 
differentially activated.  Receptor studies were limited and should be broadened to 




















A COMPARISON OF THE EFFECTS OF 
FLUTICASONE PROPIONATE AND 
BUDESONIDE ON THE PHAGOCYTIC ABILITY 







Inhaled corticosteroids (ICS) are now recommended for COPD patients with an FEV1 ≤ 
50% predicted, who experience frequent exacerbations or persistent breathlessness 
over a 12-month period (NICE guidelines, 2010), and as such, ICS are now prescribed to 
approximately 70% of COPD patients (Singanayagam et al., 2011).  ICS have been 
shown to improve symptoms, health status and reduce decline in FEV1, whilst 
decreasing exacerbation rates (Postma and Calverley, 2009).  However, the TORCH 
study, designed to look at all cause mortality in COPD, showed a non-significant (6%) 
increase in mortality in patients taking fluticasone propionate (Suissa and Barnes, 
2009).  A post-hoc analysis of these data revealed an increased risk of pneumonia of 
~50% in those patients taking inhaled corticosteroids (Crim et al., 2009).  This finding is 
of increased importance as patients with COPD that are hospitalised with pneumonia 
have been shown to have increased mortality compared to those without COPD 
(Restrepo et al., 2006;Holguin et al., 2005). 
This phenomenon has been studied further and two studies that compared the 
combination of fluticasone propionate and salmeterol with either salmeterol alone, or 
tiotropium bromide alone, have also shown an increased frequency of pneumonia in 
the fluticasone-containing treatment arm (200% and 100% increase respectively) 
(Kardos et al., 2007;Wedzicha et al., 2008).  Similarly, a Canadian population-based 
observational study reported a 70% increase in the risk of hospital admission with 
pneumonia in those COPD patients taking ICS, with the greatest increase in 
hospitalisation observed with highest doses of ICS (Ernst and Suissa, 2008).  Taken 
together, these studies indicate that ICS increase the risk of pneumonia in COPD 
patients, however, a recent meta-analysis examining treatment of COPD patients with 
budesonide showed no increased risk of pneumonia (Sin et al., 2009), with the lower 
risk of pneumonia associated with budesonide confirmed in a further comparison of 
randomised controlled trials of combination inhalers (Halpin et al., 2011).  This would 
suggest that the effect on pneumonia risk in COPD patients is not drug class 
dependent, but may be specific to fluticasone propionate. 
It remains unclear why different ICS appear to have differential effects on the 
increased risk of pneumonia.  Whilst all glucocorticoids act by binding to the 
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glucocorticoid receptor, each drug exhibits differential pharmacokinetic properties 
which may account for the clinical differences seen.  Fluticasone propionate is more 
lipophilic than budesonide, and as a result is more likely to be retained in mucus in the 
lumen of the airway and cleared via mucociliary clearance and cough (Edsbacker et al., 
2008).  Fluticasone propionate has been shown to have considerably lower plasma 
concentrations, possibly due to  increased deposition of inhaled drug in central airways 
following airways constriction (Mortimer et al., 2007).  This contrasts with budesonide 
where there is no reduction in plasma concentrations with bronchoconstriction 
(Mortimer et al., 2007).  There is now evidence that, after inhalation, fluticasone 
propionate resides for a prolonged time (hours) in the airway mucus, most likely in the 
form of undissolved particles. This contrasts with budesonide which dissolves 
completely and is absorbed into the airway tissue within a few minutes (Dalby et al., 
2009).  Whether the prolonged persistence of fluticasone propionate within the airway 
lumen may affect host defenses and account for the increased risks of pneumonia is as 
yet unknown.  
One hypothesis is that clearance of particulate fluticasone by phagocytic cells of the 
innate immune system results in high concentrations of the drug residing within the 
phagolysosomes.  Phagocytosis of pathogenic bacteria by macrophages has already 
been shown to be impaired in COPD patients (Taylor et al., 2010); therefore, any 
further impairment would lead to further reduction in clearance of bacteria from the 
lung, potentially increasing the risk of pneumonia.   
Therefore, the aim of this study is to compare the effects of two glucocorticosteroids, 
budesonide and fluticasone propionate, over a broad range of concentrations, on the 







5.2  Methods 
5.2.1 Subject recruitment 
The inclusion criteria for COPD patients were as follows: age 40-85 years, no history of 
other respiratory disease or major co-morbidity, smoking history of >10 pack years and 
no evidence of atopy on skin prick tests to common aero-allergens.  Lung function: 
FEV1% predicted <80%, FEV1: FVC ratio <0.7 and reversibility of <200ml in FEV1 (<15% 
FEV1% predicted) to inhaled β2 agonist.  In addition, patients had to be free from acute 
exacerbation or oral steroid or antibiotic usage in the preceding 6 weeks. 
5.2.2 Blood Separation 
Whole blood was taken by venepuncture after informed consent.  Granulocytes were 
separated from the PBMC fraction using Percoll gradients (see section 2.2.3).  
Monocytes from the PBMC fraction were adhered and cultured in the presence of GM-
CSF (2ng/ml) for 12d to differentiate into MDMs.  The granulocyte fraction was 
resuspended at 1x106cells/ml in D-PBS and rested at 4oC for 1 h, to reduce neutrophil 
activation.   
5.2.3 Phagocytosis Assays 
Particulate suspensions of both steroids were prepared by resuspension in 0.2% (w/w) 
Tween 80 in D-PBS.  The suspension was then sonicated for 5 min to ensure uniformity 
of particulates in solution.  Both MDMs and neutrophils were incubated with either 
budesonide or fluticasone (at concentrations 10-12 to 10-5 made up in RPMI) or vehicle 
control for 1h prior to addition of beads or bacteria.  
5.2.3.1 Phagocytosis of Beads 
Fluorescently labelled polystyrene microspheres (2.0µm diameter, yellow-green 
fluorescence (ex λ505nm/em λ515nm) were diluted in complete media to 
concentrations indicated (as described in Section 2.2.7). 
MDMs:  Bead solutions (10µl of 5x107/100µl) were added to wells containing 1x105 
MDMs and incubated at 37oC, 5% (v/v) CO2 for 4 h.  After incubation, unbound beads 
were washed off with D-PBS.  Fluorescence of extracellular particles was quenched by 
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adding 100µl/well of Trypan Blue (2% (v/v)) for 1min. Excess fluid was removed and 
fluorescence determined by fluorimetry (BMG Fluostar plate reader) at excitation 
λ480nm and emission λ520nm. 
Neutrophils:  Bead solutions (11µl of 107/100µl) were added to FACS tubes containing 
1x105 neutrophils and incubated at 37oC, 5% (v/v) CO2 for 15 min. After incubation, 
tubes were placed on ice to quench phagocytosis, then centrifuged (400xg, 5 min, 4oC) 
with ice cold D-PBS.  Cell pellets were resuspended and fixed in 300µl FACSfix (0.5% 
(v/v) paraformaldehyde in FACSflow) ready for analysis.  Samples were analysed using a 
Becton Dickinson FACSCanto machine using FACS Diva software.  Cells were gated 
according to forward and side scatter values correlating to neutrophils and for each 
analysis 10,000 events were collected (See section 2.2.7). 
5.2.3.2 Phagocytosis of Bacteria 
Stock solutions of H. influenzae and S. pneumoniae were sonicated for 1 min prior to 
use to prevent aggregation.  Bacteria were diluted to the appropriate concentrations in 
D-PBS.  For MDMs phagocytosis assays, 10µl of stock solution was transferred to wells, 
whilst for neutrophil assays 11µl of stock solution was added to FACS tubes and 
incubated, washed and analysed as described in section 2.2.7.   
5.2.4 Intracellular killing assays 
MDMs were incubated with either fluticasone or budesonide (10-5M), or media alone, 
for 1 h, prior to addition of 11µl of live bacterial stock solution and incubation at 37oC 
for 4 h.  Supernatants were removed and serial dilutions performed in D-PBS (to 10-6) 
and multiple dilutions (10 µl of each) were plated onto iso-sensitest agar plates for 
overnight incubation. This gives a count of bacteria not taken up by the cells.  Cells 
were then lysed with dH2O for 3 min, the supernatants removed, diluted to 10
-4, and 
multiple dilutions plated as before for overnight incubation. This gives a count of viable 
intracellular bacteria.  Colonies were counted the following morning and a measure of 




5.2.5 Viability assays 
MDMs were incubated with MTT solution for 30 min, before aspiration and 
solubilisation with DMSO.  Plates were read on a spectrophotometer at absorbance 
λ570nm.  The data was normalised to cell viability of the vehicle control (given as 100% 
viable). 
5.2.6 Confocal Microscopy 
Monocytes (2x105) were cultured directly on Lab-tek Permanox chamber slides and 
differentiated into MDMs by incubation for 12 d in media containing GM-CSF (2ng/ml).  
Particulate suspensions of fluticasone propionate or budesonide were added to the 
chambers and incubated for 1-4 h.  Particles not internalised were removed by 
aspiration and chambers washed repeatedly with D-PBS.   
5.2.6.1 Staining of cells 
Cells were stained with Cell Tracker Red CMPTX dye (12.5µM), followed by fixation 
with 4% (w/v) paraformaldehyde and nuclear staining with DAPI (2µM), as described in 
section 2.2.13.1.   
5.2.6.2 Visualisation 
Slides were viewed on a Leica TCS 4D Confocal microscope with images of the three 
stains overlaid using VolocityTM software.  In order to visualise internalisation of the 
particles, images were taken at sequential slices then remodelled into orthogonal 
views using VolocityTM software. 
5.2.7 Statistical Analyses 
Data points, and values in the text and figure legends, represent the mean ± s.e.m. of 
‘n’ independent donors. Statistical differences were determined using the Wilcoxon 





5.3  Results 
5.3.1 Subject demographics 
Eleven patients with COPD (GOLD stage 2-4) were recruited into the study (Table 5.1).   
Age (y) 63 +/- 3 
M:F 9:2 
Pack year history (y) 48 +/- 9 
Current smokers 7 
FEV1 (l) 1.7 +/- 0.2 
% FEV1 predicted 57.5 +/- 7 
FEV1/FVC ratio (%) 54 +/- 4 
 
Table 5.1. Subject demographics 
Data presented as mean +/- SEM. 
 
5.3.2 Effect of steroids on MDMs phagocytic responses  
No significant differences were seen in the ability of MDMs to phagocytose beads in 































Figure 5.1. Effect of budesonide or fluticasone propionate on phagocytosis of 
fluorescently labelled beads by MDMs. 
MDMs were isolated from COPD subjects, pre-incubated for 1h with steroid 
(budesonide (▲) or fluticasone propionate (■)) and then incubated with 100µl of 
50x106beads/ml containing steroid for 4h.  Analysis was then performed using a 
fluorescent plate reader.  Data shown are mean+/- SEM, n=10, where 100% is defined 
as the phagocytic response of MDMs in the presence of vehicle  
 
Neither fluticasone propionate nor budesonide led to significantly increased 
phagocytosis of H. influenzae in MDMs, nor where there any differences between the 






























Figure 5.2. Effect of budesonide or fluticasone propionate on phagocytosis of 
fluorescently labelled H. influenzae by MDMs. 
MDMs were isolated from COPD subjects, pre-incubated for 1h with steroid 
(budesonide (▲) or fluticasone propionate (■)) and then incubated with 100µl of H. 
influenzae solution containing steroid for 4h.  Analysis was then performed using a 
fluorescent plate reader.  Data shown are mean+/- SEM, n=10, where 100% is defined 
as the phagocytic response of MDMs in the presence of vehicle. 
 
Neither budesonide nor fluticasone altered phagocytosis of S. pneumoniae by MDMs 































Figure 5.3. Effect of budesonide or fluticasone propionate on phagocytosis of 
fluorescently labelled S. pneumoniae by MDMs. 
MDMs were isolated from COPD subjects, pre-incubated for 1h with steroid 
(budesonide (▲) or fluticasone propionate (■)) and then incubated with 100µl of S. 
pneumoniae solution containing steroid for 4h.  Analysis was then performed using a 
fluorescent plate reader.  Data shown are mean+/- SEM, n=10, where 100% is defined 
as the phagocytic response of MDMs in the presence of vehicle. 
 
5.3.3 Cell viability 
It was possible that some of the differences seen in phagocytosis between the steroids 
and at varying steroid doses may have resulted from altered MDMs viability.  
Therefore, cell viability assays were performed.  However, viability of MDMs was 
unaffected by increasing concentrations of either steroid when compared to vehicle 
control (Fig. 5.4 and 5.5), nor was there any difference seen in viability with the 







































Figure 5.4. Effect of budesonide or fluticasone propionate on viability of MDMs 
incubated with fluorescently labelled beads. 
MDMs were isolated from COPD subjects, pre-incubated for 1h with steroid 
(budesonide (▲) or fluticasone propionate (■)), then incubated with 100µl of 
50x106beads/ml containing steroid for 4h.  After phagocytosis assays, MTT was added 
at 50µl/well, incubated for 30 min, aspirated and DMSO added at 50µl/well.  Analysis 

















































































Figure 5.5. Effect of budesonide or fluticasone propionate on viability of MDMs 
incubated with fluorescently labelled (a) H. influenzae and (b) S. pneumoniae. 
MDMs were isolated from COPD subjects, pre-incubated for 1h with steroid 
(budesonide (▲) or fluticasone propionate (■)), then incubated with 100µl of bacterial 
solution containing steroid for 4h. After phagocytosis assays, MTT was added at 
50µl/well, incubated for 30 min, aspirated and DMSO added at 50µl/well.  Analysis was 
performed using a spectrophotometer (λ570nm).  Data are mean+/- SEM, n=5. 
 
5.3.4 Confocal Microscopy 
In order to evaluate whether steroid particles were internalised by MDMs, confocal 
microscopy was performed.   Fluticasone propionate particles were thought to be of a 
similar size to the polystyrene microspheres used (2µM; personal communication from 
Dr Anna Miller-Larsson, Astra-Zeneca R&D, Sweden).  MDMs incubated with 
polystyrene beads show internalised particles clearly evident within the cells (Fig. 5.6; 
evident as black dots).  In contrast, MDMs incubated with fluticasone propionate show 




Figure 5.6. MDMs incubated with polystyrene beads for 4 h. 
MDMs were incubated polystyrene beads for 4 h, then labelled with Cell Tracker Red 
CMPTX dye (12.5µM) for 45 min, followed by washing, fixation and mounting with 
Citifluo.  Slides were viewed on a Leica TCS 4D Confocal microscope at 40 x 
magnification.  
A = nucleus, B = cytoplasm, C = black dots where no staining of cytoplasm, suggestive 
of internalised particulate matter. 
 
 
Figure 5.7. MDMs incubated with particulate fluticasone propionate for 4 h.  
MDMs were pre-incubated with fluticasone propionate (10µM) for 4 h, followed by 
aspiration of media, then incubation with CellTracker Red CMPTX dye (12.5µM) for 45 
min.  Cells were washed, fixed and mounted with Citifluo.  Slides were viewed on a 








5.3.5 Intracellular killing 
Whilst steroids did not significantly alter the phagocytic capacity of MDMs for bacteria, 
it remained possible that these drugs could impair the bacterial killing process.  In 
order to investigate this possibility, MDMs were incubated with live bacteria (either H. 
influenzae or S. pneumoniae) and killing assessed.  However, incubation of MDMs with 
either fluticasone propionate or budesonide had no significant effect on bacterial 
killing (Figs. 5.8 and 5.9).  Whilst the data suggests that fluticasone impaired 
intracellular killing of H. influenzae compared to budesonide, with the percentage of 
live intracellular bacteria increased by ~50% in the presence of fluticasone propionate, 
this finding is not significant and is likely to be related to the low n number and 






















Figure 5.8. Effect of fluticasone propionate or budesonide on intracellular killing ability 
of MDMs incubated with H. influenzae 
MDMs were isolated from COPD subjects, pre-incubated for 1h with steroid 
(budesonide (■) or fluticasone propionate (■)) and then incubated with 11µl of stock 
bacterial solution.  Supernatant was removed, cells were lysed with dH2O, then this 
was diluted to 10-4, plated and colonies counted after overnight incubation. CFU/ml 
were calculated for cells incubated with and without steroid and % of intracellular live 
bacteria calculated (where 100% is taken as CFU/ml from control cells). Data shown 























Figure 5.9. Effect of fluticasone propionate or  budesonide on intracellular killing ability 
of MDMs incubated with S. pneumoniae  
MDMs were isolated from COPD subjects, pre-incubated for 1h with steroid 
(budesonide (■) or fluticasone propionate (■)) and then incubated with 11µl of stock 
bacterial solution.  Supernatant was removed, cells were lysed with dH2O, then this 
was diluted to 10-4, plated and colonies counted after overnight incubation. CFU/ml 
were calculated for cells incubated with and without steroid and % of intracellular live 
bacteria calculated (where 100% is taken as CFU/ml from control cells). Data shown 
are mean+/- SEM, n=4. 
 
5.3.6 Effect of steroids on neutrophil phagocytic responses  
Since steroids had little effect on MDMs phagocytosis or bacterial killing, it was 
unlikely that steroids were altering macrophage innate functions.  Therefore, the 
effect of both steroids on neutrophil phagocytosis was evaluated.  Three subjects were 
excluded either due to very high neutrophil counts suggestive of acute infection or due 
to insufficient cells for FACS analysis.  Data are presented as the percentage 
phagocytosis compared to vehicle control (i.e. the percentage of cells ingesting 
phagocytic prey) and the median fluorescent intensity (MFI) compared to vehicle 
control (i.e. the amount of phagocytic prey taken up by the neutrophils) for each 
phagocytic assay (see section 2.2.7).   
Neither budesonide nor fluticasone propionate altered uptake of beads by neutrophils 
from COPD patients (Fig. 5.10), indicating that neither steroid alters the mechanism of 
phagocytosis in neutrophils. 
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Figure 5.10. Effect of budesonide or fluticasone propionate on phagocytosis of 
fluorescently labelled beads by neutrophils. 
Neutrophils were isolated from COPD subjects, pre-incubated for 1h with steroid 
(budesonide (▲) or fluticasone propionate (■)) and then incubated with 900µl of 
10x106beads/ml containing steroid for 15 min.  Neutrophils were washed and fixed.  
Analysis was performed using flow cytometry.  Data shown are mean+/- SEM, n=7.   
 
When H. influenzae were used as phagocytic prey, the presence of either steroid again 
had no effect on the phagocytic ability of neutrophils (Fig. 5.11a). However, both 
budesonide and fluticasone propionate increased the amount of H. influenzae ingested 
by the neutrophils at all concentrations except the highest dose used (Fig. 5.11b), with 
this increase reaching statistical significance at budesonide concentrations of 100pM, 
10nM and 1µM and 1µM of fluticasone propionate (p<0.05).  Whilst both budesonide 
and fluticasone propionate led to increased uptake of H. influenzae compared to 





































































Figure 5.11. Effect of budesonide or fluticasone propionate on phagocytosis of 
fluorescently labelled H. influenzae by neutrophils. 
Neutrophils were isolated from COPD subjects, pre-incubated for 1h with steroid 
(budesonide (▲) or fluticasone propionate (■)), then incubated with 900µl of H. 
influenzae solution containing steroid for 15 min.  Cells were washed, fixed and 
analysed by flow cytometry.  Data shown are mean+/- SEM, n=7 (where * represents 
p<0.05). 
 
In contrast to the results with H. influenzae, when neutrophils were incubated with S. 
pneumoniae, neither budesonide nor fluticasone propionate had any effects on either 
the phagocytic ability of neutrophils (Fig. 5.12a), nor the amount of bacteria ingested 












































































Figure 5.12. Effect of budesonide or fluticasone propionate on phagocytosis of 
fluorescently labelled S. pneumoniae by neutrophils. 
Neutrophils were isolated from COPD subjects, pre-incubated for 1h with steroid 
(budesonide (▲) or fluticasone propionate (■)) and then incubated with 900µl of S. 
pneumoniae solution containing steroid for 15 min.  Neutrophils were washed and 


































































5.4  Discussion 
The hypothesis under investigation was that clearance of particulate fluticasone by 
phagocytic cells of the innate immune system results in impairment of 
phagocytosis/killing of bacteria, in turn resulting in impaired/delayed bacterial 
clearance and increased risk of pneumonia.  This may be due to accumulation of 
particles within the phagolysosome.  This hypothesis was developed from recent 
evidence suggesting that rates of pneumonia were higher in those COPD patients 
taking fluticasone propionate compared with budesonide (Crim et al., 2009;Sin et al., 
2009;Kardos et al., 2007;Wedzicha et al., 2008). 
Analysis of the phagocytic capacity of MDMs showed that budesonide marginally 
increased phagocytosis of beads and uptake of H. influenzae compared to control,  as 
well as increasing the uptake of  H. influenzae by neutrophils.  This improvement in 
phagocytosis of H. influenzae was seen at concentrations of budesonide that would be 
expected in the human airway during regular treatment with budesonide (Van den 
Bosch et al., 1993).  In contrast, fluticasone propionate only showed increased uptake 
of H. influenzae by neutrophils, with MDMs showing no alterations in phagocytosis 
with any phagocytic prey.   
Previously, budesonide has been shown to improve phagocytosis of H. influenzae and 
S. pneumoniae in MDMs (Taylor et al., 2010), however, it has also been shown to 
reduce phagocytosis of E. coli by alveolar macrophages (Zetterlund et al., 1998).  In 
both of the reported studies, solubilised budesonide was used, whereas in the present 
study both steroids were solubilised in Tween 80 and are assumed to remain 
particulate.  Alternatively, the differential effects on phagocytic ability seen with 
budesonide may be related to the different incubation times, for which cells are 
exposed to phagocytic prey, used in each of the studies.  Zetterlund et al incubated 
macrophages with bacteria for only 10 min, in comparison to the 1 h time point used 
by Taylor et al and the 4 h time point used in this study.  There is little in the literature 
on fluticasone and its effects on phagocytosis.   
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A mechanism by which steroids may improve phagocytosis may be related to 
alterations in receptor expression.  Dexamethasone has previously been shown to 
improve phagocytosis of latex beads and E. coli by MDMs, with an associated increase 
in expression of scavenger receptors (MARCO, mannose receptors and CD163) 
(Gratchev et al., 2005).  Similarly, in monocytes and MDMs, increased efferocytosis in 
the presence of dexamethasone has been associated with increased expression of 
CD16 and CD163 (Giles et al., 2001).  Furthermore, dexamethasone treated cells 
showed a reduction in paxillin present in podosomes, associated with reduced tyrosine 
phosphorylation, and a marked increase in levels of Rac (Giles et al., 2001).  Rac 
proteins are critical regulators of phagocytic function, involved in actin assembly, 
pseudopod extension and generation of reactive oxygen species (ROS) for pathogen 
elimination, and, in addition, are important in neutrophil migration (Costa et al., 2010).  
Therefore, it could be that different steroids have differential effects on receptor 
expression or on cytoskeletal rearrangement, in turn leading to differential bacterial 
clearance within the lung. 
In contrast to the phagocytosis data, the intracellular killing data is suggestive of 
fluticasone impairing the intracellular killing of H. influenzae compared to budesonide 
however, this alteration in intracellular killing may simply be related to the low 
numbers of this experiment that were performed, with wide variability and therefore it 
is hard to draw firm conclusions from this data.  One could postulate that if fluticasone 
were to impair intracellular killing this may in turn lead to cell necrosis with release 
viable bacteria back into the lower airway, however, the relevance of this finding to 
the increased risk of pneumonia would have increased weight if fluticasone propionate 
had shown similar impairment of MDMs killing of S. pneumoniae, as this is the bacteria 
more commonly isolated in pneumonia.   
More recently, two clinical trials have been published addressing the question of 
increased pneumonia risk in those with COPD taking ICS.  Singanayagam et al 
conducted a prospective observational study on COPD patients hospitalized with a 
primary diagnosis of pneumonia (Singanayagam et al., 2011).  They found 
approximately 78% of patients were taking ICS, with 67.9% of those taking ICS 
containing fluticasone and 21% containing budesonide (Singanayagam et al., 2011).  
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No differences were seen in the severity of pneumonia between the ICS and non-ICS 
arms, nor were there any differences in 30 day or 6 month mortality or length of 
hospital stay (Singanayagam et al., 2011). These findings were confirmed by Chen et al 
in a large retrospective cohort study in the USA, which showed a reduction in mortality 
from pneumonia at 30 and 90 days in those COPD patients taking ICS compared to 
those that were not (Chen et al., 2011).  These studies examined pneumonia as the 
primary diagnosis and therefore did not consider the incidence of developing 
pneumonia in the ICS compared to non-ICS arms.  In addition, these studies did not 
attempt to investigate the impact of different ICS on the outcome of pneumonia.  
However, these studies suggest that, if ICS do increase the risk of developing 
pneumonia, there is no associated increase in mortality or morbidity. 
It is difficult, however, to explain the discrepancy between fluticasone propionate 
appearing to increase the risk of pneumonia whilst both fluticasone propionate and 
budesonide have been shown to reduce rates of exacerbation in COPD, up to 50% of 
which are associated with bacteria.  Analysis of the INSPIRE study again showed that 
treatment with the combination of salmeterol and fluticasone propionate was 
associated with an increased risk of pneumonia compared to use of tiotropium alone 
(Calverley et al., 2011).  However, no differences were seen in the duration of the 
pneumonia or in mortality from pneumonia (Calverley et al., 2011).  Interestingly,  one 
half of the pneumonias in patients on the combination inhaler were associated with an 
ongoing or unresolved exacerbation (Calverley et al., 2011).  Therefore, it would 
appear that there may be an effect of ICS on either the host immune system or the 
pathogen which delays or prevents resolution of infection.  This study would suggest 
that the mechanism by which fluticasone causes increased rates of pneumonia is likely 
to be more complicated than simply impairment of host defences by altered 
phagocytic ability in cells of the innate immune system.   
5.4.1 Limitations 
Due to the small sample size used in this study, no significant differences were seen 
between steroids due to variability in the data.  This sample size would have to be 
increased to assess whether there were any true differences between steroids.  A 
further limitation was the use of particulate steroids in comparison to the literature 
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using solubilised steroids, therefore comparison should be made between these two 

























MECHANISM UNDERLYING DEFECTIVE 
PHAGOCYTOSIS IN SMOKER AND COPD 









Phagocytosis is a complex series of events by which particles are internalised within 
the cell. Essentially, cell surface receptors recognise and bind to a particle, in turn 
generating signals which induce actin polymerisation under the membrane, at the 
point of contact (Aderem, 2003).  Actin rich membrane extensions reach out to enfold 
the particle, fusing and forming the phagosome which is pulled into the centre of the 
cell (Aderem, 2003).  The phagosome matures by a series of fusion events to form the 
phagolysosome which kills the pathogen (Aderem, 2003).  Microtubules are involved in 
membrane trafficking during phagocytosis, and have important roles in the early 
stages of phagosome formation and in the migration of the phagosome from cell edge 
to the centre, along the microtubule network (Niedergang and Chavrier, 2004). 
Defects in phagocytosis may arise due to mechanistic changes at any point along the 
pathway.  Alterations in receptor expression, of both the mannose receptor and 
MARCO, have been shown to be related to reduced phagocytosis of bacteria by 
macrophages (Hodge et al., 2008;Baqir et al., 2008;Sun and Metzger, 2008).  Similarly, 
alterations in PI3K signalling have also been shown to be associated with reduced 
phagocytosis of NTHI in macrophages (Marti-Lliteras et al., 2009).  The data presented 
in the previous chapters, along with previous work in this laboratory, has not found 
any differences in receptor expression in phagocytic cells from different subject groups 
(Taylor et al., 2010), nor any differential sensitivity to cytochalasin (an actin 
microfilament inhibitor) in cells from different subject groups.  However, previous 
work in the laboratory has suggested increased sensitivity of COPD cells to colchicine, a 
microtubule-destabilising agent (Finney-Hayward et al., 2005). 
Microtubules are formed from α- and β-tubulin heterodimers (see Figure 6.1).  
Microtubules are dynamic organelles that constantly polymerise and depolymerise 
depending on the cellular requirements (Peachman et al., 2004).  Depolymerised (or 
dynamic) microtubules are important in cell motility and cell mitosis, whilst 
polymerised or stable microtubules are required for phagocytosis.  Colchicine acts by 
binding to tubulin dimers and preventing polymerisation (Peachman et al., 2004).  On 
the other hand, microtubules can be stabilised, using agents such as taxol, which 
reduces the dissociation of tubulin dimers from the microtubule polymer (Peachman et 
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al., 2004).  Taxol has been shown to inhibit mitosis with no associated effect on 
phagocytosis (Peachman et al., 2004). 
 
      
 
Figure 6.1. Diagram of microtubule polymerisation and depolymerisation. 
Microtubules are formed from α- and β-tubulin heterodimers.  Microtubules can exist 
in the dynamic state or in the polymerised (stable) state.  Acetylation of polymerised 
microtubules is carried out by α-tubulin acetyl-transferase, whilst deacetylation is 
carried out by HDAC6 and SIRT2. 
 
Reversible acetylation of microtubules has been implicated in the regulation of 
microtubule stability and function (Piperno et al., 1987).  Deacetylation of 
microtubules is dependent on the histone deacetylases, HDAC6 and SIRT2.  HDAC6 is 
located exclusively in the cytoplasm and associates with microtubules (Hubbert et al., 
2002), and has been shown, in vitro, to potently deacetylate α-tubulin in assembled 
microtubules, with overexpression promoting chemotactic cell movement (Hubbert et 
al., 2002).  SIRT2 (sirtuin type 2) colocalizes with microtubules and HDAC6 (North et al., 
2003).  It deacetylates lysine K-40 of α-tubulin both in vitro and in vivo (North et al., 
2003), whilst knockdown of either SIRT2 or HDAC6, using siRNA in 293T cells, caused 
hyperacetylation of α-tubulin similarly (North et al., 2003).   
Recently discovered is the acetyl transferase for α-tubulin (Akella et al., 2010; Shida et 
al., 2010).  Akella et al have shown that, in vitro, MEC-17, a protein required for the 
function of touch receptor neurons in C. elegans, exclusively acetylates K-40 of α-
tubulin (Akella et al., 2010).  Disruption of MEC-17 in Tetrahymena caused microtubule 
lability whilst overexpression led to greatly increased acetylation of microtubules 
(Akella et al., 2010).  In zebrafish, a model used to assess function in vertebrates,  
disruption of MEC-17 produced phenotypes consistent with neuromuscular defects 
α-tubulin 
β-tubulin 






(Akella et al., 2010).  Shida et al also showed that αTAT1 (C6orf134) specifically 
acetylates K40 of α-tubulin, with a preference for polymerised microtubules over 
monomeric tubulin (Shida et al., 2010), with knockdown of αTAT1 in mammalian cells 
leading to an 80% reduction in acetylation at K40 (Shida et al., 2010). 
The aim of this chapter will be to investigate whether alterations in acetylated tubulin 
in MDMs and neutrophils may be related to the phagocytic defect seen in cells from 
COPD patients.  Using Epothilone B, a microtubule stabilising agent derived from the 
mycobacterium Sorangium cellulosum, currently involved in oncology trials, the effects 
of stabilising microtubules, on both phagocytosis and levels of acetylated tubulin, will 
be examined.  Inhibition of both the acetyl transferase and the deacetylases of 
microtubules will also be examined in terms of the effects on phagocytosis and on 














6.2.1 Subject selection 
Healthy, smoking and COPD subjects were recruited as described in section 2.2.1. 
6.2.2 Blood separation 
PBMC and neutrophils were isolated from whole blood using discontinuous Percoll 
gradients as described in section 2.2.3. Monocytes were isolated from PBMC using 
adherence and cultured for 12 d in the presence of GM-CSF (2ng/ml) to derive 
monocyte-derived macrophages (MDMs).  
6.2.3 Phagocytosis Assays 
Phagocytosis assays were carried out on using fluorescently labelled beads or bacteria 
incubated with MDMs for 4 h and neutrophils for 15 min, as described in section 2.2.7. 
6.2.4 Western Blot 
Western blot was carried out as described in section 2.2.9.  Primary monoclonal 
antibodies to the protein of interest were used in the dilutions shown below; 





Table 6.1. Dilutions of primary monoclonal anti-bodies used in Western Blot 
6.2.5 Immunoprecipitation 
Immunoprecipitation of HDAC6 was carried out as described in section 2.2.15.  
Polyclonal anti-HDAC6 antibody was used at 1:20 dilution. 
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6.2.6 HDAC activity assay 
The Fluor-de-lys activity assay was carried out as per the manufacturers’ protocol, as 
described in section 2.2.15. 
6.2.7 Transfection 
Transfection with the appropriate SiRNA was carried out as described in section 2.2.13.  
In each well of a 24 well plate, 3µg of SiRNA was used, whilst 1µg of SiRNA was used 
per well in a 96 well plate. 
6.2.8 rt-PCR 
Rt-PCR was carried out as described in section 2.2.14. 
6.2.9 Confocal microscopy 
After phagocytosis assays were complete, MDMs were stained with Tubulin Tracker 
(Invitrogen, UK), (250nM), diluted in RPMI media, for 30 min at 37oC, then fixed with 
4% paraformaldehyde and imaged on a Leica SP2 upright confocal microscope as 











The previous chapters have shown that both MDMs and neutrophils from smokers and 
COPD patients show defective uptake of bacteria when compared to healthy controls.  
All cells have been shown to be capable of phagocytosis, given their equivalent ability 
to phagocytose beads, yet cells from smokers and COPD subjects show reduced uptake 
of bacteria.   
6.3.1 Effect of microtubule disruptors on phagocytosis by MDMs from 
different subject groups 
Previously, phagocytosis of E. coli had been shown to be significantly reduced in 
colchicine exposed MDMs from COPD patients, with no effect on phagocytosis by 
MDMs from either healthy or smoker volunteers (Finney-Hayward et al., 2005).  This 
suggests an enhanced susceptibility to microtubule disruptors in cells from COPD 
patients. Therefore, this potential susceptibility was investigated further.  In the first 
instance, phagocytosis experiments were repeated with H. influenzae and S. 
pneumoniae in the presence of nocodazole, an alternative microtubule disruptor.  The 
concentration of nocodazole selected (10µM) was equivalent to that used previously in 
the laboratory and by others in the investigation of phagocytosis (Cannon and 
Swanson, 1992).  Phagocytosis of beads, H. influenzae and S. pneumoniae was 
significantly reduced in COPD MDMs, compared to healthy and smoker MDMs (Fig. 




























Figure 6.2. Effects of nocodazole on phagocytosis by MDMs from different subject 
groups 
MDMs from healthy controls (■), healthy smokers (■) and COPD patients (■) were pre-
treated for 1 h with nocodazole (10µM), followed by 4 h incubation with (a) beads, (b) 
H. influenzae (HI) or (c) S. pneumoniae (SP). Phagocytosis was analysed using 












































































fluorimetry. Data are presented as percentage phagocytosis relative to control (NS), 
mean ± SEM, healthy n=5, smoker n=3, COPD n=10, where * represents p<0.05. 
6.3.2. Levels of acetylated tubulin in cells from different subject groups 
Having shown that, in COPD MDMs, phagocytosis appears to be reduced in the 
presence of microtubule disruptors, the next step was to investigate whether levels of 
stable (or acetylated) microtubules were altered in COPD MDMs.  Using Western 
blotting, MDMs were lysed and levels of acetylated tubulin analysed (Fig. 6.3a).  COPD 
MDMs had significantly less acetylated tubulin in comparison to healthy MDMs (Fig. 
6.3b).  The reduction in levels of acetylated tubulin in smoker MDMs compared to 
healthy controls did not reach statistical significance, likely due to the lower ‘n’ 
number used (Fig. 6.3b). 
(a) 

























Figure 6.3a and b.  Comparison of levels of acetylated tubulin in MDMs from different 
subject groups 
Monocytes from healthy controls (■), healthy smokers (■) and COPD patients (■)were cultured 
in complete media containing GM-CSF (2ng/ml) for 12 d to give MDMs. Cells were lysed in 





anti-acetylated tubulin antibody.  Blots were stripped and re-probed with primary anti-actin 
antibody as a loading control.  Data are presented as mean ± SEM, n=5-7 for all groups. 
To assess whether neutrophils displayed similar discrepancies in levels of acetylated 
tubulin, acetylated tubulin was measured in neutrophils from different subject groups.  
There were no differences seen in levels of acetylated tubulin in neutrophils from any 
subject group (Fig. 6.4). 
(a) Healthy (H)          Smoker (S)        COPD (C) 
 H H        H        S        S       S       C      C       C 
 























Figure 6.4a and b. Comparison of levels of acetylated tubulin in neutrophils from 
different subject groups 
Neutrophils from healthy controls (■), healthy smokers (■) and COPD patients (■) were 
snap frozen, then lysed in 2xSDS buffer and proteins separated by Western blot, 
followed by immunoblotting with primary anti-acetylated tubulin antibody.  Blots were 




(a) shows n=3 for each group.  (b) Data are presented as mean ± SEM, n=6 for all 
groups. 
6.3.3. Staining of microtubules in MDMs with tubulin tracker™ 
Tubulin tracker™ (Molecular Probes, Invitrogen, UK) stains polymerised microtubules 
within cells, and therefore was used to visualise the arrangement of microtubules 
within MDMs.  Resting microtubules reside in the MTOC (microtubule organising 
centre) which is located in the peri-nuclear region of the cell (Fig. 6.5a).  In contrast, 
MDMs exposed to prey, in this case H. influenzae, display diffuse staining of the cells as 
the microtubule network spreads out in the cytoplasm towards the cell periphery 
during the process of phagocytosis (fig. 6.5b). 
(a) MDMs (control)   (b) MDMs after exposure to H. influenzae 
 
  
Figure 6.5. MDMs stained with tubulin tracker showing the cellular location of 
polymerised microtubules. 
MDMs exposed to H. infuenzae for 4 h and MDMs (unstimulated) were stained with 
Tubulin Tracker (250nM) in RPMI media for 30 min at 37oC, washed with D-PBS and 
viewed on a fluorecent inverted microscope with a x40 objective lens. 
 
Repeat experiments were then performed with pre-incubation of MDMs with either 
nocodazole (microtubule disruptor) or Epothilone B (microtubule stabiliser) in the 
presence of labelled S. pneumoniae to assess whether alterations in polymerised 
microtubules could be examined (Fig. 6.6a-c).  In the presence of nocodazole there 
appear to be increased MTOC present in the cells, whilst in the presence of Epothilone 
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B there appears to be increased phagocytosis and increased microtubular staining, 




Figure 6.6.  MDMs stained with tubulin tracker after phagocytosis of pHrodo™ labelled 
S. pneumoniae in the presence of nocodazole or Epothilone B 
(a) MDMs  
(c) MDMs + Epothilone B  
(b) MDMs + Nocodazole  
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MDMs (unstimulated, pre-incubated for 1 h with Nocodazole (10µM) or Epothilone B 
(10nM)) were exposed to pHrodo labelled (red) S. pneumoniae for 4h, then stained 
with Tubulin Tracker (250nM) (green) and viewed on a Leica upright Sp2 confocal 
microscope with a x40 objective lens. 
6.3.4. Effects of a microtubule stabiliser (Epothilone B) on phagocytosis 
by MDMs  
Given that COPD MDMs had reduced phagocytosis in the presence of nocodazole, 
suggesting increased sensitivity to microtubule disruption, the effects of Epothilone B, 
a microtubule stabiliser, were investigated.  Cells were pre-incubated with Epothilone 
B for 1 h prior to phagocytosis assays.  In both COPD and smoker MDMs, Epothilone B 
had little effect on the phagocytosis of beads (Fig. 6.7a and b).  However, in COPD 
MDMs, Epothilone B significantly improved phagocytosis of H. influenzae (by ~20% at 
10nM), with an improvement of ~10% in phagocytosis of S. pneumoniae (Fig. 6.7a).  In 
smoker MDMs, Epothilone B again showed markedly improved bacterial phagocytosis 
(by ~30-40%) though this did not reach statistical significance (Fig. 6.7b).  In contrast, in 
































































































Figure 6.7(a-c).  Comparison of phagocytosis by MDMs from different subject groups 
after incubation with Epothilone B  
Monocytes were cultured in complete media containing GM-CSF (2ng/ml) for 12 d to 
give MDMs. MDMs were pre-treated for 1 h with Epothilone B at varying 
concentrations, followed by 4 h incubation with beads (●), H. influenzae (■) or S. 
pneumoniae (▲). Phagocytosis was analysed using fluorimetry. Data are presented as 
mean ± SEM, COPD n=10, Smoker n=6, Healthy n=4. 
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6.3.5. Effect of Epothilone B on levels of acetylated tubulin within MDMs 
Having shown that stabilising microtubules appeared to lead to small improvements in 
phagocytosis, the next step was to assess whether pre-incubation with Epothilone B 
would alter acetylated tubulin within the cells.  Epothilone B was used at a 
concentration of 10nM in these experiments, as this concentration was associated 
with significant increases in bacterial phagocytosis (Fig. 6.7).  Experiments were 
performed and showed that incubation with H. influenzae alone leads to an increase in 
levels of acetylated tubulin within the cell (Fig. 6.8a and b).  This effect of H. influenzae 
was increased in cells from smokers and healthy subjects compared with MDMs from 
COPD patients (Fig. 6.8a and b), suggesting that acetylation of tubulin in response to 
phagocytic prey is reduced in COPD macrophages.  In contrast, incubation with 
Epothilone B prior to the addition of HI leads to a significant increase in levels of 
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Figure 6.8a and b. Comparison of levels of acetylated tubulin in MDMs from different 
subject groups after incubation with Epothilone B vs. prey alone 
MDMs were pre-treated for 1 h with Epothilone B (10nM), followed by 4 h incubation 
with H. influenzae. Cells were lysed in RIPA buffer and proteins separated by Western 
blot, followed by immunoblotting with primary anti-acetylated tubulin antibody.  NS 
(non-stimulated), HI (cells exposed to H. influenzae), Epo (Epothilone B pre-treatment), 
Epo+HI (Epothilone B pre-treatment and exposure to prey). Data are presented as 
mean ± SEM, n=6 for all groups. *represents p<0.05 compared to NS, # represents 
p<0.05 HI vs. Epothilone B plus HI. 
 
6.3.6. Effects of Epothilone B on neutrophil phagocytosis  
Exposure of MDMs to Epothilone B led to improvements in phagocytosis of bacteria, 
therefore, whether similar effects would be seen with neutrophils was determined.  




































































































Pre-incubation of neutrophils with Epothilone B had no effect on phagocytosis, with no 
improvements seen in phagocytosis of either H. influenzae (Fig. 6.9a) or S. pneumoniae 
(Fig. 6.9b) in COPD or smoker neutrophils. 
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Figure 6.9.  Comparison of phagocytosis by neutrophils from COPD and smokers after 
incubation with Epothilone B  
Neutrophils were isolated from whole blood of smoker (■) and COPD (●) subjects, pre-
treated for 1 h with Epothilone B at varying concentrations, followed by 15 min 
incubation with H. influenzae (a) or S. pneumoniae (b). Phagocytosis was analysed by 
flow cytometry. Data are presented as mean ± SEM, COPD n=6-8, Smoker n=4. 
 
This data suggests that while microtubule stability plays a part in the defective 
phagocytosis seen in MDMs, there may be an alternative defect in neutrophils.  
Therefore, further investigation of the microtubule abnormality was confined to 
MDMs work.  
 
6.3.7. HDAC6 activity within MDMs derived from different subject groups 
As microtubules switch between dynamic and stable states their acetylation status also 
changes, with the more stable microtubules becoming acetylated (Shida et al., 2010).  
The tubulin deacetylases present in cells are HDAC6 and SIRT2 (Hubbert et al., 
2002;North et al., 2003).  The data presented in this chapter has shown that the levels 
of acetylated tubulin are lower in COPD and smoker MDMs, which could in turn be 
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related to increased expression or activity of deacetylases.  Therefore, an HDAC6 
activity assay was performed by immunoprecipitating HDAC6 from MDMs from all 
subject groups and performing a fluor-de-lys activity assay for HDAC6 (Enzo 
Lifesciences, UK).  HDAC6 protein from the same samples was quantified by western 
blot to give a final measure of HDAC6 activity relative to protein in each sample.   
There was no significant difference in the HDAC6 activity of healthy, smoker or COPD 

































Figure 6.10.  Investigation of HDAC6 activity in MDMs from different subject groups  
Monocytes from healthy controls (■), healthy smokers (■) and COPD patients (■) were 
cultured in complete media containing GM-CSF (2ng/ml) for 12 d to give MDMs. Cells 
were lysed in RIPA buffer and HDAC6 immunoprecipitated.  A Fluor-de-Lys™ HDAC6 
activity assay, analysed by fluorimetry, was performed along with a protein assay to 
determine HDAC6 protein concentrations in the samples. Data are presented as mean 
± SEM, n=6 for healthy and COPD, n=4 for smokers. 
 
6.3.8. Effects of HDAC6 inhibitor (Tubacin) on phagocytosis and levels of 
acetylated tubulin in COPD MDMs 
To further investigate the role of the deacetylases on phagocytosis by MDMs, specific 
inhibitors to either HDAC6 or SIRT2 were used.  Firstly, MDMs were exposed to 
Tubacin, a specific HDAC6 inhibitor, prior to phagocytosis assays.  Tubacin significantly 
improved bead phagocytosis at 10µM, whilst having little effect on phagocytosis of S. 
 196 
pneumoniae and causing a significant reduction, of approximately 25%, in phagocytosis 































Figure 6.11. Comparison of phagocytosis by COPD MDMs after pre-incubation with 
Tubacin  
Monocytes were cultured in complete media containing GM-CSF (2ng/ml) for 12 d to 
give MDMs. MDMs were pre-treated for 1 h with Tubacin at varying concentrations, 
followed by 4 h incubation with beads (●), H. influenzae (■) or S. pneumoniae (▲). 




Since tubacin did not improve bacterial phagocytosis, the effect of this drug on the 
acetylation of microtubules was assessed.  Addition of tubacin to COPD MDMs with 
and without incubation with H. influenzae led to a significant increase in levels of 











Figure 6.12. Effect of HDAC6 inhibitor (tubacin) on levels of acetylated tubulin within 
MDMs 
MDMs from COPD patients were pre-treated for 1 h with tubacin (10µM), followed by 
4 h incubation with H. influenzae (HI). Cells were lysed in RIPA buffer and proteins 
separated by Western blot, followed by immunoblotting with primary anti-acetylated 
tubulin antibody.  Blots were then stripped and re-probed with primary anti-actin 
antibody.  Representative of n=4. 
 
6.3.9. Effects of SIRT2 inhibitor (AGK2) on phagocytosis and levels of 
acetylated tubulin in COPD MDMs 
Although an HDAC6 inhibitor increased acetylated tubulin, it did not alter bacterial 
phagocytosis.  Therefore a SIRT2 inhibitor was investigated.  Addition of AGK2, a SIRT2 
inhibitor, showed a significant improvement in bead phagocytosis at 1µM, had little 
effect on phagocytosis of S. pneumoniae and significantly reduced phagocytosis of H. 

































Figure 6.13. Comparison of phagocytosis by COPD MDMs after incubation with AGK2  
Monocytes were cultured in complete media containing GM-CSF (2ng/ml) for 12 d to 
give MDMs. MDMs were pre-treated for 1 h with AGK2 at varying concentrations, 
followed by 4h incubation with beads (●), H. influenzae (■) or S. pneumoniae (▲). 
Phagocytosis was analysed using fluorimetry. Data are presented as mean ± SEM, 
COPD n=7. 
Since AGK2 did not improve bacterial phagocytosis, the ability of this drug to increase 
levels of acetylated tubulin was examined.  In contrast to the increase in levels of 
acetylated tubulin seen with tubacin, addition of AGK2 to COPD MDMs with or without 
incubation with H. influenzae did not increase levels of acetylated tubulin compared to 
addition of prey alone (Fig. 6.14). 
 
Figure 6.14.  Effect of SIRT2 inhibitor (AGK2) on levels of acetylated tubulin within 
COPD MDMs 
MDMs were pre-treated for 1 h with AGK2 (10µM), followed by 4 h incubation with H. 
influenzae (HI). Cells were lysed in RIPA buffer and proteins separated by Western blot, 
followed by immunoblotting with primary anti-acetylated tubulin antibody.  Blots were 
then stripped and re-probed with primary anti-actin antibody.  Representative of n=2. 
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6.3.10. Transfection of COPD MDMs with siRNA to knockdown SIRT2 
Since the SIRT2 inhibitor, AGK2, had no effect on bacterial phagocytosis nor on levels 
of acetylated tubulin, it may simply be that this drug is ineffective in this system.   
AGK2 is thought to be the most selective SIRT2 inhibitor, 15-fold more selective for 
SIRT2 than SIRT1 and SIRT 3 (IC50 = 3.5µM).  Therefore, COPD MDMs were transfected 
with siRNA to knockdown SIRT2 and phagocytosis assays performed.  Transfection with 
SIRT2 siRNA led to approximately an 80% knockdown of SIRT2 as analysed by rt-qPCR 
























Figure 6.15. Rt-PCR analysis of degree of SIRT2 knockdown after siRNA transfection  
Monocytes from COPD subjects were cultured in complete media containing GM-CSF 
(2ng/ml) for 12 d to give MDMs. MDMs were transfected using HiPerfect (Qiagen, UK) 
with either 12µM of SIRT2 siRNA or scramble siRNA (All stars negative control, Qiagen, 
UK) for 48 h.  MDMs were lysed in RLT buffer and RNA extracted using RNA mini-prep 























Figure 6.16. Viability of MDMs after SIRT2 knockdown by siRNA transfection  
Monocytes from COPD subjects were cultured in complete media containing GM-CSF 
(2ng/ml) for 12 d to give MDMs. MDMs were transfected using HiPerfect (Qiagen, UK) 
with either 12µM of SIRT2 siRNA or scramble siRNA (All stars negative control, Qiagen, 
UK) for 48 h.  Viability of MDMs was assessed by MTT assay and analysed by 
spectrophotometry at λ570nm.  Data are presented as mean ± SEM, COPD n=4. 
 
6.3.11 Effect of knockdown of SIRT2 on the phagocytic ability of COPD 
MDMs 
Having shown that transfection of COPD MDMs achieved an approximate 80% 
knockdown of SIRT2 with no loss of viability, these transfected cells were then used in 
phagocytosis assays.  Transfected cells were exposed to beads, H. influenzae or S. 
pneumoniae for 4 h, however, no significant differences were seen in the ability of 















Figure 6.17.  Phagocytosis by transfected COPD MDMs after SIRT2 knockdown  
Monocytes from COPD subjects were cultured in complete media containing GM-CSF 
(2ng/ml) for 12 d to give MDMs. MDMs were transfected using HiPerfect (Qiagen, UK) 
with either 12µM of SIRT2 siRNA or scramble siRNA (All stars negative control, Qiagen, 
UK) for 48 h.  Phagocytosis assays were performed with incubation with prey for 4 h, 
prior to analysis by fluorimetry.  Data are presented as mean ± SEM, n=4. 
 
6.3.12. Transfection of COPD MDMs with siRNA to knockdown HDAC6 
Since knockdown of SIRT2 in COPD MDMs had no significant effect on phagocytosis, 
the next step was to investigate whether HDAC6 knockdown would have any effect on 
phagocytosis.  Transfection with HDAC6 siRNA led to approximately 70% knockdown of 



















































































Figure 6.18.  Rt-PCR analysis of degree of HDAC6 knockdown after siRNA transfection  
Monocytes from COPD subjects were cultured in complete media containing GM-CSF 
(2ng/ml) for 12 d to give MDMs. MDMs were transfected using HiPerfect (Qiagen, UK) 
with either 12µM of HDAC6 siRNA or scramble siRNA (All stars negative control, 
Qiagen, UK) for 48 h.  MDMs were lysed in RLT buffer and RNA extracted using RNA 
mini-prep kit (Qiagen, UK) prior to rt-PCR using Taqman.  Data are presented as mean 





















Figure 6.19. Viability of MDMs after HDAC6 knockdown by siRNA transfection  
Monocytes from COPD subjects were cultured in complete media containing GM-CSF 
(2ng/ml) for 12 d to give MDMs. MDMs were transfected using HiPerfect (Qiagen, UK) 
with either 12µM of HDAC6 siRNA or scramble siRNA (All stars negative control, 
Qiagen, UK) for 48 h.  Viability of MDMs was assessed by MTT assay and analysed by 
spectrophotometry at λ570nm.  Data are presented as mean ± SEM, COPD n=5. 
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6.3.13 Effect of knockdown of HDAC6 on the level of acetylated tubulin in 
COPD MDMs 
Having shown that HDAC6 could be knocked down by transfection with siRNA, western 
blots were performed to investigate whether knock down of HDAC6 led to increased 
acetylation of tubulin.  Increased levels of acetylated tubulin can be seen in cells with 
HDAC6 knockdown, both alone and after exposure to H. influenzae, in comparison to 




Figure 6.20. Western blot of acetylated tubulin levels in COPD MDMs transfected with 
HDAC6 siRNA  
Monocytes from COPD subjects were cultured in complete media containing GM-CSF 
(2ng/ml) for 12 d to give MDMs. MDMs were transfected using HiPerfect (Qiagen, UK) 
with either 12µM of HDAC6 siRNA or scramble siRNA (All stars negative control, 
Qiagen, UK) for 48 h.  HI was then added for 4 h. MDMs were lysed in RIPA buffer and 
proteins separated by Western blot, followed by immunoblotting with primary anti-
acetylated tubulin antibody.  Blots were then stripped and re-probed with primary 
anti-actin antibody.  Representative of n=2, where NS = control cells, HI = control cells 
exposed to H. influenzae, +ve = HDAC6 knockdown, +HI = HDAC6 knockdown exposed 
to H. influenzae, neg = scramble siRNA and neg + HI = scramble plus H. influenzae.  
 
6.3.14 Effect of knockdown of HDAC6 on the phagocytic ability of COPD 
MDMs 
Having shown that transfection of COPD MDMs achieved an approximate 70% 
knockdown of HDAC6 with no loss of viability, and furthermore, that knockdown 
results in increased acetylation of tubulin, these cells were then used in phagocytosis 
assays.  Transfected cells were exposed to beads, H. influenzae or S. pneumoniae for 4 
h, however, no significant differences were seen in the ability of transfected COPD 
MDMs to phagocytose either beads or bacteria (Fig. 6.21). 
 
Ac-tubulin 
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Figure 6.21.  Phagocytosis by transfected COPD MDMs after HDAC6 knockdown  
Monocytes from COPD subjects were cultured in complete media containing GM-CSF 
(2ng/ml) for 12 d to give MDMs. MDMs were transfected using HiPerfect (Qiagen, UK) 
with either 12µM of HDAC6 SiRNA or scramble SiRNA (All stars negative control, 
Qiagen, UK) for 48 h.  Phagocytosis assays were performed with incubation with prey 
for 4 h, prior to analysis by fluorimetry.  Data are presented as mean ± SEM, n=6. 
 
6.3.15. Transfection of Healthy MDMs with siRNA to knockdown 
C6orf134 
Inhibition of the deacetylases by either inhibitors or knockdown of the genes failed to 
lead to improvements in bacterial phagocytosis.  Therefore, the low levels of 
acetylated tubulin in COPD and smoker cells may be as a result of reduced expression 
or activity of the acetyl-transferase involved in acetylation of microtubules.  The next 
step in the investigation into this defect was to examine the effects of knocking down 
C6orf134 (α-tubulin acetyl transferase 1) in healthy MDMs, to see if the defect 
observed in COPD MDMs could be replicated.  Transfection with C6orf134 siRNA led to 
approximately a 60% knockdown of C6orf134 as analysed by rt-PCR (Fig. 6.22), with no 












































































Figure 6.22. Rt-PCR analysis of degree of C6orf134 knockdown after siRNA transfection  
Monocytes from non-smoker subjects were cultured in complete media containing 
GM-CSF (2ng/ml) for 12 d to give MDMs. MDMs were transfected using HiPerfect 
(Qiagen, UK) with either 12µM of C6orf134 siRNA or scramble siRNA (All stars negative 
control, Qiagen, UK) for 48 h.  MDMs were lysed in RLT buffer and RNA extracted using 
RNA mini-prep kit (Qiagen, UK) prior to rt-PCR using Taqman.  Data are presented as 
























Figure 6.23. Viability of MDMs after HDAC6 knockdown by siRNA transfection  
Monocytes from non-smoker subjects were cultured in complete media containing 
GM-CSF (2ng/ml) for 12 d to give MDMs. MDMs were transfected using HiPerfect 
(Qiagen, UK) with either 12µM of C6orf134 siRNA or scramble siRNA (All stars negative 
control, Qiagen, UK) for 48 h.  Viability of MDMs was assessed by MTT assay and 
analysed by spectrophotometry at λ570nm.  Data are presented as mean ± SEM, COPD 
n=4. 
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6.3.16. Effect of knockdown of C6orf134 on the phagocytic ability of non-
smoker MDMs 
Having shown that transfection of non-smoker MDMs with C6orf134 could be 
achieved, with an approximate 60% knockdown and no loss of viability, these cells 
were then used in phagocytosis assays.  Transfected cells were exposed to beads, H. 
influenzae or S. pneumoniae for 4 h.  Transfected cells showed no differences in ability 
to phagocytose beads (Fig. 6.24a), however, they showed significantly reduced 
phagocytosis of both H. influenzae and S. pneumoniae, with reductions in bacterial 
phagocytosis of ~20% (Fig. 6.24b and c). 







Figure 6.24.  Phagocytosis by transfected healthy MDMs after C6orf134 knockdown  
Monocytes from healthy (non-smoker) subjects were cultured in complete media 
containing GM-CSF (2ng/ml) for 12 d to give MDMs. MDMs were transfected using 
HiPerfect (Qiagen, UK) with either 12µM of C6orf134 SiRNA or scramble SiRNA (All 
stars negative control, Qiagen, UK) for 48 h.  Phagocytosis assays were performed with 
incubation with prey for 4 h, prior to analysis by fluorimetry.  Data are presented as 
mean ± SEM, n=6, where * represents p<0.05 knockdown vs. NS. 
 
6.3.17. Investigation of levels of C6orf134 in COPD subjects compared to 
healthy subjects 
This data suggests that knocking down C6orf134 in healthy MDMs leads to reduced 
phagocytosis, mimicking the defect seen in COPD subjects.  Therefore, to investigate 
this phenomenon, the next step was to examine whether C6orf134 was expressed at 
lower levels in MDMs from COPD patients compared to healthy subjects.  Quantitative 


























































COPD MDMs (Fig. 6.25).  Whilst the level of expression of C6orf134 appeared to be 
significantly reduced in COPD compared to healthy MDMs, (Fig. 6.26a), this reduction 
in gene expression was mimicked in the housekeeping gene (HPRT1), which was also 






















Figure 6.25. Quantitative rt- PCR of C6orf134 in healthy vs. COPD MDMs 
MDMs were lysed in RLT buffer and RNA extracted using RNA mini-prep kit (Qiagen, 
UK) prior to conversion to cDNA.  Equivalent amounts of cDNA were then used for rt-
PCR using Taqman.  Amount of gene (pg) could be extrapolated from a standard curve 
of known quantities of cDNA run on the same plate.  Data are expressed as expression 
of C6orf134 (pg) relative to HPRT1 expression, mean ± SEM, n=9 for each group. 






























Figure 6.26a and b. Quantitative rt- PCR of C6 orf134 and HPRT1 in healthy vs. COPD 
MDMs 
MDMs were lysed in RLT buffer and RNA extracted using RNA mini-prep kit (Qiagen, 
UK) prior to conversion to cDNA.  Equivalent amounts of cDNA were then used for rt-
PCR using Taqman.  Data are presented as mean ± SEM, n=9 for each group. 
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6.3.18. Effect of knockdown of C6orf134 on the levels of acetylated 
tubulin within healthy MDMs 
As COPD MDMs have altered bacterial phagocytosis associated with reduced levels of 
acetylated tubulin, and having shown that knockdown of C6orf134 in healthy MDMs 
models the reduced bacterial phagocytosis, levels of acetylated tubulin within the cells 
were then examined.  Healthy MDMs were transfected with C6orf134, prior to 
exposure to H. influenzae for 4 h and analysis of levels of acetylated tubulin by 
Western blot (Fig 6.27a).  Levels of acetylated tubulin increased after addition of H. 
influenzae in all cells (NS, knockdown and negative control) compared to baseline (Fig. 
6.27a and b).  Importantly, however, MDMs transfected with C6orf134 clearly show 
reduced levels of acetylated tubulin both at baseline and after exposure to H. 







































Figure 6.27a and b. Effect of C6orf134 knockdown on levels of acetylated tubulin 
within non-smoker MDMs 
Monocytes from healthy subjects were cultured in complete media containing GM-CSF 
(2ng/ml) for 12 d to give MDMs. MDMs were treated with HiPerfect alone (NS (■)), or 
transfected with either 12µM of C6orf134 siRNA (■) or scramble siRNA (All stars 
negative control, Qiagen, UK) (■) for 48h, prior to 4 h incubation with H. influenzae. 
Cells were lysed in RIPA buffer and proteins separated by Western blot, followed by 
immunoblotting with primary anti-acetylated tubulin antibody.  Blots were then 
stripped and re-probed with primary anti-actin antibody.  Representative of n=2, 
where NS = control cells, HI = control cells exposed to H. influenzae, C6 = C6orf134 
knockdown, C6+HI = C6orf134 knockdown exposed to H. influenzae, neg = scramble 









Previous work in our laboratory has shown an increased sensitivity of COPD 
macrophages to the presence of colchicine, a microtubule disruptor, with significant 
reductions in phagocytosis (Finney-Hayward et al., 2005).  In the present study, a 
similar observation, though less marked, was observed in the presence of nocodazole, 
a microtubule disruptor with similar activity to colchicine.   COPD MDMs had 
significantly reduced phagocytosis of beads and bacteria in the presence of 
nocodazole, compared to healthy MDMs.  Similarly, smoker MDMs showed increased 
sensitivity to microtubule disruptors, with equivalent reductions in phagocytosis 
compared to COPD MDMs; the statistical significance of this reduction, compared to 
healthy cells, was not analysed due to the low ‘n’ numbers.  Previous studies using 
human MDMs have shown that FcγR-mediated phagocytosis was unresponsive to 
nocodazole, whilst complement receptor mediated phagocytosis was inhibited 
(Newman et al., 1991).   A further study has shown that non-primed peritoneal 
macrophages were susceptible to the effects of colchicine on phagocytosis of IgG-
opsonised erythrocytes, an effect that was abolished on activation of macrophages 
(Khandani et al., 2007).  However, the macrophages used herein are all non-primed 
and the prey used is unopsonised, therefore neither of these mechanisms should 
account for the differences observed in phagocytosis, suggesting that disease may 
account for the differences seen. 
Reversible acetylation of microtubules has been implicated in the regulation of 
microtubule stability and function (Piperno et al., 1987), with acetylation used as a 
marker of stable microtubules.  In the present study, levels of acetylated tubulin were 
found to be significantly lower in COPD patients compared to healthy subjects, 
suggesting that this reduction in microtubule acetylation may relate to microtubule 
instability and to the alterations seen in phagocytosis.  Similarly, smoker MDMs 
showed reduced levels of acetylated tubulin, similar to COPD patients, compared to 
healthy subjects, though this reduction did not reach statistical significance due to the 
low ‘n’ number.  In contrast, there were no differences seen in acetylated tubulin in 
neutrophils from different subject groups.   
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The addition of a microtubule stabiliser, Epothilone B, led to significant improvements 
in levels of acetylated tubulin and in bacterial phagocytosis in both smoker and COPD 
MDMs, increasing phagocytosis by up to 20% in COPD and up to 30-40% in smoker 
MDMs.  In healthy MDMs, despite increasing levels of acetylated tubulin, Epothilone B 
did not increase phagocytosis, which may suggest that phagocytosis in healthy cells is 
already taking place at or near maximal capacity.  Epothilone B had no effect on 
neutrophil phagocytosis of bacteria.  This suggests that, while alterations in 
microtubule stability appear to be related to defective phagocytosis in macrophages, 
the defect is different in neutrophils.  Given the rapidity of neutrophil phagocytosis, 
with a maximal response at 2 min, compared to hours for macrophages, it would 
appear that an alternative mechanism underlies the defect seen in phagocytosis in 
neutrophils, particularly as microtubule turnover has a reported half-life of 5-10 
minutes (McNally, 1996).  The defect underlying alterations in neutrophil phagocytosis 
requires further investigation; expression of scavenger receptors and the effect of PI3K 
inhibitors, shown to improve chemotaxis in COPD neutrophils, (Sapey et al., 2011) 
have not previously been examined in phagocytosis by neutrophils from different 
subject groups. 
Given that COPD MDMs showed lower levels of acetylated tubulin, levels of the tubulin 
deacetylases were investigated; if levels of these enzymes were elevated it may 
account for the reduced acetylation of tubulin.  However, reduction in levels of 
acetylated tubulin could occur as a result of either reduced acetyl-transferase activity 
(αTAT1) or increased activity of one or both of the deacetylases, HDAC6 and SIRT2. 
 
There was a trend showing increased HDAC6 activity in COPD MDMs.  Treatment of 
COPD cells with tubacin, a selective inhibitor of HDAC6 (IC50=4nM), led to 
hyperacetylation of tubulin, however, despite an increase in levels of acetylated 
tubulin, no associated improvement in bacterial phagocytosis was seen.  This 
hyperacetylation of tubulin after tubacin treatment corresponds with the current 
literature, where A549 cells treated with tubacin (10µM) showed a three-fold increase 
in levels of acetylated α-tubulin (Haggarty et al., 2003).  Rather than an improvement 
in phagocytosis, in fact a reduction in phagocytosis of H. influenzae was seen with both 
tubacin and AGK2, which was not seen to the same extent with knockdown of either 
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HDAC6 or SIRT2.  Both tubacin and AGK2 are highly selective for deacetylation of 
HDAC6 and SIRT2 respectively, with the IC50 for other HDACs or sirtuins 1000 fold and 
>15 fold greater respectively.  This suggests that both tubacin and AGK2 may be having 
an off target effect leading to the reduction in H. influenzae phagocytosis.  Knockdown 
of COPD MDMs with either HDAC6 or SIRT2 siRNA confirmed the lack of improvement 
in phagocytosis, with knockdown of HDAC6 also showing increased acetylation of 
tubulin.  Contrasting this with the findings with Epothilone B (increased acetylation and 
improved phagocytosis) suggests that it may be microtubule stability and not simply 
microtubule acetylation that is altered in COPD.  
Previously, HDAC6 was thought to control both stability and acetylation of 
microtubules.  It has been shown that the acetylation site on α-tubulin is located on 
the interior of microtubules (Nogales et al., 1999).  Therefore, it is suggested that 
acetylation occurs on microtubule polymers, whilst deacetylation preferentially occurs 
on tubulin dimers and is linked to depolymerisation (Black et al., 1989).  Cells exposed 
to the HDAC6 inhibitor, trichostatin A, were shown to be highly acetylated and more 
resistant to de-polymerisation by colchicine, compared to control cells (Matsuyama et 
al., 2002).  In addition, over-expression of HDAC6 led to accelerated depolymerisation 
by colchicine (Matsuyama et al., 2002).  In contrast, Haggarty et al have shown that 
whilst tubacin treatment always increased levels of acetylated α-tubulin, no 
stabilisation of microtubules was observed in the presence of nocodazole or exposure 
to cold (0oC) (Haggarty et al., 2003).  These findings suggest that increasing tubulin 
acetylation by inhibition of deacetylases is not sufficient to stabilise microtubules.  This 
supports the findings in this chapter whereby increasing tubulin acetylation by 
inhibition of deacetylases has no effect on phagocytosis, whilst stabilising microtubules 
in the presence of Epothilone B leads to an improvement in phagocytosis.  
Furthermore, this suggests that the defect leading to altered phagocytosis in COPD is 
one of microtubule instability as opposed to altered acetylation. 
The recent discovery of the α-tubulin acetyl-transferase (αTAT1, also known as 
C6orf134 or MEC-17) allowed investigation of whether alterations in this enzyme could 
account for the altered phagocytosis seen.  Knockdown of C6orf134 in healthy MDMs 
was suggestive of not only reduced levels of acetylated α-tubulin in the cells, but more 
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significantly, of a reduction in bacterial phagocytosis, by ~20%, with unchanged bead 
phagocytosis.  Therefore, knocking down C6orf134 appears to mimic the defect seen in 
COPD cells.  One would therefore expect that levels of C6orf134 would be lower in 
COPD patients compared to healthy to account for the defects seen in COPD 
macrophages.  Quantitative rt-PCR initially appeared to confirm this, however, COPD 
MDMs also showed a reduction in HPRT1 (the housekeeping gene) compared to 
healthy cells, therefore, expression of C6orf134 was not altered in COPD.  Western 
blotting also did not allow for differentitation of levels of C6orf134 in MDMs from 
different subject groups due to poor specificity of the anti-bodies available.  Therefore, 
an activity assay will be established to examine whether COPD MDMs have reduced 
ability to acetylate tubulin compared to healthy cells.   
In conclusion, this chapter has shown that the mechanistic defect underlying the 
alterations in phagocytosis seen in MDMs and neutrophils from COPD patients and 
smokers is not the same, and further work is required to elucidate the defect in 
neutrophils.  In COPD MDMs, improving levels of tubulin acetylation was only 
associated with an increase in phagocytosis by the use of microtubule stabilisers, 
suggesting that the defect leading to altered phagocytosis in COPD is one of 
microtubule instability as opposed to altered acetylation.  Finally, knockdown of 
C6orf134 in healthy MDMs appears to mimic the defect seen in COPD cells, with 
reduced acetylation of tubulin and reduced phagocytosis. This would suggest that 
C6orf134 must be acting not only as an acetyl-transferase but may also act as a 
microtubule stabilising protein.   
6.4.1 Limitations 
The sample size used in the mechanistic part of the study needs to be increased 
throughout, as in some of the latter experiments, results are suggestive of a difference 
but this would need to be confirmed with increased numbers.  Work into the role of 
C6orf134 was limited due to its recent identification and lack of available antibodies or 






















The hypothesis for this thesis states that defective innate immunity in COPD patients 
leads to a reduction in bacterial phagocytosis and that this defective phagocytosis may 
relate to microtubule instability.  The data presented herein has shown reduced 
uptake of both gram positive and gram negative bacteria by MDMs from smokers and 
COPD patients compared to controls.  This is on a background of MDMs from all 
subject groups ingesting equivalent amounts of latex beads, confirming that MDMs 
from all subject groups are capable of phagocytosis.  Furthermore, neutrophils from 
smokers and COPD patients have also been shown to have defective phagocytosis, 
with significantly reduced uptake of bacteria, but again not of latex beads.  Studies to 
date in the literature have shown either reduced phagocytosis of E. coli by neutrophils 
from COPD patients, compared to healthy controls, or reduced phagocytosis of 
bacteria by healthy neutrophils exposed to cigarette smoke extract (Stringer et al., 
2007; Prieto et al., 2001; Guzik et al., 2011).  The finding of reduced uptake of common 
respiratory pathogens by neutrophils from COPD patients compared to controls has 
not previously been shown.  Finally, the work presented herein has shown that, for the 
first time, it appears to be a defect of microtubule instability that is associated with 
altered bacterial phagocytosis in COPD MDMs.  This may suggest a novel mechanism 
for defective phagocytosis in COPD MDMs and identifies a new target for the 
development of therapies for COPD.  
This study confirms the findings of defective bacterial phagocytosis by COPD MDMs, as 
previously shown by Taylor et al, 2010, whilst showing that COPD patients also have 
reduced uptake of bacteria by neutrophils.  No relationship was seen between the 
severity of the phagocytic defect in macrophages and either increasing age, smoking 
history or lung function (Chapter 3).  This suggests that the defect in phagocytosis is 
inherent in the cell and is not altered by ageing, disease severity or the length of 
exposure to cigarette smoke.  Of particular note, these are circulating cells, therefore, 
these cells do not display an altered phenotype after exposure to the lung 
environment.  One might postulate that in COPD patients, cells with an inherent defect 
in uptake of bacteria will migrate into the lung, and there be exposed to oxidative 
stress, cigarette smoke and bacteria, which may in turn cause further reductions in the 
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ability of these cells to take up bacteria.  One of the limitations of this study is the use 
of MDMs as a model of alveolar macrophages.  Whilst this has had its advantages, in 
that it displays the defect is inherent within circulating cells, to consolidate the findings 
in this study, one needs to confirm the defect in alveolar macrophages from smokers 
and COPD patients, comparing these to alveolar macrophages from healthy 
individuals.   
Whilst MDMs from smokers appeared to show the greatest reduction in ability to take 
up bacteria, suggesting active smoking may have an additional direct effect on 
reducing uptake of bacteria, this is not the case for neutrophils, with cells from COPD 
patients showing a more significant defect in uptake of bacteria in comparison to 
smokers.  Whether, the differences in the ability of neutrophils to phagocytose 
bacteria is the reason that smokers do not appear to suffer with recurrent 
exacerbations, in contrast to COPD patients, is not known (Bagaitkar et al., 2008).  
Though both smoker and COPD neutrophils and macrophages have reduced ability to 
take up bacteria, this defect may deteriorate further in the lung environment, reaching 
a critical point at which the rate of bacterial growth exceeds that of clearance allowing 
bacterial colonisation and infection.  If this were not the case, smokers and COPD 
patients should have increased susceptibility to infections outside the lung, however, 
there is no evidence for such risks.   
One of the interesting questions that arose from this study was whether the defect in 
bacterial phagocytosis in COPD patients could have an impact on exacerbation 
frequency.  Previously, it has been shown that patients who exhibit frequent 
exacerbations have higher rates of bacterial colonisation when compared to 
infrequent exacerbators (Patel et al., 2002).  Therefore, reduced uptake of bacteria by 
both macrophages and neutrophils could predispose the patient to bacterial 
colonisation and increased bacterial load, which in turn, may predispose to more 
frequent exacerbations.  This is important because frequent exacerbations of COPD are 
associated with more rapid decline in FEV1, increased hospitalisations, poorer 
performance status, increased mortality and increased costs (Wedzicha and 
Seemungal, 2007).  Moreover, frequent exacerbations have a marked effect on patient 
quality of life, with increased dyspnoea, reduced exercise capacity and a greater 
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likelihood of becoming housebound (Sapey and Stockley, 2006).  Therefore, the COPD 
cohort studied herein, was classified on the basis of their exacerbation history over the 
preceding year, as exacerbation frequency remains stable over a period of several 
years (Wedzicha and Seemungal, 2007).  When baseline MDMs phagocytosis values 
were compared for those COPD patients with a history of infrequent exacerbations 
versus those with frequent exacerbations, phagocytosis of both gram positive and 
gram negative bacteria was significantly reduced in those COPD patients with more 
frequent exacerbations.  Therefore, examining the ability of macrophages from COPD 
patients to take up bacteria could be used as a simple, and cost-effective, test to 
highlight a group of patients in whom targeted, aggressive, anti-microbial therapy at 
time of exacerbation, or the use of maintenance anti-microbial therapy, may have 
significant benefits. Given that the cells used in this study are circulating cells and have 
not been exposed to the lung environment; and given that acute exacerbations of 
COPD did not significantly alter phagocytosis beyond baseline levels, it adds support to 
the evidence that the defect leading to reduced bacterial phagocytosis is inherent.  
Furthermore, given that the frequent exacerbators were not those with more severe 
COPD, nor those with an increased smoking history, it suggests that it may be the 
degree of the defect in phagocytosis that drives the frequent exacerbation phenotype.  
A limitation of the exacerbation data presented is the relatively small sample size, and 
in order to confirm that acute exacerbations truly have no additional effect on 
phagocytosis, a larger sample size (n of >30) should be investigated.  Furthermore, to 
add strength to the finding that the defects seen in phagocytosis increase as 
exacerbation frequency increases, one would need to include COPD patients with a 
greater range of exacerbation frequencies in the preceding year.  If this gave rise to a 
strong correlation between phagocytosis and exacerbation frequency, this would 
provide more robust evidence for the defect in phagocytosis to be driving the frequent 
exacerbation phenotype.  In addition, investigating whether defective phagocytosis is 
present in other phenotypes of COPD, where chronic bronchitis and bacterial 
colonisation are less prominent in the course of disease, or alternatively in conditions 
where chronic bacterial colonisation is a major feature of disease, such as 
bronchiectasis, would give further information regarding whether the phagocytic 
defect is unique to COPD and, furthermore, whether it drives disease phenotype. 
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Reductions in the rate of exacerbations of COPD have been shown with the use of 
inhaled glucocorticosteroids, with several large randomised controlled trials showing 
ICS reduce exacerbation frequency by up to 25% and reduce decline in FEV1 (Calverley 
et al., 2003a;Calverley et al., 2003b;Qaseem et al., 2011).  Given that COPD patients 
have been shown to have relative corticosteroid resistance, with reduced expression 
of histone deacetylase (HDAC) 2 and HDAC activity (Ito et al., 2005), the beneficial 
effects of inhaled corticosteroids on exacerbation frequency and lung function decline 
may be suggested to be related to improvements in phagocytosis rather than the 
direct anti-inflammatory effects of inhaled corticosteroids. The data presented in this 
thesis (Chapter 5) lends support to this conclusion, with the finding that the greatest 
improvements in phagocytosis with ICS are seen in neutrophil uptake of H. influenzae, 
the bacteria more likely to be involved in COPD exacerbations.  The present study has 
also shown that frequent exacerbators have significantly reduced phagocytic ability 
compared to infrequent exacerbators, therefore, it may be that ICS have a more 
pronounced effect in frequent exacerbators, with improvements in phagocytosis 
caused by the ICS sufficient to lead to improvements in exacerbation frequency in 
these patients.   
How fluticasone propionate can simultaneously reduce the rate of exacerbations in 
COPD, up to 50% of which are associated with bacteria, whilst being shown to increase 
the risk of pneumonia (Calverley et al., 2007) is difficult to explain.  However, it may be 
that all ICS give a slight increased risk of pneumonia, possibly related to impaired 
resolution of exacerbations (Calverley et al., 2011), with the lesser risk seen with 
budesonide being more related to its ability to improve the underlying impairment of 
phagocytosis seen in COPD to a greater extent than fluticasone propionate, rather than 
fluticasone propionate further impairing bacterial clearance.  The greatest 
improvements in phagocytosis by both MDMs and neutrophils, pre-incubated with 
either steroid, were seen with H. influenzae. This perhaps explains the greater effect of 
ICS on improving a proportion of exacerbations of COPD, as opposed to the effect of 
ICS on pneumonia or those exacerbations that go on to cause pneumonia, which may 
be caused by S. pneumoniae, as there was little effect on phagocytosis of S. 
pneumoniae.  
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It is important to understand the mechanism driving defective phagocytosis and MDMs 
from COPD patients appeared to have increased sensitivity to microtubule disruptors.  
In addition, COPD MDMs were found to have reduced levels of acetylated tubulin 
compared to controls.  Acetylated tubulin is used as a marker of microtubule stability.  
The use of Epothilone B, a microtubule stabilizer, gave clear improvements in bacterial 
phagocytosis in COPD MDMs with an associated increase in acetylated tubulin.  In 
contrast, knockdown of either of the tubulin deacetylases, HDAC6 or SIRT2, in COPD 
MDMs, led to an increase in tubulin acetylation but no concomitant improvement in 
bacterial phagocytosis.  Therefore, altered microtubule stability, and not simply altered 
acetylation of microtubules, appears to be the defect underlying altered phagocytosis 
in COPD.  Strikingly, knockdown of αTAT1 in healthy MDMs appeared to mimic the 
defect seen in COPD MDMs, with reduced acetylation of tubulin and reduced bacterial 
phagocytosis, whilst bead phagocytosis remained unaltered.  This suggests that COPD 
patients may have reduced activity of tubulin acetyl-transferase (C6orf134), as no 
differences were seen in gene expression, which may relate to reduced bacterial 
uptake by macrophages. 
How defective microtubule stability impacts on bacterial but not bead phagocytosis is 
not entirely clear.  It may be related to differential recognition and internalization, 
dependent upon specific cell surface receptors.  Microtubules are required in 
phagocytosis via complement and scavenger receptors A, but not via the Fc receptor 
(Newman, 1991).  Whilst the prey used in this study are not opsonised, and therefore 
are likely to be taken up by scavenger receptors, it may be that, like the FcR, there may 
be some classes of scavenger receptor where microtubules do not play as prominent a 
role in internalisation, thereby allowing phagocytosis to take place as normal.  
Alternatively, it may be related to the involvement of microtubules in conformational 
changes of receptors (Newman, 1991), with again differential involvement of 
microtubules in receptors involved in bacterial as opposed to bead phagocytosis.  
Finally, with the predominant role of microtubules in phagocytosis being their role in 
trafficking of the phagosome through the cell (Allen, 1996), it may be that 
microtubules are differentially invoked to phagosomes containing beads as opposed to 
bacteria.  
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Given that knockdown of C6orf134 in healthy MDMs mimics exactly the phagocytic 
defect seen in COPD, it may suggest altered activity of C6orf134 in COPD patients.  As 
previously discussed, this defect is seen within circulating cells which suggests either a 
genetic predisposition or a systemic effect of cigarette smoking, perhaps on the bone 
marrow itself.  Large genome wide studies of COPD have shown no alterations on 
chromosome 6 where C6orf134 is located (Bakke et al., 2011).  Further genome studies 
should concentrate on this chromosome, investigating whether there is any alteration 
in this gene in large COPD populations in comparison to healthy controls.  It may be, 
however, that the defect in these cells arises through the systemic effects of cigarette 
smoking, perhaps through epigenetic modifications rather than a specific genetic 
defect. 
Neutrophils also displayed defective phagocytosis of bacteria, however, in contrast to 
MDMs, there was no altered acetylation of tubulin nor was there any improvement in 
phagocytosis with Epothilone B.  Therefore, it would appear that the defect in 
neutrophils is not related to microtubule instability; given the speed of uptake of prey 
in neutrophils is faster than that of the turnover of microtubules it points to an 
alternative defect.  COPD neutrophils have also been shown to have altered 
chemotaxis.  The use of PI3-kinase inhibitors led to a reduction in the distance 
travelled by COPD neutrophils, with improved directed speed and accuracy towards 
chemoattractants; in contrast the inhibitors had minimal effect in healthy and smoker 
cells (Sapey et al., 2011).   In mouse macrophages, inhibition of PI3K with the PI3K 
inhibitor LY294002, directly resulted in reduced phagocytosis of NTHI (Marti-Lliteras et 
al., 2009).  Activation of the PI3K pathway is required for phagocytosis, resulting in the 
localisation of F-actin to the peri-phagosomal region at the cell membrane (Greenberg 
and Grinstein, 2002).  Therefore, it may be that there is a common defect in the 
signalling pathway accounting for both defects in chemotaxis and phagocytosis in 
neutrophils in COPD and this requires further investigation. 
In conclusion, this thesis has shown defective uptake of bacteria by both MDMs and 
neutrophils in both smokers and COPD patients, which in MDMs is related to altered 
microtubule stability.  Given that smokers also show altered microtubule stability and 
altered levels of acetylated tubulin compared to healthy controls, it may be that this 
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could be used as a susceptibility test for those smokers who are likely to go on to 
develop COPD.  In turn, this would allow targeted smoking cessation therapy, an 
extremely cost effective intervention if it will prevent disease progression.  
Furthermore, this thesis has shown that COPD patients with a frequent exacerbator 
phenotype have significantly worse phagocytosis than those with infrequent 
exacerbations.  Again, detection of this defect in COPD patients may allow earlier 
phenotyping of these patients, identifying those patients who are likely to develop 
frequent exacerbations as disease progresses, enabling earlier intervention with 
aggressive anti-microbial therapy and inhaled therapy to try and reduce exacerbation 
frequency, with considerable cost benefit implications and improvements in patient 
quality of life.  The use of microtubule stabilisers has been shown to improve 
phagocytosis in the region of 20%; currently these drugs are licensed as anti-cancer 
drugs, as stabilising microtubules reduces cell division, and are therefore associated 
with significant systemic side effects.  It may be that there is a role for these drugs as 
inhaled therapy so reducing systemic effects.   One may also have to review the risk to 
benefit ratio of using these drugs, as to whether even systemic usage is worth trialling. 
Studies have quoted a 5 y mortality of ~25% in those frequent exacerbators who incur 
recurrent hospital admissions (Soriano et al., 2000), a survival statistic worse than 
many common cancers, therefore, it may be that the increased side effects of a 
treatment may be acceptable if there was evidence of significant improvements in 
patient health and quality of life.  More importantly, the finding of altered microtubule 
stability allows for the focused development of new therapies which could be targeted 
to this defect. 
Currently, the mainstay of exacerbation treatment is antibiotics and steroids, both of 
which have variable effectiveness due to the heterogeneity of exacerbations.  This 
thesis has shown evidence suggestive of altered activity of tubulin acetyl-transferase 
(αTAT) in COPD cells compared to those from healthy controls, causing reduced 
microtubule stability and reduced phagocytosis.  Therefore, targeting tubulin acetyl-
transferase, by stimulating αTAT to increase activity may allow for a novel therapy 
directed at reducing bacterial colonisation and exacerbation frequency.  A novel 
therapy targeting improvement in phagocytosis may have significant benefits for 
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patients, in terms of quality of life, disease progression and mortality, with resultant 






















7.2 Future work 
There are a number of questions that remain following the completion of this thesis, 
and a number of experiments could be performed to address many of these questions. 
 
To define in greater detail the phagocytic defect in MDMs, two populations of COPD 
patients should be used; those with and those without evidence of stable state 
bacterial colonisation.  The premise would be that those with bacterial colonisation 
would show a greater reduction in phagocytic ability than those without.  This would 
lend weight to the hypothesis that defective phagocytosis leads to increased bacterial 
colonisation and in turn increased exacerbation frequency. 
Using these two groups as the starting point, phagocytosis experiments would be 
repeated as well as looking at exacerbation frequency within the two groups (dividing 
each group again into frequent and infrequent exacerbators) and comparing 
phagocytic ability across the groups.  Where possible at stable state, experiments 
should be repeated using alveolar macrophages to confirm the defect. 
If differences were seen in phagocytosis between the two groups then further 
experiments on the mechanistic defect underlying this could be performed on those 
MDMs displaying reduced phagocytosis (to further investigate the relevance of 
C6orf134 to the reductions seen in phagocytosis, including setting up an activity assay 
to assess whether there is reduced activity in COPD) 
Both as part of the MDMs work and the exacerbation work, it would be important to 
know the colonising strain and then one could assess whether cells show a greater 
defect in phagocytosis of this particular pathogen over and above other pathogens.  
Similarly, at times of exacerbation, the type of exacerbation should be analysed, and 
then it can be ascertained whether there are alterations in phagocytosis based on the 
type of exacerbation (viral or bacterial) and in the case of bacterial exacerbations, 
whether change in bacterial strain has a greater or lesser effect on phagocytic ability.  
Furthermore, at times of exacerbation the length of time to recovery and the time to 
next exacerbation should be investigated, along with any associate relationship to 
differences in phagocytic ability. 
In parallel with the MDMs work, neutrophils should be investigated from the same 





























SiRNA target sequences 
Hs_HDAC6_5   CACCGTCAACGTGGCATGGAA 
Hs_HDAC6_6   CACTTCGAAGCGAAATATTAA 
Hs_HDAC6_10   CCGGAGGGTCCTTATCGTAGA 
Hs_HDAC6_2   CCGCATTATCCTTATCCTAGA 
 
Hs_C6orf134_7  GAGGCTCATAATGAGGTAGAA 
Hs_C6orf134_9  ACCGCACCAACTGGCAATTGA 
Hs_C6orf134_5  AACCGCCATGTTGTTTATATT 
Hs_C6orf134_6  CCCGCCGACCCGGAACCACAA 
 
Hs_SIRT2_6   AATCTCCACATCCGCAGGCAT 
Hs_SIRT2_1   ACCGGCCTCTATGACAACCTA 
Hs_SIRT2_3   CCCGCTAAGCTGGATGAAAGA 








Example of an Rt-PCR graph 
 
The graph (amplification plot) shows the number of PCR cycles plotted against 
increasing fluorescence.  The horizontal line is the threshold (set on each experiment) 
– the point at which the amplification plot crosses the threshold is given as the Ct 
value (cross threshold value), with the lower the Ct value, the greater the starting 
amount of DNA in the sample. 
Example of δδCT calculation 
This is an approximation method to give the fold change in the target and reference 
(control) genes, thereby allowing the calculation of a fold change corrected for any 
variations in the reference gene  
Using the example below, in the top table are the rt-PCR Ct values for the reference 
gene, with the target gene, C6orf134, in the lower table (where NS = control sample, 
K’down = HDAC6 siRNA, scramble = negative control siRNA) 
Reference gene   
NS K'down Scramble 
21.7719 21.7269 23.0287 
21.7721 21.8967 21.8633 
22.6617 21.337 21.0856 
Average    
22.06857 21.65353 21.99253 






Fold changes are then calculated in two steps: 
Taking the control sample as an example, first the target gene is subtracted from the 
house keeping gene (eg. 22.06857-24.14337 = -2.0748) 
Then, from the values generated in step 1, the control value is subtracted from the 
knockdown values (eg. -3.63863-(-2.0748) = -1.56383 
sample NS -2.0748  1  1 
 48+ -3.63863  -1.56383  0.338251 
 48- -1.83957  0.235233  1.177097 
 
Finally the degree of change in gene expression is calculated by 2 to the power of the 
number generated, for eg. 2 -1.56383 = 0.338251.  This value, subtracted from 1 and  









Target gene   
NS K'down Scramble 
24.9472 25.4794 24.0794 
24.1687 27.0698 24.0092 
23.3142 23.3273 23.4077 
Average   
24.14337 25.29217 23.8321 
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